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ABSTRACT  
Introduction: Fluorescence-guided surgery could improve the operative decision-making 
process. Near Infrared Cholangiography (NIR-FC) with Indocyanine Green (ICG) in 
laparoscopic cholecystectomy (LC) may aid visualisation of bile duct anatomy. The c-met 
transmembrane protein is over-expressed in colorectal cancer (CRC). EMI-137 is a c-Met 
specific peptide coupled to fluorophore.  
Methods: Twenty-two participants requiring LC were allocated to four dosing subgroups and 
received a single intravenous (I.V) dose of ICG before surgery. Biliary anatomy was assessed 
with NIR-FC and surgeon satisfaction was evaluated. 
c-Met transcription in HT-29 CRC cells was silenced with targeted SiRNA to demonstrate 
specificity of EMI-137.  A HT-29 xenograft model was developed in female BALB/C mice. EMI-
137 (0.18mg/kg) was injected into tail veins and biodistribution analysed by fluorescent 
imaging. c-Met immunopositivity was graded in matched normal and CRC tissue TMA samples 
obtained from the MRC CLASICC trial.    
Nine participants with colon cancer, received IV EMI-137 1-3 hours before laparoscopic 
tumour resection surgery. Tumour and lymph node (LN) fluorescence were assessed with a 
fluorescent laparoscope. Immunohistochemistry analysed c-Met expression. 
Results: A prolonged ICG dosing interval consistently increased structure identification at LC 
and was preferred by the operating surgeon.  
c-Met was consistently overexpressed in CRC relative to normal tissue and could be visualised 
with EMI-137, comparable to indirect c-Met identification methods. EMI-137 uptake in tumour 
xenografts was observed for 6 hours post-administration 
At clinical trial, no serious adverse events related to EMI-137 were reported. Marked 
background fluorescence was observed in all participants; 4/9 showed mild increase in tumour 
fluorescence over background; 5/9 had histological LN metastases; no fluorescent LN were 
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detected intraoperatively. All primary tumours (8/8) and malignant LN (15) exhibited moderate-
high c-Met protein expression.  
Conclusion: Prolonged ICG dosing improves visualisation of structures with NIR-FC at LC. 
EMI-137, binds specifically to the human c-Met protein, is safe but its intra-operative utility is 
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1. CHAPTER ONE 
FLUORESCENCE GUIDED SURGERY: INTRA-OPERATIVE 
FLUORESCENT IMAGING IN LAPAROSCOPIC COLONIC TUMOUR 
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INTRODUCTION 
1.1 The Principles of Fluorescence  
A fluorophore is defined as a molecule capable of absorbing and emitting light energy. 
Fluorophores exist in a lower energy unexcited “ground state”, or S0 state, until excited by 
light of an appropriate wavelength. Fluorescence is a three-step process, excitation, excitation 
state lifespan, and emission. During excitation the fluorophore absorbs a photon of light energy 
and undergoes a conformational change to exist in a higher, unstable energy state. This 
unstable state only lasts around one picosecond (10−12 seconds) before the fluorophore 
quickly starts to dissipate the absorbed the photon of light energy. As it returns to a more 
stable, lower energy state (S1), it releases energy as kinetic energy or transfers the energy to 
other electrons, a process sometimes known as vibrational relaxation and internal conversion 
respectively. The time taken to dissipate energy to reach a lower energy state varies slightly 
between different fluorophores and is referred to as the excited state lifespan. Once at the 
lower energy S1 state, the fluorophore can then slowly emit the photon light energy absorbed 
as light to return to its low energy ground state, S0. The process of energy dissipation means 
the fluorophore is already at a lower energy state when it enters the emission phase of 
fluorescence (S1 to S0). The efficiency of this light conversion process is dependent on the 
fluorescent quantum yield (Φf); defined as “number of fluorescence photons emitted per 
excitation photon absorbed”(1–3). 
This unique photo-physical property of fluorophores means the emitted light energy is of a 
longer wavelength - the colour of the light emitted differs from the colour absorbed. The 
difference between the excitation and emission wavelength is known as the Stoke shift value. 
Unless a fluorophore is “photobleached”, when irreversible structural damage from high 
intensity light excitation occurs, it can be repeatedly excited or “re-radiated” for sustained 
detection. It is these essential properties of fluorophores that allows differentiation between 
absorbed and emitted light and facilitates their multiple diagnostic utilities, including perfusion 
assessment and tumour localisation. Jablonski first describe fluorescence in pictorial form in 
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the 1930s and these graphs are commonly referred to as “Jablonski diagrams”(1,4) (Figure 
1).  
 
Figure 1: Simplified Jablonski diagram of energy transfer in fluorescence adapted from 
Davidson et al (2017)(5). 
 
 
Figure 2: The Near Infrared optical window. It is useful for in vivo imaging because of 
minimal light absorption by haemoglobin (<650 nm) and water (>900 nm) Adapted from 
Weissleder et al (2001)(6).  
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1.2 Laparoscopic Cholecystectomy and Indocyanine Green 
Indocyanine Green (ICG)  
Background and Pharmacology 
Indocyanine Green (ICG) is a tricarbocyanine dye (C43H47N2NaO6S2) with fluorescent 
properties. It is supplied as a sterile lyophilised powder with no more than 5% sodium iodide 
content(7). ICG was developed by Eastman Kodak® as a sensitising agent in photographic 
processing in the early 1950s. The Mayo Clinic started investigating the medical applications 
of ICG in 1956 and it gained US Food and Drug Authority (FDA) approval soon after(8). The 
chemical formula of ICG is 2,2’-indo6,7,6’,7’, dibenzocarbocyanine sodium. It has a complex 
structure (Figure 3) with a molecular weight of 774.96 g/mol and pH 6.5 in aqueous solution(7). 
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Excretion and Pharmacokinetics  
ICG should be reconstituted with sterile water immediately prior to injection(11). Once injected 
intravenously, it rapidly and fully binds to serum lipoprotein complexes and plasma proteins, 
favouring α1 lipoproteins, especially High Density Lipoprotein (HDL)(12,13). Reconstituted 
ICG is rapidly degraded by exposure to light, but if bound to intravascular plasma proteins 
photo-degradation can be slowed for up to several days.  
ICG is exclusively excreted in bile and does not undergo any forms of intrahepatic conjugation, 
metabolism or enterohepatic circulation(10,14). ICG excretion is a continuous biphasic 
process(15). ICG extraction and biliary excretion is reliant on energy depend transmembrane 
carrier proteins. The first stage is uptake across the basolateral sinusoidal plasma membrane 
of hepatocytes by ATPase dependent carrier proteins(10,16) and extraction by hepatic 
enzymes including glutathione S-transferase(17).  
The second stage is transport through the cell and excretion at the apical membrane into bile 
fluid. This is the ATPase dependent rate limiting step of ICG clearance. The plateau seen in 
linear graphs of plasma disappearance and hepatic uptake following injection of ICG is 
explained by saturation of these carrier proteins. ATPase dependent Multi-drug resistant P-
glycoprotein (Mdr2) phospholipid translocator is vitally important and facilitates the formation 
of biliary phospholipid vesicles containing ICG and excretion of the unaltered ICG into bile. 
This explains the biphasic elimination profile of ICG. The first t½ is only around 3 to 4 minutes 
whilst the second t½ is highly variable and dose dependent(18). 
The accepted pharmacokinetics of ICG is based, in part, upon the early animal studies of 
Wheeler et al and Ketterer et al and relates only to healthy tissue. They report peak biliary 
excretion two to three hours after administration and almost complete drug recovery in bile 
within five hours in anaesthetised dogs(19,20). Cherrick et al’s human studies from the same 
era validated this observation(14). After intravenous injection, ICG was first detected in bile 
within 15 minutes, concentration peaked at two hours, but levels remained high at trial 
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termination at seven hours post administration, indicating a possible longer elimination profile 
in humans. ICG shows almost complete intravascular confinement in healthy tissue, but 
delayed washout of up to 72 hours in diseased and malignant tissue(21). Alacam et al 
proposed disruption to the basement membrane and therefore leaky capillaries in cancerous 
tumours to explain extravascular retention of ICG in mammillary adenocarcinoma in in vivo 
studies(22).  
Several factors adversely affect the clearance of ICG. Bilirubin is a competitive inhibitor of ICG 
uptake by hepatocytes, as is hypo-perfusion and altered hepatic microcirculation. In clinical 
practice, severe liver disease with severely reduced hepatocyte function, raised serum 
bilirubin and low albumin states and hypotension all adversely affect ICG and clearance rates. 
The expression of the canicular transporter protein, Mdr-2, is moderately decreased in human 
livers with alcoholic cirrhosis(23). Calorific restriction, as often seen in sepsis and pre-
operative fasting regimens, also increases ICG hepatic clearance(24).  
 
Spectral Properties 
ICG demonstrates an anomaly in its spectral properties, whereby there is variation in its 
absorption and emission depending on the “nature of the solvent medium” it is reconstituted 
in and the concentration achieved(25,26). ICG has a very broad optical window, overlapping 
the edge of the visible light and Near-Infra Red (NIR) region of the electromagnetic spectrum. 
The peak absorption wavelength is 780nm in water and shifts to 800nm in albumin(25,27), 
whilst the peak emission wavelength for ICG is 820nm in water and 830nm in whole blood(28). 
ICG monomers peak at a lower wavelength than ICG oligomers and protein bound ICG. ICG 
does not obey Beer-Lambert Law linear relation between concentration and fluorescence in 
solution due to its tendency to form aggregates and oligomers(9,29). Owing to dye-protein 
interactions, the maximum fluorescence intensity in blood is observed at 80 mg/ml. Above this, 
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self-quenching occurs and the fluorescent intensity of ICG decreases in a non-linear 
fashion(15). 
 
Figure 4: Spectral properties of ICG in human whole blood in 100µL cell at excitation 
wavelength 765nm. Adapted from Benson (1978)(28) 
 
Safety 
ICG is safe, with very few adverse reactions reported. The manufacturers of medicinal ICG 
quote the risk of anaphylaxis as less than 1 in 10,000 and using case report data estimate the 
risk of death from an anaphylactic reaction as less than 1 in 330,000(11). The risk is increased 
in patients with severe renal insufficiency, previously documented iodine allergy, and when 
ICG is reconstituted with any solvent other than the recommended sterile water(11,17,30). 
Rudolf et al, confirmed the safety of ICG in pregnancy; by simultaneously measuring levels of 
ICG in maternal and foetal cord blood they confirmed ICG does not cross the placenta(31).  
 
Clinical Applications of ICG 
Since the discovery of ICG, it has been used for a myriad of clinical applications. The majority 
have focused on the intravascular administration of ICG as part of angiographic studies. ICG 
lends itself well to angiography because of its spectral and intravascular confinement 
28 
  
Name: Gemma Armstrong  
Student No: 201073014 
properties. At the 800nm wavelength, ICG shows peak absorption and this wavelength 
conveniently overlaps with the exact point whereby the optical density of oxygenated 
haemoglobin is comparable to that of deoxygenated haemoglobin, facilitating methods of NIR 
imaging in all three fluid mediums, bloods, plasma and serum(32). ICG is also favoured for 
fluorescence-guided surgery because the depth of tissue penetrance possible increases with 
this longer wavelength of light. Stolik et al ex vivo tissue study characterised the average depth 
of detectable fluorescent light penetrance in liver tissue (post-mortem tissue) was 2.9mm 
(S.D±0.3mm) at emission wavelength 780nm and 3.68mm (±0.35mm) at 835nm. Whilst this 
was considerably shorter for whole serum blood with the same emission wavelengths applied, 
the distance was only at 0.42mm (±0.02mm) and 0.51mm (±0.02mm) respectively(33).  
Another accepted application of ICG is retention testing (ICGR-15) as part of functional 
hepatocyte assessment prior to hepatic major resection surgery. Liver resection surgery is a 
fine balancing act between resecting the underlying pathology and retaining enough functional 
liver parenchyma; overly extensive resection can lead to the catastrophic complication of post-
operative liver failure. The pharmacokinetic and biexponential decay curve of ICG make it an 
ideal marker for hepatocyte reserve assessment(34). The serum concentration of ICG 15 
minutes after intravenous administration can act as an accurate surrogate marker of both 
hepatocyte volume, function, and blood flow. An ICGR-15 score over 14% (healthy adults 8-
14%) is highly predictive of poor post-operative outcomes, including mortality in patients 
undergoing major liver resection surgery(35,36). 
 
Laparoscopic Surgery  
The term laparoscopic originates from the Latin laparo - "wall of the abdomen" and scope, to 
visualise or explore. The first documented laparoscopic surgical procedure on a human 
subject was performed in 1910 by the Swedish physician Jacobaeus. He recognised the 
immense diagnostic and therapeutic potential of laparoscopic surgery, but also the risk of 
29 
  
Name: Gemma Armstrong  
Student No: 201073014 
bowel injury with introduction of the trocar in the abdominal cavity(37). The technique and 
equipment required for laparoscopy was explored and refined over the ensuing decades. It 
was not until 1981 that Semm et al performed the first laparoscopic appendicectomy(38). 
Mühe et al then performed the first laparoscopic cholecystectomy four years after(39). 
Thereafter, several pioneers and early adopters around the world started to regularly use the 
technique and apply it to a myriad of surgical procedures, traditionally performed via an open 
approach. Today, laparoscopic surgery has become the standard approach for many 
procedures and significant technological advances have been made. Laparoscopic surgery 
requires the introduction of a light source into the abdominal or pelvic cavity. A natural 
progression has been the development of fluorescence enabled laparoscopic technology. The 
addition of a fluorescent light source and detector coupled with administration of a dedicated 
fluorophore can improve structure visualisation and surgical accuracy.  
 
Intraoperative Applications of ICG 
Tumour Localisation with ICG 
Recently, ICG with NIR technology has moved into the operating theatre and has been applied 
as a dynamic imaging modality for begin and malignant pathologies in both open and 
laparoscopic surgery. The intraoperative applications of ICG can broadly be divided into 
angiographic perfusion and lesion localisation studies.  
Of interest, is ICG guided navigation in laparoscopic liver resection surgery. The hope is it will 
compensate, at least in part, for the lack of tactile feedback available in minimally invasive 
surgery. First trialled by Ishizara et al and explored by his colleagues Kudo et al and Morita et 
al, ICG has proved highly valuable in Hepatocellular Carcinoma (HCC) resection, in part 
because of its convenient dosing regimen. HCC localisation can utilise the residual ICG from 
preoperative ICGR-15 functional reserve assessments and possibly the leaky basement 
membrane of tumour capillaries. By administering ICG between 3 and 28 days prior to surgery 
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the three groups were able to delineate all tumours within 5mm of the liver capsule and 
visualise multiple tumours invisible on white light inspection alone(40–43). ICG had a HCC 
localisation sensitivity of 96%(42), produced uniform fluorescence in all lesions, and was felt 
to aide intraoperative decision-making(41). From their early phase assessments, the optimal 
dosing interval has not yet been established.  
Liver metastases are common in the natural history of many cancers, especially colorectal 
cancer, and must be resected if any attempt at long-term survival is to be made. Therefore, 
the natural progression for ICG guided NIRF was the field of liver metastases resection. HCC 
tumours show a characteristic uniform fluorescence with ICG, whereas colorectal liver 
metastases show ring enhancement with retention of the fluorophore in the tumour stromal 
and normal liver tissue junction(44). Handgraaf et al, found NIRF helped surgeons to identify 
significantly more CRLM intra-operatively (25% vs 13%, p = 0.04) (n = 86 NIRF arm vs. n = 
87 control arm). Many of the additional lesions were small at less than 5mm, subcapsular and 
only detectable with NIRF. In the 21 (21/86) patients with additional CRLM identified with 
NIRF, 52% did not have any evidence of liver recurrence at 3-year follow-up(45). The overall 
sensitivity and specificity of NIRF detection of malignant liver lesions is limited by the depth of 
penetration achieved with deeper parenchymal lesions(41). Kudo et al’s trial of NIRF guided 
resection of HCC lesions yielded a sensitivity of 69% (detecting 11 out of 16 lesions)(41). 
Whereas, Handgraaf et al’s subgroup analysis of the sensitivity of NIRF imaging in CRLM 
yielded an overall sensitivity for all lesions of 83%, but for superficial lesions (<8 mm 
subcapsular location) it was highly sensitive and yielded a detection rate of 100%(45). 
 
Sentinel Lymph Node Biopsy (SLNB) 
In the last two decades, biopsy of the Sentinel Lymph Node (SLN) in multiple forms of cancer 
with a propensity with early lymph node metastasis has been incorporated into surgical routine 
practice. Accurately staging the lymph node burden allows risk stratification and 
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individualisation of surgery and postoperative adjuvant therapies. Identification of high-risk 
patients who are likely to benefit from extended regional lymph node clearance spares those 
with low risk localised and/or node negative disease the associated surgical morbidity.  
Localisation of the SLN in the axilla and confirmation of its cancer status is vital to breast 
cancer management. Axillary node clearance with lumpectomy in early breast cancer has a 
greater postoperative morbidity, but does not offer any survival advantage over the less 
invasive procedure of lumpectomy and SLN dissection(46,47).  The gold standard technique 
for SLN identification intraoperatively is subcuticular and intraparenchymal injection of the 
radioisotope Technetium-99m (99mTc) before surgery and/or with a blue colloid dye such as 
Isosulfan blue(48). The combination of 99mTc and blue dye lymphoscintigraphy yields a SNL 
detection rate and false negative rate of 94.4%(49) and respectively 7%, whilst blue dye as 
the sole agent has a false negative of 9.9%(50). 99mTc is costly to manufacture and requires 
comprehensive radiation safety precautions to safeguard clinical staff from the risks 
associated with cumulative radiation exposure. Isosulfan blue dye can interfere with 
intraoperative pulse oximetry readings(51), carries a risk of serious allergic reaction in the 
region of 1 - 3%(52), and can cause permanent blue skin tattooing or skin necrosis at the 
injection site(53).   
ICG has been investigated as a potential superior alternative to these agents because of its 
favourable dosing regimen, safety profile, and lower financial cost. Proof-of-principle and 
efficacy of ICG guided SLNB was confirmed by Motomura et al using a prototype NIR device 
two decades ago(54). Guo et al’s prospective trial of SNLB with subdermal peri-areolar 
infiltration of ICG had a diagnostic yield of 97%(55). Wishart et al compared detection rates 
between SLN mapping modalities. ICG was superior to 99mTc and isosulfan blue used in 
isolation and even when used as a combined imaging modality. ICG detected all 201 SLN 
(yield 100%)(56).  
In a similar way to breast cancer surgery, dissection of the SLN has also been applied to 
gynaecology oncology surgery. In the UK, there is disagreement on the merits of routine SLN 
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biopsy during laparoscopic hysterectomy and bilateral salingo-oophrectomy in the treatment 
of the most common form of gynaecological cancer - endometrial adenocarcinoma(57). 
Although lymph node status is important for prognosis prediction, the vast majority of cancers 
present as early stage I or II and therefore the likelihood of a positive SLN is slim. The Royal 
College of Obstetricians and Gynaecologists recommends 99mTc and/or a blue dye to detect 
the SLN in high grade aggressive endometrial cancers only. There is considerable variability 
in the techniques and doses used, but the French SENTI-ENDO prospective trial of superficial 
infiltration of 99mTc and isosulfan blue dye in early endometrial cancer described an overall 
SLN detection rate of 80%(58). Whereas, ICG guided NIR laparoscopic surgery yielded an 
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Near Infrared Fluorescent Angiography (NIR-FA) Anastomosis 
Perfusion Assessment 
In the field of gastrointestinal surgery, and especially colorectal surgery, NIR-FA with ICG has 
been widely applied to anastomosis perfusion assessment. Anastomotic leak (AL) defined as 
“a leak of luminal contents from a surgical join between two hollow viscera”(60) is a 
catastrophic complication of gastrointestinal resectional surgery. The underlying aetiology of 
AL is multifactorial, with a complex interplay between patient and surgical factors determining 
healing of the surgical join. However, perfusion of the anastomotic joint is one of the few 
modifiable operative factors within the control of the operating surgeon.  
Jafari et al published the PILLAR II clinical trial results in 2015 reporting an astonishingly low 
leak rate of only 1.4% in patients undergoing left sided and anterior resection surgery with a 
mean anastomosis 10 ±4cm from the anal verge(61). Their multicentre prospective trial of 147 
patients undergoing surgery with primary anastomosis assessed with NIR-FA included 
different clinical indications, including malignancy, diverticular disease, and inflammatory 
bowel disease. Intravenous administration of ICG rapidly and predictably mapped the 
perfusion of the bowel in 99% of patients. The addition of NIRFA lead to a change in operative 
strategy in 8% (n = 11). Of these patients, none experienced a clinical or radiological 
anastomotic leak. Jafari et al successfully showed that NIRFA was a feasible and useful 
adjuvant to colorectal anastomosis construction. However, with such a small and highly 
variable cohort of patients, and a lack of pre-operative randomisation, it is difficult to argue 
NIRFA can produce a five to ten-fold reduction in anastomotic leak rate without further robust 
clinical research(61).  
The PILLAR III trial (ClinicalTrials.gov registry identifier NCT02205307) was a randomised 
controlled trial of NIR-FA in low anterior resection surgery (anastomosis ≤10 cm from the anal 
verge) versus a white light control arm, in the United States that closed early due to poor 
recruitment and biased surgeon equipoise. The trial recruited only 347 of the planned 550-900 
patients. The preliminary modified intent-to-treat data found no difference in AL rate at 8 weeks 
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post-operatively between low anterior resection with NIR-FA and white light standard care 
(10/175 (5.7%) versus 7/168 (4.7%) respectively). However, interpretation of the efficacy of 
NIR-FA in anterior resection for the prevention of AL is severely limited with these results. The 
PILLAR III trial is statistically underpowered to draw any meaningful conclusions(62). Despite 
this, NIR-FA appears remarkably popular and well-received by US colorectal surgeons, but 
currently lacks a body of high-quality evidence of its efficacy or robust data to support the 
claims proposed by early adopters of the technology.  
 
Biliary Pathology, Cholecystectomy and NIR-FC 
Cholelithiasis, the formation of choleliths (gallstones) in the gallbladder or biliary tree is very 
common. It is estimated that 15% of adults in the Western World have gallstones(63). The 
majority of patients with gallstones are asymptomatic, but between 1 to 4% will develop a 
complication associated with gallstones every year(64), with men more likely to be 
symptomatic(65). Most (>75%) choleliths are cholesterol stones formed of cholesterol 
monohydrate crystals. Less commonly they are composed of bilirubin polymers or calcium 
bilirubinate and these are referred to as brown and black pigment stones respectively(66). The 
primary metabolic pathophysiological step in biliary calculous disease is supersaturation of 
the bile with cholesterol or bilirubin pigments. This is often accompanied by impaired bile salts 
recycling and gallbladder dysmotility, reduced production of solubilising substances, and 
increased mucus production. Bacterial infection of the static bile also contributes to gallstone 
formation in some cases(67,68). The gallbladder and ducts become filled with a saturated 
mucin-rich “biliary sludge”. Nucleation of the saturated bile forms crystals and these aggregate 
in to choleliths(69). 
Several complications of cholelithiasis can arise and require treatment by excision of the 
gallbladder, a procedure called cholecystectomy. The majority of symptomatic patients 
complain of biliary colic; episodic postprandial upper abdominal pain with or without 
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vomiting(70). Biliary colic results from gallbladder spasm in response to transient Cystic Duct 
(CD) obstruction by a gallstone or intrinsic gallbladder irritation(70,71). Prolonged obstruction 
of the gallbladder can lead to acute calculous cholecystitis. The gallbladder becomes inflamed, 
the wall of the gallbladder thickens, and an exudate of pericholecystic fluid can develop. 
Secondary bacterial infection with anaerobic colonisers of the gastrointestinal tract often 
follows(65). These patients typically present with constant abdominal pain and signs of a 
systemic inflammatory response. Other life-threatening complications of cholelithiasis also 
include gallstone pancreatitis and ascending cholangitis(71). These diagnoses can overlap.  
 
Laparoscopic Cholecystectomy 
In 2014, 66,660 cholecystectomy surgeries were performed in the United Kingdom, with the 
vast majority (92%) completed via a laparoscopic “keyhole” surgical approach(63). 
Laparoscopic cholecystectomy is the gold standard for the treatment of acute and elective 
biliary pathology, having replaced open surgery in the majority of cases(63,72–74).  
Laparoscopic cholecystectomy was adopted into standard surgical practice in the early 
1990s(39,72). Initially, laparoscopic cholecystectomy surgery took on average 3 hours to 
complete and had a conversion to open rate in the region of 15%(75,76). Until relatively 
recently, acute cholecystitis and gallstone-induced pancreatitis were a contra-indication to 
early laparoscopic excision of the gallbladder. Early adopters of emergency laparoscopic 
cholecystectomy in acute cholecystitis reported the procedure feasible but with high rates of 
morbidity, namely high intra-operative blood loss and bile duct injury with an unacceptable 
incidence in excess of 5%(72). Many centres, therefore, continued to endorse open 
cholecystectomy or delayed laparoscopic cholecystectomy (DLC) for this subgroup of 
patients.  
Emergency or “index admission” laparoscopic cholecystectomy (IALC) for acute cholecystitis 
is now the gold-standard treatment. NICE (National Institute for Healthcare Clinical 
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Excellence) recommends hospital trusts “offer early laparoscopic cholecystectomy (to be 
carried out within 1 week of diagnosis) to people with acute cholecystitis”(63). Multiple 
comparative studies have confirmed IALC to be cost-efficient, costing £4,570 compared to 
£4,720 for DLC(77) and dismissed early concerns around higher rates of bile duct injury and 
open conversion(78,79).  
Importantly, there is marked patient morbidity in the delayed group with almost 20% of patients 
waiting for a DLC representing in the interim. Of those who re-present, 30% will have biliary 
obstruction or gallstone pancreatitis(77,80). Despite this, only 54.8% of patients presenting 
with acute cholecystitis to UK hospitals receive an IALC. The varies between UK hospitals 
(26% to 52.7%)(81,82). The rate of IALC variables considerably crossed the developed world. 
In Singapore, around 67% of patients receive surgery within 7 days of presentation(83), 
whereas in Australia rates of IALC are as high as 89.9% in large urban centres(84). 
 
Bile Duct Injury (BDI) during Laparoscopic Cholecystectomy  
Bile Duct Injury  
The most feared complication of laparoscopic or open cholecystectomy is a bile duct injury 
(BDI). The implications can be catastrophic, with a significant mortality and morbidity for the 
patient and medico-legal ramifications for the surgeon and hospital trust involved(85–89). 
Many years after the bile duct injury, patients can continue to suffer physical and psychological 
complications. These often have a severely negative impact on their overall quality of life(90).  
Prior to the introduction of laparoscopic cholecystectomy surgery into standard care in the 
early 1990s, the overall bile duct injury rate for open cholecystectomy surgery was low at 0.2% 
to 0.32%(91,92). Thereafter, the incidence of iatrogenic bile duct injury reported in the 
literature has varied greatly. Earlier case series encompassing the “learning curve” period, 
quote higher rates than more recent series from experienced hepatobiliary centres. The 
largest early US series, retrospectively analysing 1,570,361 laparoscopic cholecystectomies 
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performed between 1992 and 1999, found an overall incidence of bile duct injury of 0.5%(87). 
Strasberg et al’s review of bile duct injury during laparoscopic cholecystectomy published in 
1995 also estimates the incidence at 0.52%(91) and Deziel et al from 1993 quotes a similar 
figure of 0.6%(93).  
In the early years of laparoscopic cholecystectomy associated bile duct injury, 26% of patients 
who sustained an injury died within one year of the event, compared to only 6.6% of the 
uncomplicated group. Even when considering independent risk factors, the adjusted hazard 
ratio (HR) for mortality was 2.8 for the bile duct injury cohort(85). Large European studies from 
the same period report similar rates of bile duct injury; Italy 0.42%(94), Sweden 0.40%(95), 
Switzerland 0.3%(96) and Buanes et al’s Norwegian national review of cholecystectomies 
performed in the early 1990s reported a higher bile duct injury incidence of 0.8%(97).  
Iatrogenic bile duct injury should be considered preventable. Multiple mechanisms and errors 
contribute to its occurrence. It remains debatable to what extent lack of technical skill, 
perception error, or combinations of these factors are the key underlying cause of bile duct 
injury. Misidentification of the CD is a recurring theme in retrospective analyses(91). Way et 
al estimate that just 3% of bile duct injury are due to a true lack of technical ability(98). They 
analysed 252 bile duct injury cases, regardless of the extent and grade of bile duct injury 
sustained and found the underlying cause in most cases was the surgeon mistaking an 
extrahepatic duct for the CD. The surgeon persistently continued to interpret the operative 
image to fit with their perception of the anatomy and disregarded any information that 
contradicted their perception. However, previous studies attribute far more blame to the 
technical skill of the surgeon. Nuzzo et al, attributed “improper use of monopolar coagulation” 
and an inability to achieve early haemostasis as the primary mechanism of bile duct injury in 
nearly 20% of reported cases(94). 
The argument for lack of technical skill as a primary cause of bile duct injury is validated by 
the trend of bile duct injuries rates being higher in surgeons inexperienced in laparoscopic 
cholecystectomy surgery, in junior surgeons, and in centres with low volume case-load(99). 
38 
  
Name: Gemma Armstrong  
Student No: 201073014 
Sarli et al compared 200 patients from a single centre who underwent laparoscopic 
cholecystectomy early on the learning curve in 1991 to 1992 to a matched cohort from 1995 
to 1996 and reported an overall reduction in all operative complications including bile duct 
injury from 9% to 2.5% (p<0.01). The Relative Risk (RR) of complications was also far higher 
with open compared to laparoscopic cholecystectomy (RR 5.4; p=0.0007)(100). In recent 
years, the procedure of single-incision cholecystectomy has emerged and gained momentum. 
Performed relatively infrequency, and mostly by surgeons relatively early on the learning curve 
with this new technique, it carries a worryingly high rate of bile duct injury of 0.72%(101). This 
adds further support to the “learning curve” theory of bile duct injury in any form of minimally 
invasive hepatobiliary surgery.  
The safety of laparoscopic cholecystectomy surgery has dramatically improved since the early 
days of minimally invasive surgery. UK centres that limit laparoscopic cholecystectomy 
surgery to surgeons who have a declared interest in upper gastrointestinal surgery and/or 
minimally invasive hepatobiliary surgery report extremely low rates of open conversion and 
bile duct injury; 3.0-3.8% and 0.1% respectively(81,102,103). High-volume American centres 
also report a bile duct injury incidence of around 0.08% in their most recent published 
data(104).  
 
Medico-Legal Implications of Iatrogenic Bile Duct Injuries  
Aside from the mortality and morbidity associated with bile duct injury there is also a significant 
medico-legal burden for the surgeon and hospital trust. In our litigious society, patients are 
more likely to bring successful legal cases against a trust when they are the victim of any 
perceived avoidable compilation or medical negligence. Surgeons are most at risk of litigation 
when performing laparoscopic cholecystectomy compared to any other general surgical 
procedure(88). In the UK, all legal cases of alleged clinical negligence are processed via the 
NHS Litigation Authority (NHSLA). Between 1995 and 2009, 418 cases of alleged medical 
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negligence emanating from laparoscopic cholecystectomy in the NHS were considered, with 
303 cases settled, and 179 of cases related to bile duct injury. Cases of bile duct injury had 
the highest success rate (77.9%) of all laparoscopic cholecystectomy litigation cases, and 
commanded one of the highest average payments at £114,324 per case(86). In the United 
States, average settlements for clinical negligence relating to laparoscopic cholecystectomy 
can be four times higher than in the UK(89).  
The management of bile duct injury is also vitally important to the likelihood of ligation being 
brought against a surgeon and the case being upheld. Roy et al’s review of bile duct injury 
cases brought to the NHSLA between 2000 and 2005 found “only half of claims for injuries 
that had been recognised promptly were successful”, compared to 90% of cases where the 
bile duct injury was recognised late(88,89). A late diagnosis of bile duct injury also resulted in 
a higher average financial settlement. In the Netherlands, patients diagnosed with bile duct 
injury more than seven days after initial surgery received on average 2.4 times higher pay-out 
from their ligation case than those diagnosed within one week(85). In the UK, the difference 
in financial settlement between early and late diagnosis is roughly 3.6 times(88).  
 
Critical View of Safety and Protocol Directed Laparoscopic 
Cholecystectomy Surgery 
Strasberg proposed the “critical view of safety” (CVS) in laparoscopic cholecystectomy in 
1995(91) (Figure 5). Since 2006, the Dutch Society of Surgery has demanded all teaching 
hospitals in the Netherlands produce an institution-specific laparoscopic cholecystectomy 
protocol in accordance with their best practice guidelines. This mandates the CVS must be 
recorded photographically prior to transection of the CD and CA(105).  Over 97% of Dutch 
surgeons self-report establishing and confirming the CVS as their usual and preferred method 
of performing laparoscopic cholecystectomy(106).  
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The consensus report from the European Association of Endoscopic Surgery (EAES) also 
recommends a modified surgical technique very similar to Strasberg’s CVS. An EAES expert 
panel recommend using an oblique 30° or 45° angled laparoscope to allow full 360° rotational 
viewing of the Common Bile Duct (CBD). They emphasise firm lateral retraction of the 
gallbladder to open up the hepatocystic triangle, cautious electrocautery near to the bile ducts, 
establishment of the CVS with only two tubular structures entering the gallbladder - the CD 
and Cystic Artery (CA)(107). Along with many expert sources, EAES recommends surgeons 
maintain a low threshold for open conversion should they be unable to safety obtain the CVS 
or encounter indeterminate anatomy that cannot be safety identified prior to ductal division. 
 
Figure 5: The critical view of safety (CVS). Adapted from Strasberg (1995)(91). 
The triangle of Calot (hepatocystic triangle) dissected free of all tissue except for the CD and 
artery with the base of the liver bed is exposed. The surgeon can safely assume the only two 
structures entering the gallbladder are the CD and CA.  
 
On-Table Cholangiogram 
Since the introduction of laparoscopic cholecystectomy, multiple strategies to reduce bile duct 
injury have been proposed and intraoperative cholangiography, often referred to as an on-
table cholangiogram (OTC), is one of the most accepted. The advantage of OTC is that it can 
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visualise both the intra and extrahepatic biliary anatomy, the presence of any ductal choleliths, 
and the flow of contrast into the duodenum. The most common reason for conducting an OTC 
is to exclude choledocholithiasis. A meta-analysis by Jamal et al found OTC yielded a pooled 
sensitivity and specificity of 87% and 98% for identification of choledocholithiasis(108). 
However, OTC can be problematic and time-consuming to perform, increasing operative 
length by around 16 to 24 minutes per case(109,110). The catheterisation process risks injury 
to the bile ducts and introduction of infection into the biliary system. The intervention also 
carries a radiation dose, both to the patient and the operating theatre staff, and utilises 
additional resources.   
Proponents of OTC argue it improves outcomes, reduces bile duct injury, and aids 
intraoperative decision making; a viewpoint not held by all laparoscopic and hepatobiliary 
surgeons. Flum et al’s retrospective review of over one and a half million laparoscopic 
cholecystectomies performed during 1992 and 1999 concluded that, regardless of patient and 
surgeon factors, the relative risk of bile duct injury was higher (RR 1.71) when OTC was 
omitted(111). Fletcher et al’s review of bile duct injury in Western Australia, from introduction 
up until 1994, demonstrated the greatest protective effect of OTC in complex biliary pathology, 
reducing the incidence of bile duct injury from 16.9 to 2.2 per 1000 for both open and 
laparoscopic cholecystectomy(112). Waage et al concluded that OTC reduced the incidence 
of bile duct injury by 34% (OR, 0.66; 95% CI, 0.54-0.79) in Sweden between 1987 and 
2001(95). This early period of laparoscopic cholecystectomy was largely experimental without 
consensus on timing or indication for surgery. It is noteworthy that many centres viewed 
complex and acute biliary disease as a contraindication to minimally invasive surgery, limiting 
access to emergency laparoscopic cholecystectomy at that time. 
Iatrogenic extrahepatic bile duct injuries are often missed by the operating surgeon. Only 18% 
- 54%(85,99,113,114) of bile duct injuries are recognised intra-operatively, and a high 
proportion are not diagnosed until after discharge from hospitall(85). There is a wealth of 
evidence that outcomes are better when the repair is performed by an experienced 
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hepatobiliary surgeon not involved in the primary surgery(114). This was first reported by 
Stewart et al in 1995 who noted only 17% (11 of 64) of repairs performed by the primary 
surgeon were successful, and not requiring any further radiological or surgical re-
intervention(98). Flum et al report that mortality was 11% higher when repair surgery was 
performed by the original operating surgeon(87).    
The most recent data available found that 24% of laparoscopic surgeons in the UK and about 
a third in the United States perform routine OTC with every laparoscopic 
cholecystectomy(115,116). In the Netherlands, where surgeons adhere to a laparoscopic 
cholecystectomy protocol incorporating the critical view of safety described by Strasberg(91), 
only 2.6% perform routine OTC(117). Preoperative deranged liver function tests and the 
clinical presentation of cholangitis are independent risk factors for choledocholithiesis(118). 
Therefore, many surgeons use selective OTC when laboratory, radiological or intraoperative 
findings raise suspicion of intraductal pathology.  
It is argued that OTC only increases intraoperative detection of bile duct injurie but does not 
reduce the actual incidence. Ludwig et al reported that routine OTC reduced the incidence of, 
and increased the rate of intra-operative bile duct injury identification, from 0.43% to 0.21% 
and from 44.5% to 87% respectively when compared to selective OTC(113). On preliminary 
analysis, Sheffield et al concurred with Ludwig et al and reported a reduction in bile duct injury 
with OTC from 0.36% to 0.21% between 2000 and 2009(99,113). However, after adjustment 
for unmeasurable cofounders, and subjecting the data to more rigorous statistical analysis, 
the difference in outcomes when using routine OTC was not statistically significant (p=0.31). 
Other retrospective analyses support this conclusion(116).  Good quality data from large 
prospective randomised controlled trials of the protective effect of OTC during 
cholecystectomy is lacking. Systematic review of four small trials found that failure to perform 
OTC did not increase the risk of bile duct injury in the elective cholecystectomy population 
(OR: 0.36; 95% CI: 0.01–8.92; p=0.53)(110).  
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Other authorities argue that OTC is not cost effective and does not reduce intraoperative 
complications. This often ignores late re-presentation with complications from missed ductal 
stones or stenosis. Khan et al disclosed four patients allocated to the control (no OTC) arm of 
their RCT presenting within one year of surgery with deranged LFTs and pain in their 
study(119). Without intraoperative imaging, the presumption was of retained ductal stones, 
which required extensive investigation that might have been avoided had OTC been 
performed. It is clear OTC has an important role in biliary anatomy mapping, identification of 
luminal cholelithiasis, and intraoperative identification of bile duct injury. However, there is not 
a clear consensus to recommend OTC in straightforward laparoscopic cholecystectomy owing 
to its increased financial cost, prolongation of operative duration, and radiation dose. A 
sensible recommendation is for OTC to be employed liberally in any complex case, where 
there is ambiguity of the anatomy, suspicion of ductal stones, stricture, or potential bile duct 
injury. OTC if often more challenging to perform in difficult and complex laparoscopic 
cholecystectomy surgery and it is these cases that are more likely to sustain bile duct injury 
or have missed ductal cholelithiasis.  
 
Near Infrared Fluorescent Cholangiography (NIR-FC) 
The technical difficulties associated with performing OTC, combined with the quest to reduce 
rates of bile duct injury, with its associated morbidity and financial ramifications, makes 
alternative strategies, such as Near Infrared Fluorescent Cholangiography (NIR-FC) with ICG, 
attractive as potential adjuvants to laparoscopic cholecystectomy. The potential to delineate 
the extrahepatic biliary anatomy with NIR-FC may aid surgeons in the accurate identification 
of biliary structures and potentially reduce the incidence of bile duct injuries. Some proponents 
of this new technology believe it may even negate the need for traditional intra-operative 
cholangiogram in certain settings. The technique is simple; patients receive a preoperative 
dose of ICG, and the fluorescent biliary anatomy is viewed with a NIR laparoscope, allowing 
dynamic real-time bile duct mapping.  
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Various teams have performed standard laparoscopic, single incision and robotic 
cholecystectomy with NIR-FC and ICG (Table 1). However, there is no consensus on dose, 
timing of administration, or clinical endpoints. The small sample sizes, and differing methods, 
mean there is a lack of comparative data. Figueiredo et al explored NIR-FC in a mouse model 
and concluded the peak intraoperative signal to noise ratio was achieved 25 minutes after 
intravenous administration(120). The first human application of ICG guided laparoscopic 
cholecystectomy was reported by Ishizawa et al in 2009 using a prototype NIR 
device(121,122). They deemed the administration of a single intravenous dose of 2.5mg ICG 
two hours prior to surgery a success and reported ease of visualisation of the CD and the 
Common Hepatic Duct (CHD).  
A small number of non-randomised, prospective NIR-FC trials have followed. A single pre-
operative intravenous bolus of 2.5mg ICG is the most popular.  Zarrinpar et al attempted to 
define the optimal dose and timing interval and refuted the consensus view that a 2.5mg dose 
is optimal in hepatobiliary surgery(123).  Although small, involving 37 patients in total, and 
including cholecystectomies and partial hepatectomies, there was a clear improvement in the 
visualisation of important extrahepatic biliary structures with higher doses of ICG administered 
at a longer pre-operative interval. Using a semi-quantitative scoring system, they suggested 
“a dose of 0.25mg/kg administered at least 45 minutes prior to visualisation facilitates 
intraoperative anatomical identification”.  This is well within the safe adult total daily dose limit 
of 5mg/kg of ICG(32).  
The exact timing of administration of ICG is also contentious and must take into consideration 
the noise to signal ratio created by background liver fluorescence. Previous studies were 
guided by the elimination properties of ICG and administered a dose prior to induction of 
anaesthesia, however this ranged from 15 minutes to more than 3 hours prior to the start of 
surgery. Verbeek attempted to define the optimal dosing regimen in open hepatic surgery prior 
to application in laparoscopic cholecystectomy(124). Pushing the limits of ICG detectable 
fluorescence, they proposed 10mg administered 24 hours prior to cholecystectomy as the 
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optimal dose. They reported far lower liver background signal and therefore greater contrast 
between the liver and the CBD and favourable navigation for the operating surgeon with 
prolonged dosing. However, in a surgical setting, where most laparoscopic cholecystectomies 
are performed on a day-case basis, the feasibility of administering intravenous ICG the day 
before surgery is questionable. Zarrinpar et al observed improved contrast between the liver, 
bile ducts, and fat with prolonged dosing (3 hours), but compromised to a more achievable 45 
minutes with the addition of a higher ICG dose to compensate(123).  
A major drawback of NIR-FC is its limited depth of tissue penetration, somewhere in the region 
of 5 to 10mm. In the UK in 2019, 67% of men and 60% of woman in the England were 
considered overweight or obese(125). This figure continues to rise and is higher than when 
laparoscopic cholecystectomy was first introduced into NHS surgical practice. Operating on 
patients with a high Body Mass Index (BMI), and therefore large volumes of intraabdominal 
adipose tissue, is now a common occurrence and poses its own challenges. Japanese and 
American teams piloting NIR-FC have attempted to explore the effect of obesity on 
extrahepatic ductal visualisation. Osayi et al used a single ICG dose of 2.5mg in total in their 
USA based study – they only visualise the CBD in 64% of patients with a BMI over 35kg/m2 
and in one super morbidly obese patient with a BMI of 63kg/m2 the CD was the only structure 
detected with NIR-FC(126).  
Other teams reported similar difficulties with NIR-FC in the overweight or obese patient, 
including the need for extensive dissection in Calot’s triangle to achieve any visualisation and 
a longer operative time(127,128). Kono et al contradicts this view, stating “BMI had no 
predictive value for detection” of the CD and CBD confluence(127), although the median BMI 
was only 23.5kg/m2 in Kono et al’s study, as compared to a mean 31.49kg/m2 in Osayi et al’s 
later USA based publication(126). In other fields of NIRF surgery using ICG as the fluorophore, 
high BMI was found to adversely affected structure visualisation. Jewel et al found the median 
BMI of patients with unmapped SLN in endometrial cancer was 41.2kg/m2 versus only 
30.1kg/m2 (p = 0.01) in the mapped group(129). The inflammatory process underling 
46 
  
Name: Gemma Armstrong  
Student No: 201073014 
cholecystitis and gallstone pancreatitis further compounds the difficulties of using NIR-FC in a 
population with endemic levels of obesity. The characteristic pathological processes of 
pericholecystic and peri-hilar inflammation and tissue oedema leads to thickening of the 
gallbladder wall and inflammatory exudate in the surrounding tissues, which all increase the 
tissue density and depth between fluorescent structures and the laparoscopic camera, 
reducing the diagnostic yield of NIR-FC.   
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Procedure Dose (mg) 
Pre-operative ICG dosing interval 
(1. as per methodology and 2. 
Actual dosing interval) 
Mode of 
admission 






2.  n/a 
Elective 
Buchs(131) Switzerland 2013 23 
Robotic single site 
cholecystectomy 
2.5 
1. “30-45min” pre-op. 
2. n/a  
Elective 
Osayi(126) USA 2015 82 LC 2.5 
1. n/a 
2. Mean 73.8±26.4m to incision 
Elective 




1. 1-2 h pre-op 
2. n/a 
Elective 
Boni(132) Italy 2015 52 LC 0.4mg/kg 
1. n/a  




Schols(133) Netherlands 2013 15 LC 2.5 
1. n/a 
2. Mean 33m (range 19-67m) 
To 1st visualisation 
Elective 
Daskalaki(134) USA 2014 184 
Robotic LC 
(112 multiport & 72 






Spinoglio(135) Italy 2013 45 Robotic single port 2.5 
1. 45m  
2. n/a 
Elective 
Igami(136) Japan 2016 21 Single incision LC 2.5 
1. n/a 
2. 39m±4 (to 1st incision) 
Elective 
Ishizawa(137) Japan 2011 7 Single incision LC 2.5 
1.  
2. 35 – 75m prior  
(to 1st visualisation) 
Elective 
Ishizawa(40) Japan 2009 1 LC 2.5 1. 2 h “pre-operatively” Elective 
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2. n/a 
Kono(127) Japan 2015 108 LC 2.5 
1. n/a 
2. Median 90m (range 15 -165m) 
Elective & 
Acute 
Ishizawa(138) Japan 2010 52 LC 2.5 
1. n/a 
2. 110m mean (range 35 -165m) to 
1st incision 
Elective 
Zarrinpar(123) USA 2016 37 
LC (13)  
open 
cholecystectomy (1)  
laparoscopic bile 
duct exploration (2) 
laparoscopic partial 
liver resection (6) 






2. 3 groups 
a) 10m±3m,  
b) 45m±15m 
c)  3h±1h 
Elective & 
acute 
Table 1: Summary of NIR-FC with ICG cholecystectomy clinical trials. Abbreviations: Minute (m), hour (h) 
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1.3  Laparoscopic Colon Cancer Resection and EMI-137 
Colorectal Cancer 
Colorectal cancer (CRC) is the fourth most common cancer in the UK, with 42,000 new cases 
diagnosed in each year between 2014 and 2016(139). The incidence of CRC is strongly 
related to age, with 44% of cases diagnosed in those aged 75 and over(139). CRC continues 
to be the second highest cause of cancer related mortality in the UK. It accounts for 10% of 
all cancer related deaths - over 16000 UK deaths were attributed to CRC in 2016. This figure 
is greater in the most deprived social groups. CRC mortality is 30% higher in males from the 
poorest areas than in their age-standardised counterparts from the least deprived areas. CRC 
poses a significant disease burden, with the NHS continuing to see a year on year rise in 
cases, often in an older population with significant co-morbidities(139).  
The anatomical distribution of CRC varies slightly between genders and with age.  However, 
more than 65% of tumours are in the colon. There is a left-sided predominance, with over 30% 
of CRC seen in the rectum/rectosigmoid junction and a further quarter in the sigmoid colon up 
to the splenic flexure(140). 
 
Figure 6: Anatomical distribution of primary colorectal cancer by percentage. Adapted from 
Cancer Research UK (2016)(140). 
Average calculated from yearly total between 2012 and 2014 inclusive. Average total 
number of patients analysed 23,282 male and 18,317 female.  
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Survival rates in CRC are strongly correlated to the stage of disease at diagnosis. One-year 
survival data from 2012 shows 98% of patients presenting with stage I disease were alive after 
one year compared to only 46% with stage IV disease(141). Long-term survival can usually 
only be achieved with curative resection. This involves segmental colectomy and en-bloc 
resection of the draining lymph node field. Currently, there is significant variance of opinion 
regarding the necessary radicality of resection and, in particular, the extent of 
lymphadenectomy(142). Despite oncological advancements, locoregional recurrence remains 
a significant problem in colon cancer; the incidence of local recurrence at 5 years is reported 
to range between 6.1 and 11.5%(143,144).  
 
National Screening 
In 2006, the National Bowel Cancer Screening Program was introduced into the NHS in 
England(145). In England, all patients aged 60 to 74 years are invited to undertake screening 
every two years. The original system used Faecal Occult Blood Test (FOBT) home screening 
kits, but this was changed to the more sensitive Faecal Immunochemical Test (FIT) system in 
2018(146). Those with a positive FOBT or FIT result are offered further investigation. In 2017, 
one-off flexible sigmoidoscopy screening for adults aged 55 was also rolled out in England to 
further aid detection of early cancer and pre-cancerous colorectal polyps(146,147). Since the 
introduction of national screening more than 25000 cases of bowel cancer have been 
diagnosed.  
Ten-year longitudinal data from Scotland and Wales, where FOBT screening was introduced 
in 2003 for 50 to 74 years old, shows a statically significant change in both detection rates and 
the stage at presentation. FOBT screening detected 18% of CRCs and reduced emergency 
presentations from 20 to 13%(145). Importantly, the introduction of screening has led to an 
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increase in the early detection of CRC. The percentage total of stage I CRC detected rose 
from 17% in the pre-screening to 28% in the post-screening era(63,145,148).  
Evidence for the introduction of sigmoidoscopy comes from the long term follow-up data from 
Atkin et al’s randomised controlled trial of flexible sigmoidoscopy screening for UK adults aged 
55 to 64(147). With a median follow-up of 17 years, the incidence of colorectal cancer was 
reduced by 26% (Hazard Ratio (HR) 0·74 [95% CI 0·70–0·80]; p = <0·0001) and the cancer-
specific mortality was reduced by 30% (0·70 [0·62–0·79]; p = <0·0001) in the intervention 
group versus the control group respectively with screening.   
 
Surgical Resection Strategies 
To maximise the chances of oncological clearance and therefore long-term disease-free 
survival, the colon cancer needs to be removed with clear surgical margins and along with the 
draining lymphatic basin. The lymph nodes are divided into three tiers: tier I nodes are next to 
the bowel lumen (D1), tier II are contained within the mesentery along the supplying segmental 
artery (D2), and tier III are in close proximity the origin of the segmental vessels (D3). 
Resection of twelve or more lymph nodes is recommended for accurate histological 
assessment and staging(149). 
Loco-regional recurrence following cancer surgery occurs due to residual cancer cells left 
behind at surgery, either due to inadequate resection or intraperitoneal dissemination. 
Although distant metastases is the more common pattern of disease recurrence in colon 
cancer, locoregional recurrence remains a significant problem. The incidence of local 
recurrence at 5 years is reported to range between 6.1 -11.5%(143,144). Despite this, it has 
not been the focus of research in the same way as in rectal cancer. Liska et al found the 
median time interval to locoregional recurrence in colon cancer was 21 months post-surgery 
and, half of cases occurred in the presence of distant metastases(150). For patients with stage 
III disease at diagnosis, 8.6% developed locoregional recurrence (HR10.8, [95% CI 2.6–
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45.8]). The ability to accurately determine pre-operative stage and achieve adequate 
oncological resection is vitally important to long-term survival.  
 
Laparoscopic Colectomy Surgery  
Laparoscopic colectomy for colonic cancer was first trialed in the early 1990s(151).  Thorough 
evaluation of the technique followed; trials such as the Medical Research Council (MRC) 
CLASICC (Conventional versus Laparoscopic-Assisted Surgery in Colorectal Cancer; Clinical 
Trial Number ISRCTN 74883561) dismissed concerns regarding increased rates of port-site 
recurrence and inferior lymph node yields(152,153). Today, laparoscopic colectomy is the 
preferred elective approach for colorectal cancer resections in most centres(152,154,155). 
There are several advantages of laparoscopic as compared to open surgery, including quicker 
patient recovery, fewer complications, and shorter hospital stay(155,156). Initially, operation 
length was around a third longer with laparoscopic surgery. However, as colorectal surgeons 
have become more experienced in laparoscopic surgery this difference has been reduced. 
 
Complete Mesocolic Excision (CME) 
Whilst survival rates in rectal cancer have significantly improved in recent years, the rates for 
colon cancer have been less marked. The improved survival seen in rectal cancer is attributed 
to the introduction of a standardised approach for low and middle rectal cancers, referred to 
as Total Mesorectal Excision (TME), along with more sophisticated preoperative imaging, 
(chemo)radiotherapy and better histopathological assessment. TME requires meticulous 
dissection of the mesorectum along the mesorectal fascial plane to remove the cancer in its 
contained embryological fascial envelope(157,158). 
The same logic is being applied to colonic cancer in an attempt to improve survival(159), with 
the concept of Complete Mesocolic Excision (CME) and D3 lymphadenectomy. CME can be 
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performed open or laparoscopically and involves dissection of the mesocolon as an intact 
“package”. D3 lymphadenectomy refers to central ligation of the feeding vessels at their origin 
and adequate segmental colectomy to maximise lymph node clearance, both in the vertical 
and longitudinal direction(142,160,161). Several case series have shown CME with D3 
lymphadenectomy to produce higher lymph node yields with a reduction in locoregional 
recurrence rates. In a recent Danish non-randomised population study, the cumulative 4-year 
disease-free survival for stages I-III was 85·8% after CME as compared to 73·4% after non-
CME surgery (log-rank p=0·001). Specifically, for the stage III cohort, the difference in survival 
was 73·5% compared to 67·5% (HR 0·64 [CI 0·42–1·00])(161). This compliments the low local 
recurrence rate of 3.6% described by Hohenberger et al in their 2009 prospective study of 
CME(142). 
CME with D3 lymphadenectomy may be beneficial in patients with lymph node involvement, 
however this patient cohort is the minority. In 2017, 24% of CRC cases in patients aged 60-
74, and therefore eligible for screening, were diagnosed via the National Bowel Cancer 
Screening Programme(162). The majority of these were early cancers, with 78.7% of cases 
being lymph node negative (N0 status) at diagnosis(148). CME with D3 lymphadenectomy 
carries the risk of greater morbidity, meaning that patients without lymph node disease will be 
subjected to increased surgical risk without proven benefit. A selective approach is therefore 
required whereby patients with lymph node disease are offered radical CME with D3 
lymphadenectomy, accepting a potential increased morbidity, whilst patients without lymph 
node disease undergo a less radical CME with D2 resection, with no compromise to their 
oncological outcome. This requires a means of accurately identifying lymph node status either 
preoperatively or intraoperatively. Currently, preoperative radiological staging in colon cancer 
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Colorimetric Dye 
A drawback of laparoscopic surgery is the lack of tactile feedback from the laparoscopic 
instruments, which can make accurate localisation of the site of a colon cancer difficult. To aid 
intra-operative identification of a colonic tumour, it is standard practice to preoperatively mark 
the site with a colorimetric dye (India ink) at colonoscopy. Although luminal tattooing is 
inexpensive and quick to perform at colonoscopy, it is operator dependent and often 
imprecise.  
Several studies have assessed the efficacy and safety of luminal tattooing. The most common 
complication is transmural inoculation and intraperitoneal spillage. A meta-analysis by Acuna 
et al found luminal tattooing at colonoscopy still had a localisation error rate of 9.5%(163). 
Free India ink staining of the peritoneal cavity and adjacent viscera negates the diagnostic 
yield and can cause localised inflammation. This can obscure the plane of dissection and 
cause adhesions. Conversely, if the inoculation is too superficial it might not be visible at 
laparoscopy, necessitating further intra-operative colonoscopy. There is also a small risk of 
serious complications, in particular, abscess formation and bowel perforation with localised 
peritonitis with colonoscopy and luminal tattooing(163–165). The need for accurate intra-
operative identification of colonic cancers, and the limitations of colorimetric tattooing, has 
driven the search for a real-time intraoperative method for cancer localisation.  
 
Lymph Node Staging in Colon Cancer 
Although Computed Tomography (CT) scanning is used for preoperative staging and 
operative planning, it lacks the required sensitivity and specificity in colonic cancer to inform 
accurate planning of the radicality of surgery. Whilst MRI is now commonly used in the pre-
operative staging of rectal cancer, movement artefact prohibits its application in colonic cancer 
staging. The FOxTROT pilot study (clinical trial number ISRCTN number 87163246), led by 
the University of Birmingham, found that CT only accurately discriminated tumour stage, T3 
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from T4 cancers in 47% of cases. CT lacks the required specificity and overestimates disease 
spread. Only 56% of cases classified as radiologically node-positive were confirmed node-
positive on pathological assessment, whilst only 48% were correctly identified as having 
extramural vascular invasion on both CT scan and at final pathology assessment(166). There 
is no validated method for determining if a lymph node contains cancer on pre-operative CT. 
The clinical experience of the radiologist and several imaging characteristics are used to 
assess the probability of lymph node metastasis, but there remains a subjective element to 
this assessment.   
Rollvén et al found common criteria such as node size greater than 5mm, when examined in 
isolation, had a specificity of 31% and positive predictive value of 39% (p = 0.002) in predicting 
stage 3 colon cancer(167). More definitive CT characteristics, such as internal node 
heterogeneity (specificity 84%; positive predictive value 74% and OR  20.0 p = <0.001) and 
irregular node boarder (specificity 81%; positive predictive value 61% and OR 6.23 p = 
<0.001), were more useful, but were present in relative few of the patients analysed and still 
did not show complete concordance with final pathological stage.  
 
Sentinel Lymph Node Mapping in Colon Cancer Surgery  
Sentinel lymph node (SLN) mapping has become part of standard care in the treatment and 
staging of many solid organ tumours. Breast cancer, for example, often behaves in a 
predictable progressive manner. Micro-metastases spread in a logical stepwise sequence to 
the nearest draining lymph node chain. In resection of breast cancer, if the closest draining 
lymph node is free of cancer, then it can be safely assumed the patient is node negative and 
avoid the morbidity associated with radial en-bloc lymph node dissection. However, trials of 
colon cancer SLN mapping have not produced the same level of accuracy and improved 
clinical outcomes. Bertagnolli et al found that for “patients with node-positive colon cancer 
sentinel lymph node examination failed to predict nodal status in 54% of cases”(168). This 
56 
  
Name: Gemma Armstrong  
Student No: 201073014 
high false negative rate was reproduced in other similar studies in colon cancer(169). This 
relates to the unpredictable metastatic pattern of colon cancer. Tan et al identified the first 
metastatic lymph node directly below the tumour in only 52% of colon cancer cases 
analysed(170). For 18% of cases, the pattern of metastasis was highly unpredictable and 
skipped the pericolic nodes entirely; the first metastatic node was detected more than 5cm 
away from the primary tumour site. No predictive factors for site of lymph node micro-
metastases were identified(170).  
The unpredictable behaviour of colon cancer lymph node metastases, and the propensity to 
skip the adjacent draining lymph node basin, limits the adoption of SLN mapping techniques. 
SLN mapping in its current form would under-stage a high proportion of patients, resulting in 
undertreatment of the cancer. An alternative method of identifying metastatic lymph nodes 
within the regional lymphatic basin is required.  
 
Fluorescence Guided Colorectal Tumour and Lymph Node Mapping 
Intra-Operatively 
Laparoscopic surgery is now the standard approach for the resection of many gastrointestinal 
and intra-abdominal malignancies. This minimally invasive approach involves the introduction 
of a narrow rigid laparoscope, with a built-in light, into the abdominal cavity. 
Pneumoperitoneum is established with the insufflation of carbon dioxide gas and the 
necessary operative instruments are introduced via strategically sited ports in the abdominal 
wall.  
Laparoscopic surgery naturally lends itself to the concept of integrated fluorescence guided 
surgery. The standard white light laparoscope and light source used can be adapted to emit 
narrow specific wavelengths of light and used to excite and detect small molecule fluorophores 
during surgery. This combination creates a myriad of potential opportunities for using 
fluorescence to improve tumour localisation, lymph node mapping, and perfusion assessment. 
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Although in its infancy, fluorescence guided surgery could utilise many untargeted 
fluorophores and will no doubt drive the development of more sophisticated molecules 
including novel targeted fluorophores. The ability to couple a cancer specific targeted peptide 
to a safe fluorophore has the potential to increase the accuracy of resectional surgery and 
facilitate patient individualised surgery where radicality is tailored to the cancer location and 
biology.  
 
Fluorescence Guided Tumour Detection  
The GLiStEN (Next Generation intraoperative Lymph node staging for Stratified colon cancer 
surgery - Developmental phase; Clinical Trial Number ISRCTN79949827)(171,172) clinical 
trial led by Professor D. Jayne at the University of Leeds, used the oral administration of 5-
aminolevulinic acid (5-ALA) to map metastatic lymph nodes in patients with stage III colon 
cancer.  
Protoporphyrin IX (PpIX) is a naturally occurring protein found in nearly all human cells. The 
delta amino acid 5-ALA is taken up by mitochondria and converted to the intermediate 
Protoporphyrin IX (PpIX). It is then chelated with iron by the enzyme ferrochelatase to form 
heme in the heme synthesis pathway. Aminolevulinic acid is a pro-drug to the photosensitive 
protein PpIX. Light in the blue-violet bandwidth (wavelength 405nm) excites PpIX and it emits 
a red fluorescent signal (wavelength 630 to 700 nm)(171–173). Tumour cells of epithelial or 
mesenchymal origin preferentially uptake exogenous 5-ALA and convert it to the fluorescent 
PpIX. This can be detected with intraoperative fluorescent imaging devices and creates a 
marked signal to noise gradient in malignant and normal tissue.  
Multiple studies have shown 5-ALA to be beneficial in the resection of primary and recurrent 
high-grade glioma brain tumours. The positive predictive value of intra-operative 5-ALA guided 
fluorescence in pathological areas of known recurrent glioma is reported at over 97% and for 
fluorescence in non-pathological areas up to 80%. The Food and Drug Administration (FDA) 
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in the USA approved 5-ALA for the intraoperative mapping of high grade gliomas in 
2017(174,175). However, the GLiStEN trial failed to show similar results in colon cancer. 
Participants suffered photosensitive skin rashes post-operatively and the high false negative 
rate led to early termination of the trial(176).  
 
Peptide Targeted Intra-Operative Fluorescent Imaging 
Previous studies of fluorescent guided cancer surgery, such as GLiStEN and those using ICG, 
have all used untargeted fluorophores for intraoperative imaging. Advances in molecular 
chemistry have introduced the possibility to conjugate a fluorescent tag to a cancer specific 
targeted molecule. An interesting example of this evolving technology was published by 
Hoogstins et al in 2016(177). They explored a compound called OTL38, a folate receptor alpha 
(FRa) ligand coupled to a NIR fluorescent dye (excitation at 776 nm, emission at 796 nm), in 
a small randomised controlled trial of 12 patients undergoing open cytoreductive surgery in 
ovarian cancer. The administration of OTL38 increased the yield of true positive metastatic 
lesions by 29%; 18 of the 62 lesions were invisible in white light assessment. This exploratory 
work demonstrates the value of these new fluorescent agents and the potential for 
individualised fluorescent-guided abdominal cancer resection surgery.  
 
Hepatocyte Growth Factor and c-Met  
Hepatocyte Growth Factor (HGF) 
The remarkable properties of the liver to regenerate after injury, and its ability to facilitate live-
donor transplantation, has been of great interest for decades, but the exact mechanism 
remained elusive until relatively recently. Nakamara et al extracted a powerful hepatrophic 
stimulator of rat liver regeneration from platelets in the 1980s and termed it Hepatocyte Growth 
Factor (HGF)(178,179). Soon after, HGF was purified from the serum of patients with fulminant 
liver failure(180) and those who had undergone partial hepatectomy(181,182). It was quickly 
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established that HGF was indistinguishable to “Scatter Factor” (SF); a potent stimulator of 
epithelial cell motility extracted from normal human embryo fibroblasts described by Stoker et 
al. In vitro studies showed SF to be a potent driver of immature epithelial cell motility and 
conversion to a more motile phenotype in the absence of a chemotactic agent(183–185). 
Weidner et al quickly discredited Stoker et al’s observation of “no scatter factor is released 
from cancer cell lines…nor are such lines responsive to the factor”(186). They showed SF to 
be a significant stimulator of tumour cell line invasiveness and therefore metastasis. The 
HGF/SF protein increased cell motility and could scatter a sheet of continuous cells, hence 
the name Scatter Factor. It was quickly established that HGF/SF played an important role in 
a diverse range of cell-to-cell interactions(183,184,187).  
HGF is the only known endogenous ligand of the c-Met transmembrane receptor. HGF is 
secreted as an inactive polypeptide and cleaved to its active form by serum protein kinases. 
The gene for human HGF is encoded by chromosome 7q21. Active HGF is a large heterodimer 
molecule consisting of a 69kDa alpha-subunit bound to a 34kDa beta-subunit(188). The free 
amine group N terminus of the alpha subunit contains the c-Met binding domain and the beta 
subunit directly actives the c-Met protein with associated downstream tyrosine kinase 
activation cascade(189). The HGF protein is produced by cells of mesenchymal origin and 
acts in a paracrine fashion. HGF was the first distinct member of the plasminogen-related 
growth factor family to be identified(190). Although its domain structure and mechanism of 
activation resemble those of the blood protease plasminogen, it lacks protease activity(191).  
 
c-Met 
The cellular mesenchymal-epithelial transition (c-Met) receptor is the only known target for the 
endogenous HGF ligand. In 1984, Cooper et al discovered the epithelial cell line transforming 
properties of carcinogen treated human osteosarcoma cells and mapped the Met proto-
oncogene locus, but were unable to establish it’s activating protein(192). It was the work of 
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Bottaro et al that linked HGF to the c-Met receptor in 1991(193). Encoded by the 21 exon MET 
gene on chromosome 7q21 -31, the c-Met receptor consists of a 50kD extracellular alpha unit 
with three functional domains linked to a large 145kD beta unit with both extracellular, 
transmembrane and intracellular domains with tyrosine kinase phosphorylation activity via a 
disulphide bridge(193–195). HGF has a high affinity for the c-Met receptor, but only binding of 
the β unit of the HGF ligand can activate cellular pathways. Dimerisation of the c-Met receptor 
leads to autophosphorylation of the tyrosine residues Tyr1349 and Try1356(191,194). The 
conformational change at the multi-function docking site leads to recruitment of several 
adapter and intermediate molecules. Activation of Gab1 and Grb2 via tyrosine phosphorylation 
is crucial to downstream kinetic pathway activation and recruitment including phosphoinositide 
3-kinases PI3K, rat sarcoma (Ras), and extracellular signal regulated kinas (ERK) activation, 
promoting the mitogenic and morphogenic properties of c-Met-HGF complex coupling(191). 
A wealth of evidence has developed around the multitude of biological applications of the 
HGF/c-Met pathway in recent years. HGF is vital to embryogenesis and for cell development 
and migration in adult life. HGF is a potent mitogen and morphogen. The importance of 
functioning HGF and receptor c-Met in organogenesis has been demonstrated mainly by 
knock-out studies. In embryogenesis, complete knock-out is always fatal. Homozygous HGF 
null mutated mice embryos show severely restricted hepatic development, in part because the 
anti-apoptotic function of HGF/c-Met is lost195. There is also poor trophoblast migration into 
the placenta and vascularisation. The migration stimulating properties are also vital for limb 
bud and central nervous system development. The homozygous state of HGF/c-Met mutation 
is always incompatible with life(196,197).  
HGF/c-Met function is not just a regulator of organogenesis, with HGF/c-met pathways being 
vital for adult tissue regeneration and proliferation. Acquired c-Met/HGF dysfunction impairs 
epithelialisation and therefore wound healing and allows sustained, unregulated proliferation 
of cells to occur. The overexpression and/or upregulation of the c-met receptor protein has 
been demonstrated in the stroma of several malignancies. The complex tumour and metastatic 
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microenvironment is composed of multiple cellular and acellular components. The abundant 
Cancer Associated Fibroblasts (CAFs) in the tumour microenvironment, secretes several 
soluble factors and activates the HGF/c-Met pathway through the direct release of HGF or by 
the indirect stimulation of resident cancer cells to secrete HGF via the release of intermediately 
pro-inflammatory cytokines and interleukins, such as IL-6, prostaglandins or Platelet Derived 
Growth Factor (PDGF-β). This upregulation promotes infiltration of immune cells and de novo 
angiogenesis(198,199). There is both autocrine and paracrine activation of the pathway. 
Dysregulation of the c-met pathway is seen as a crucial step in angiogenesis and proliferation 
in colorectal and other cancers(182,188,200,201). In addition, tumour hypoxia induces 
increased c-Met RNA transcription and overexpression of c-Met protein. This adaptive 
response gives malignant cells a survival benefit in the hypoxic tumour microenvironment. It 
may also produce resistance to anti-cancer therapies, especially those that rely on the 
generation of reactive oxygen species for their therapeutic effect(202).  
 
c-Met in Colorectal Cancer 
Expression of the c-Met receptor by colorectal cancer is known to correlate with adverse 
tumour characteristics and invasiveness(203–205). Levels of c-Met protein, c-Met rRNA, and 
its ligand HGF are often elevated in metastatic colorectal cancer(205) Experimental 
suppression of c-Met transcription attenuates the migratory and invasive properties of parent 
and invasive CRC cell lines in culture(206). Meta-analysis by Liu et al confirmed that high c-
Met expression in colorectal tumours was linked to worse overall survival (HR 1.41 [95% CI 
1.08-1.74])(207). Takeuchi et al, found that the level of c-Met expressed in CRC specimens 
directly correlated with tumour T stage (p =0.0005) and lymph node status (p=0.06)(208), 
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Mutations of the c-Met protein do not act in insolation; they interact with other well-described 
steps in the adenoma-adenocarcinoma mutation pathogenic sequence(209) and alter the 
tumour microenvironment. Mutated p53 is observed in a significant proportion of colorectal 
cancers. Normal function of this gene and its protein is vital for tumour suppression; p53 
regulates DNA repair, cell cycle arrest and apoptosis. Genomic instability in the p53 gene 
leads to unregulated cellular proliferation and uninhibited maturation of abnormal 
cells(210,211).  
The tumorigenic effects of c-Met are amplified in the presence of inactivated p53 tumour 
suppressor function. Muller et al have demonstrated increased intracellular phosphorylation 
of c-Met and increased sensitivity to HGF stimulation in the presence of p53 mutation(212). 
Increased downstream signaling leads to enhanced cell migration and invasiveness. This 
research confirms that c-Met activation in CRC can act in an autocrine manner and in synergic 
amplification with other known tumorigenic pathways(210). c-Met amplification drives tumour 
development and resistance to biologic therapies via crosstalk with other tyrosine kinase 
pathways. C-Met amplification confers resistance to Epidermal Growth Factor Receptor 
(EGFR) agents in metastatic CRC and reduced disease-free survival(213,214). 
The evolving knowledge of c-Met and its role in neoplastic growth and metastases makes it 
an exciting diagnostic and therapeutic target in gastrointestinal cancer, including colorectal 
cancer. The small molecule monoclonal antibody to HGF, Rilotumumab, has been explored 
in early phase clinical trials. Iveson et al assessed Rilotumumab in unresectable gastric and 
oesophageal junction cancer (Clinical Trials Number NCT00719550). The early phase IIa 
study of Rilotumumab with conventional chemotherapy marginally increased the progression 
free survival interval with an acceptable adverse event profile compared to the placebo 
arm(215). However, the follow-up phase III ROLIMET-1 trial in the same patient population 
screened for c-Met tumour status (Clinical Trial Number NCT01697072) was halted early. 
Mortality was significantly higher in the treatment arm and futility criteria were met at early 
review. Rolitumumab was considered “of no benefit to patients with gastro-eosophageal 
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cancer”. The study found median overall survival was shorter in the Rilotumumab group than 
the placebo group (8·8 months vs 10·7 months; HR 1·34 [95% CI 1·10–1·63]). Time to disease 
progression was shorter and the objective response rate to therapy was also lower in the 
treatment arm(216).  
A possible alternative approach to therapeutic c-Met targeting has been trialed in advanced 
metastatic colorectal cancer. The human immunoglobulin G2 antibody called Samsung 
Advance Institute of Technology-301 (SAIT301) binds and inhibits c-Met transmembrane 
protein function. In their small unblinded dose escalation trial, Lee et al were able to induce 
partial response or maintain stable disease in patients with metastatic colorectal cancer, for 
whom all conventional treatment had failed(217). Further research is needed.  
 
EMI-137 
EMI-137, developed by GE Healthcare Technologies Ltd and Edinburgh Molecular Imaging 
(EM Imaging) Ltd, has been shown to be safe and effective in human and animal 
studies(218,219). The molecular formula of EMI-137 is C156H213N34O52S8 (Figure 7). It is 
supplied as a blue powder, has a molecular weight of 3653.2u (unified atomic mass units), is 
high soluble in water with a pH between 4 and 7. EMI-137 consists of a fluorescent cyanine 
dye coupled to a propriety 26 L-amino acid cyclic peptide targeted to the c-Met receptor. When 
reconstituted with water, EMI-137 possesses photo-stability in white light, with peak 
florescence at excitation wavelength 653nm and emission at 675nm.  EMI-137 is highly 
selective and has a high affinity for the extra-cellular domain of the human c-Met receptor 
owing to its low nanomolar dissociation constant (~2 nM). It binds completely without activation 
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Figure 7: Structural formula of EMI-137 salt free. Adapted from Edinburgh Molecular Imaging 
Ltd. (2017)(220) 










Figure 8: Schematic representation of EMI-137 targeting the c-Met receptor. Adapted from 
Esfahani et al (2016)(221) 
The optical imaging agent binds to the extracellular domain of the c-Met receptor without 
activation leading to detectable membrane fluorescence. EMI-137 is internalised when it 
binds to the receptor in the presence of HGF yielding detectable cytoplasmic and 
membranous fluorescence.  
 
To date, c-Met targeting has failed to demonstrate clear beneficial therapeutic anti-cancer 
properties in small early phase clinical trials. However, c-Met targeting with an inert fluorescent 
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probe could be a potential novel solution to the difficulties of intra-operative visualisation of 
colon cancers and lymph nodes metastases.  
Burggraaf et al have demonstrated the safety and efficacy of EMI-137 for the visualisation of 
colonic polyps at colonoscopy. Their single centre study from Leiden, Netherlands, used 
healthy volunteers and patients deemed at high risk of colorectal cancer to establish the 
optimal dose and timing of administration in an early phase clinical trial. This was found to be 
0.13mg/kg of EMI-137 given intravenously 3 hours prior to colonoscopy. Higher doses 
(0.18mg/kg), although safe, created excessive background (noise) fluorescence and reduced 
fluorescent visualisation of the target tissue. Importantly, no serious adverse reactions related 
to the administration of EMI-137 were reported(218).  
 
Figure 9: a-c colonic lesions easily visible in white light (left) and showing enhanced 
fluorescence with EMI-137 (right); e-f colonic lesions difficult to detect with white light (left) 
but easily visible with EMI-137 during fluorescent colonoscopy. Adapted from Burggraaf et al 
(2015)(218). 
 
Administration of EMI-137 to 15 patients at high risk of colonic neoplasms led to the 
visualisation of an additional 22 polyps, of which 17 colonic polyps were only visible with 
fluorescent light as compared to white light colonoscopy. These were mostly non-polypoidal 
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and small lesions. Histopathological examination of the resected polyps showed a clear 
relationship between the degree of fluorescence and the histological dysplasia grade of the 
polyp. This was mirrored in the immunohistochemical examination of the resected polyps with 
dysplastic polyps and adenomas showing greater c-Met expression as compared to normal 
tissue.  All the adenomas identified with white light colonoscopy also showed increased 
fluorescence with EMI-137. 
With the problems associated with accurately staging colon cancer and planning the radicality 
of surgery on an individual patient basis, EMI-137 may offer a novel solution. The potential to 
apply a safe and targeted imaging agent to intraoperatively map the tumour and any metastatic 
lymph nodes could aid the decision-making process and allow surgery to be tailored to the 
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 CHAPTER TWO 
CLINICAL FEASIBILITY STUDY OF NEAR INFRARED FLUORESCENCE 
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2.1  AIMS AND OBJECTIVES 
Trial Overview 
The need for a dynamic, safe, and cost-effective method of intraoperatively assessing biliary 
anatomy during laparoscopic cholecystectomy has been a priority for surgeons for some time. 
The persistently stubborn rate of bile duct injury, even in experienced hands and long after the 
“learning curve” in laparoscopic surgery has plateaued, combined with the catastrophic 
physical, psychological and fiscal consequences make any method to improve extrahepatic 
ductal identification and reduced the bile duct injury rate of high clinical importance.  The 
stability and favourable safety profile of ICG, and the increasing number of high quality and 
relatively inexpensive NIR laparoscopic systems, makes this an exciting and highly applicable 
technology. Small international studies have explored applications of ICG in laparoscopic and 
robotic-assisted cholecystectomy, but there have not been any published randomised 
controlled trials and there is no consensus on dose, timing interval or study end points.    
 
Aims 
I aimed to explore and investigate the potential applications of NIR-FC with ICG within a 
tertiary referral NHS hepatobiliary surgery unit. My aims included:  
i) To appraise the safety and efficacy of NIR-FC with ICG as an intraoperative 
imaging modality in laparoscopic cholecystectomy surgery with a phase IIa clinical 
trial.  
ii) To explore the applications and limitations of ICG aided NIR-FC during 
laparoscopic cholecystectomy surgery performed by skilled consultant Hepatic and 
Pancreatico-Biliary surgeons highly competent in the management of complex 
hepatobiliary disease.  
iii) To explore participant and operative factors that adversely affected extra-hepatic 
biliary structure identification with NIR-FC.  
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iv) To explore and evaluate ICG dosing regimens, in particular to explore delayed 
dosing intervals and the possible benefit of ICG accumulation in bile and increased 
fluorescent biliary structure visualisation.  
v) To investigate surgical team satisfaction with the technology and explore likely 
enthusiasm for adoption of NIR-FC.  
 
2.2  MATERIALS AND METHODS 
The trial endpoints as defined in the study protocol: 
Primary Endpoints: 
1.  Successful identification of biliary structures; Cystic Duct (CD), Common Bile Duct (CBD) 
Common Hepatic Duct (CHD) Left Hepatic Duct (LHD), Right Hepatic Duct (RHD) and 
Cystic Artery (CA).  
2. Dose optimisation of ICG in laparoscopic cholecystectomy. Investigation of the optimal 
dose and timing of ICG for visualisation of biliary anatomy using NIR-FC.  
Secondary Endpoints: 
1. Rates of bile duct injury 
2. Rates of vascular injury 
3. Rate of intraoperative conversion to open cholecystectomy procedure 
4. Length of procedure 
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2.2.1 Trial Design 
This trial was designed as a single-centre, prospective, non-randomised, open label, early 
phase cohort study. The trial explored the feasibility and effectiveness of fluorescence guided 
bile duct mapping during laparoscopic cholecystectomy surgery at St James’ University 
Hospital, Leeds, between 22nd July 2016 and 27th November 2018. Allocation to dose sub-
groups was systematic and dependent on recruitment to trial date. Progression between 
dosing interval phases was sequential and was dictated by the outcome of regular interim 
review of trial progress and data. The overall trial schema is outlined in Figure 10.  
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Figure 10: Clinical feasibility study of Near Infrared Fluorescence Cholangiography in 
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Regulatory Approval  
Ethical approval for the trial was granted by the North East - Newcastle & North Tyneside 2 
Research Ethics Committee on 8th June 2015 (Ref: 15/NE/0131) - approval letter in Appendix. 
Local approval from Leeds Teaching Hospitals NHS Trust (LTHT) was obtained prior to 
commencing recruitment and participant data collection. The trial was conducted in 
accordance with all quality assurance and ethical best practice guidelines and there were 
robust systems in place for reporting of any protocol breaches or adverse events to the trial 
sponsor, the University of Leeds, and the regulatory authorities as appropriate. LTHT Surgical 
Clinical Trials Unit (CTU) supported the trial and were actively involved in participant 
screening, recruitment, and data collection for the duration of the trial.  The use of Indocyanine 
Green as the fluorophore was considered a non-CTIMP (Clinical Trial Investigational Medical 
Product) clinical trial by the regulatory authorities and therefore Medicines and Healthcare 
products Regulatory Agency (MHRA) approval was not required.  
 
Substantial Amendments  
A substantial amendment to the protocol was approved by the REC on 8th February 2017. The 
amendment extended the dosing interval for the participant subgroups and allowed a cohort 
of patients to receive 0.25mg/kg of ICG the day before their surgical procedure. Defining the 
optimum dosing interval as a trial endpoint definition was also added for clarity.  
 
Training  
The operating surgeons, Research Fellow (GRA), and key members of the theatre clinical 
team received thorough training from an Elemental Healthcare™ representative on behalf of 
Stryker/Novadaq® Ltd. on how to use the Novadaq PinPoint® Endoscopic Fluorescence 
Imaging System (Stryker/Novadaq  Endoscopy HQ, San Jose, CA, USA) prior to recruitment 
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of the first patient. An equipment manual was always available, and the local company 
representative could be contacted during office hours for technical advice. To assist with 
training, and to familiarise the trial team and theatre staff with the equipment, a training case 
was performed once regulatory authority approval was in place and prior to commencement 
of the trial. The participant was screened for eligibility as per trial design and full informed 
consent was obtained using the approved trial documents.    
With the Elemental Healthcare™ representative present in theatre, a laparoscopic 
cholecystectomy procedure was performed with the PinPoint® Endoscopic Fluorescence 
Imaging System. This was beneficial to all members of staff and aimed to curtail any early 
“learning curve” experienced with new technology. During this training procedure, the Case 
Reporting Forms (CRF) were appraised and their suitability for data collection confirmed.  
 
Study Population  
Male and female patients over the age of 18 years with a diagnosis of biliary pathology 
(including but not limited to, cholelithiasis, cholecystitis, gallstone pancreatitis, biliary 
dyskinesia or gallbladder polyps) awaiting laparoscopic cholecystectomy at LTHT under the 
care of one of the five participating consultant HPB surgeons were eligible to participate. The 
participating consultant surgeons were Mr. A.M Smith, Mr. G Toogood, Mr. C Macutkiewicz, 
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Eligibility  
The eligibility criteria for the trial are defined in Table 2.  
Inclusion criteria Exclusion criteria 
• Able to give informed consent and be 
willing to follow trial protocol 
• Aged over 18 
• Fit for laparoscopic surgery 
• American Society of Anaesthesiologists 
(ASA) classification ≤ 3 
• Normal renal function on most recent 
blood tests (to be within 30 days prior to 
surgery). For the purposes of the trial 
normal renal function can be defined as 
GFR ≥ 40 mls/min/1.73m2 or Creatinine 
within 10% of upper value for normal 
institutional limits. 
• Patients with symptomatic biliary disease 
(chronic cholecystitis, cholelithiasis, 
biliary dyskinesia, acute cholecystitis, 
gallstone pancreatitis and cholangitis) 
eligible for laparoscopic cholecystectomy 
• History of hypersensitivity reactions or 
known allergy to ICG, iodine or iodine 
dyes 
• Pregnant (positive pregnancy test) or 
breast-feeding ICG has unknown 
teratogenic and abortifacient effects. 
• In women of childbearing potential 
(defined as any female who has 
experienced menarche and who is not 
postmenopausal or permanently 
sterilised (e.g. tubal occlusion, 
hysterectomy, bilateral salpingectomy). 
A pregnancy test will be performed and 
evidence of a negative result will be 
required prior to entry into the study. 
• Patients with hyperthyroidism, patients 
with autonomic thyroid adenomas 
• Poorly controlled or serious medical or 
psychiatric illness that, in the 
Investigator’s opinion, is likely to 
interfere with participation and/or 
compliance in this clinical trial. 
• Patients taking cyclopropane, 
probenecid, or rifamycin, which can 
increase the absorption of ICG 
Table 2: Eligibility criteria for Clinical Feasibility study of Near Infrared Fluorescence 
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Screening and Recruitment 
Potential participants were identified thorough the LTHT inpatient registry, the LTHT theatre 
booking platform, or during outpatient clinic appointments. All participant eligibility screening 
and recruitment was performed by the clinical research fellow (GRA), the participating 
consultant surgeons, or by medically trained members of LTHT Surgical Clinical Trials Unit 
(CTU). 
Screened participants deemed to meet all the eligibility criteria were approached to participate 
either in face-to-face interactions or over the telephone. All participants were provided with 
written information in the form of a Participant Information Sheet (PIS) and given verbal 
information about the trial at least 24 hours prior to involvement. All potential participants were 
given the opportunity to ask questions and provided with the name and contact details of a 
delegated member of the research team if they wished to discuss their involvement further at 
a later date. All members of the research team were experienced in gaining consent for a 
clinical trial and had valid GCP training. It was stressed to all potential participants that their 
involvement was voluntary, they could withdraw at any time, and refusal to participate would 
not adversely affect the care they received in any way. No incentives were offered to 
participate. 
Patients wishing to participate were asked to sign a trial specific patient consent form prior to 
receiving ICG and undergoing NIR-FC guided LC surgery. Their usual General Practitioner 
(GP) was also informed of their trial involvement. Patients were assigned a unique trial 
participant number and baseline preoperative demographics were collected including age, 
gender, Body Mass Index (BMI), pre-operative blood test results, imaging results, co-




Name: Gemma Armstrong  
Student No: 201073014 
2.2.2 Trial Intervention 
Indocyanine Green  
The ICG was supplied by the LTHT clinical trials pharmacy department. The ICG (Verdye®, 
Diagnostic Green GmbH, Aschheim-Dornach, Germany) was supplied as a green dry powder 
25mg/5ml preparation. It was reconstituted with 5mL of sterile water immediately prior to 
intravenous administration as per manufacturer’s instructions. All dose calculations, 
preparation, and administration of the ICG, and prescribing of the trial agent were the 
responsibility of the clinical research fellow. To adhere to safe prescribing and drug 
administration best practices, the prepared drug and dose calculations were verified with 
another clinically trained member of staff prior to administration of the fluorophore. The ICG 
was administered as single intravenous (I.V) bolus via a peripherally sited cannula device. 
This was immediately followed by a flush of 10mL of 0.9% saline solution. The sterile water 
for reconstitution and 0.9% normal saline flush were also supplied to the research team as a 
standard pharmacy stock supply item by LTHT pharmacy department.  
The four possible dosing groups in the trial are listed in the flow chart (Figure 10). Participants 
received a single intravenous bolus of ICG pre-operatively as per protocol allocation. They 
were monitored for adverse events and provided with information relating to the possible 
adverse reactions for which they needed to seek urgent medical attention. The dosing interval 
allocation was disclosed to all involved parties. 
 
Surgical Procedure 
All peri-operative care was as per standard LTHT practice. Participation in the trial did not 
involve any deviation from routine care or from standard surgical technique. The trial 
intervention assessed the intraoperative identification of extrahepatic biliary anatomy using 
NIR-FC at specific points during the cholecystectomy procedure. This was achieved by 
intravenous administration of ICG and utilisation of a licensed and CE marked NIR 
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laparoscopic system in place of the standard white light system available within the trust. The 
Stryker®/Novadaq® PinPoint® Endoscopic Fluorescence Imaging System (Stryker UK Ltd, 
Newbury, Berkshire, UK) was used to perform all NIR-FC during laparoscopic 
cholecystectomy.  
Laparoscopic cholecystectomy was performed as per surgeon’s preference. Participation in 
the clinical trial did not require any change to operative plan or technique. The anaesthetised 
patient was transferred to the operating theatre and all safe surgery precautions, including the 
World Health Organisation (WHO) surgical safety checklist and confirmation of instrument 
sterility, were completed. Surgery commenced with introduction of the laparoscopic ports and 
establishment of a pneumoperitoneum with carbon dioxide insufflation. Then, the gallbladder 
was located and retracted to gain an initial view. Any adhesions prohibiting visualisation were 
divided.  Surgery was always initiated in white light (WL) mode. Once the initial view was 
obtained, the Novadaq® PinPoint® Endoscopic Fluorescence Imaging System was switched 
to fluorescent light (FL) mode to assess the extrahepatic biliary anatomy with NIR-FC.   
The assessment could be performed in any of the fluorescent modes available on the NIR 
laparoscopic system. The assessment was the subjective opinion of the most senior operating 
surgeon in theatre. The assessment was recorded using a semi-quantifiably scale. The 
assessment was made relative to background liver fluorescence. The overall assessment was 
a culmination of either a single mode or a combination of modes that together provided the 
greatest overall diagnostic yield of extrahepatic biliary structures in the opinion of the operating 
surgeon.  
The three modes available on the Novadaq® PinPoint® Endoscopic Fluorescence Imaging 
System were a pure fluorescence black and white mode called “SPY Fluorescence”; a High 
Definition (HD) colour mode with fluorescent green overlay called “PINPOINT fluorescence”; 
or the proprietary colour substitution mode referred to as Color Segmented Fluorescence 
Mode (CSF). CSF mode artificially overlays a colour on to the screen image depending on the 
amount of fluorescence detected as a form of semi-quantification of fluorescence. Essentially, 
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this consists of a colour graduated system artificially colourising areas of maximal 
fluorescence brown to red, moderate fluorescence purple and minimal fluorescence blue. 
Assessment of visible structures could be made using a single or combination of modes and 
appraisal of demarcation was made on the best imaging obtained. Assessment of crucial 
biliary anatomy, the Cystic Duct (CD), Common Hepatic Duct (CHD), Common Bile Duct 
(CBD), Cystic Artery (CA), Left and Right Hepatic Duct (LHD) and (RHD) was made using a 
semi quantifiable scale consisting of: easily identifiable; partially identifiable; equivocal; not 
seen at three specified points. The results were captured on an intraoperative CRF (appendix 
– trial documents). The three points of assessment were:  
1) Initial view 
After introduction of the laparoscopic ports and establishment of pneumoperitoneum, the 
liver was retracted, and the gallbladder extended to facilitate a view prior to any dissection 
or opening the peritoneum.  
2) Partial dissection 
 A second assessment was made after partial dissection in the hepatocystic triangle, after 
opening of the anterior peritoneum but prior to skeletisation of the CD or CA. 
3) Critical View 
A third assessment was made after complete dissection in the hepatocystic triangle and 
after obtaining the critical view of safety. The CD and CA were skeletonised and identified 
as the only structures entering the gallbladder. This assessment made was prior to division 
of any presumed ductal structures. 
4) On-Table Cholangiography (OTC) 
An OTC was performed when clinically indicated and at the surgeon’s discretion. The 
cystic duct was cannulated with a cholangiogram catheter and a bolus of radio-opaque 
contrast media injected. A portable C-arm was positioned, and fluoroscopy screening 
79 
  
Name: Gemma Armstrong  
Student No: 201073014 
performed to visualise the intra and extrahepatic bile ducts and observe the flow of contrast 
into the duodenum. The same semi-quantifiable scale was used to record the identifiable 
biliary structures as in the NIR-FC assessment, excluding the CA which is not visible via 
OTC assessment. The remainder of the surgical procedure could be performed in either 
the standard WL, or any of the FL modes available, or a combination of these modes as 
per surgeon’s preference.  
Once the first phase of the trial with a standardised dose and dosing regimen was 
completed and analysed during interim analysis, a dose optimisation amendment was 
incorporated into the trial design. A further three subgroups were added (Figure 10) to 
explore optimal dose and dosing interval and the efficacy of each regimen in the clinical 
setting.  
 
Surgeon Satisfaction  
The operating surgeon completed a questionnaire at the end of each NIR-FC case. A Likert 
scale design provided a semi-quantifiable method allowing surgeons to rate their satisfaction 
with the equipment, the image obtained, and express an opinion on the usefulness of NIR-FC. 
A free-text box also allowed for further elaboration. Selection of “strongly agree” or “agree” 
was considered a positive response. 
 
Follow-up 
Patients received standard post-operative care. As is routine practice in uncomplicated 
cholecystectomy, patients were not recalled for clinic follow-up after discharge from hospital.  
Subjects received a trial specific follow-up telephone call 30 days after the date of surgery. If 
a patient was uncontactable via telephone multiple attempts were made for one week after 
the expected follow-up date. Alternative means to contact the patient were also sought, this 
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included review of LTHT electronic medical records to exclude readmission to hospital and 
contacting a participant’s GP to seek an alternative telephone number.  During the telephone 
consultation a postoperative CRF was completed. At this point, trial involvement ceased, and 
no further data was collected.  
 
Secondary Review and Interim Analysis  
When 21 participants had been recruited to the trial, with a minimum of four participants per 
subgroup, an interim analysis with secondary review of the operative videos was conducted. 
Two consultant hepatobiliary surgeons from LTHT reviewed all the anonymised NIR-FC 
videos and OTC for each trial participant. They used the same semi-quantifiable scale used 
intraoperatively to describe the number of extrahepatic biliary structures identified. The 
surgeons were also encouraged to provide further free text feedback for analysis.  
 
Data Management 
All trial data was captured on trial specific Case Report Forms (CRF) and entered into a 
Microsoft Excel spreadsheet saved on a secure, recoverable Leeds Teaching Hospitals Trust 
(LTHT) clinical trial network drive. The intraoperative NIR-FC assessment was recorded on to 
the hard drive of the Pinpoint fluorescent imaging system and transferred to the LTHT network 
drive for secure storage. The videos were edited and still images were captured by the trial 
research fellow. Confidentially was maintained throughout and in accordance with the Data 
Protection Act and the General Data Protection Regulation. The data collected will be stored 
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Statistical Analysis 
Microsoft Excel and GraphPad Prism 7 (GraphPad V7.04 Software, Inc., California, USA) was 
used for statistical analysis. One-way ANOVA was used to test the statistical significance of 
the number of structures identifiable at each time point. A paired student t- test was used to 
compare the average number of structures identified at the third assessment point and the 
radiological OTC.  
 
Trial Closure 
Following interim analysis, a further patient was recruited to the delayed dosing interval group 
(0.25mg/kg 12 – 24 hours prior to surgery) in November 2018. The operative video was 
reviewed by two consultant hepatobiliary surgeons with the research fellow in January 2019. 
All parties agreed the results supported the outcome summary from the interim analysis and 
further recruitment to the trial would not advance the technique or provide additional useful 
data. The end of trial was the last visit of the last subject (LVLS) as per protocol. An end of 
trial notification was submitted to Newcastle & North Tyneside 2 Research Ethics Committee 
in February 2019 and trial closure proceeded as per protocol and in accordance with local 
Standard Operating Procedure (SOP. An end of trial report was submitted to the REC within 
12 months of trial closure.  
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2.3  RESULTS 
Primary Phase of Trial 
Recruitment & Screening  
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The first participant enrolled into the trial underwent surgery on 22nd July 2016. A consort 
diagram of participant recruitment into the first phase of the trial is shown in  
Figure 11. Two participants received ICG but did not undergo trial-specific NIR-FC 
laparoscopic cholecystectomy: one training case was conducted to reduce any learning curve 
effect at the start of the trial and one participant allocated to the prolonged dosing interval 
group (administration of ICG ≥12 hours before surgery) received ICG but the procedure was 
cancelled due to theatre staffing issues on morning of surgery. Both participants received 30-
day follow-up as per protocol for purposes of safety reporting and feasibility assessment but 
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Patient Demographics 
A total of twenty-two participants recruited to the trial underwent NIR-FC laparoscopic 
cholecystectomy as per protocol. The participant demographics are described in Table 3.  
Dose of ICG 2.5mg 0.25mg/kg 
Target interval 20-40min 20 - 40min 90min – 180min 12 – 36 hours 
N = 22 8 4 5 5 
Age (years) (±S.D) 44 (±10.2) 53 (±11.2) 57 (±17.6) 48±14) 
Gender M: F 0:7 2:2 0:5 1:4 
BMI (kg/m2) (±S.D) 29.1 (±4) 29.7 (±0.5) 27.3 (±3.6) 26.8 (±3.6) 
Pre-operative 
Albumin g/L (±S.D) 
36.1 (±5.8) 36.2 (±4.8) 37(±4.8) 40.6 (±3.9) 
Indication for surgery 
Biliary colic 3 1 2 2 
Gallstone 
pancreatitis 
2 0 2 1 
Acute cholecystitis 2 3 1 2 
Biliary dyskinesia 1 0 0 0 
Acute: Elective 
Admission 
3: 5 1: 3 1: 4 1: 4 
Table 3: Summary of NIR-FC feasibility study participant demographics by dosing sub-group  
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Primary Endpoint Assessment 
Individual Participant Results 
Demographics 1st assessment 2nd assessment 3rd assessment OTC 
 2.5mg 20 to 40 minutes 
Participant 1 







Time Interval 0:35 0:43 0:44 n/a 
CD Easily identifiable Easily identifiable Easily identifiable Easily identifiable 
CHD Easily identifiable Easily identifiable Easily identifiable Easily identifiable 
CBD Partially identifiable Easily identifiable Easily identifiable Easily identifiable 
LHD Partially identifiable Partially seen Partially identifiable Easily identifiable 
RHD Not seen Not seen Not seen Easily identifiable 











Time interval 0:27 0:40 0:48 n/a 
CD Not seen Easily identifiable Easily identifiable Easily identifiable 
CHD Easily identifiable Easily identifiable Easily identifiable Easily identifiable 
CBD Easily identifiable Easily identifiable Easily identifiable Easily identifiable 
LHD Easily identifiable Easily identifiable Easily identifiable Easily identifiable 
RHD Easily identifiable Easily identifiable Easily identifiable Easily identifiable 
CA Not seen Not seen Easily identifiable n/a 
  
Participant 3 
   
n/a 
52y Female 




Time interval 1:05 1:10 1:32 n/a 
CD Not seen Easily identifiable Easily identifiable 
n/a 
CHD Not seen Easily identifiable Easily identifiable 
CBD Not seen Partially identifiable Easily identifiable 
LHD Easily identifiable Easily identifiable Easily identifiable 
RHD Partially identifiable Easily identifiable Easily identifiable 




BMI 26.3 kg/m2 
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Indication: Biliary 
colic 
    
2.5mg 
Time interval 0:34 0:40 0:41 n/a 
CD Easily identifiable Easily identifiable Easily identifiable Easily identifiable 
CHD Easily identifiable Easily identifiable Easily identifiable Easily identifiable 
CBD Easily identifiable Easily identifiable Easily identifiable Easily identifiable 
LHD Not seen Not seen Not seen Easily identifiable 
RHD Not seen Not seen Not seen Easily identifiable 




   
 
36y Female 




Time interval 0:52 1:34 1:56 n/a 
CD Not seen Not seen Easily identifiable Easily identifiable 
CHD Partially seen Partially seen Equivocal Easily identifiable 
CBD Partially seen Easily identifiable Equivocal Easily identifiable 
LHD Not seen Equivocal Not seen Easily identifiable 
RHA Not seen Equivocal Not seen Easily identifiable 











Time Interval 0:40 0:48 Not performed n/a 
CD Not seen Not seen Not performed Easily identifiable 
CHD Not seen Not seen Not performed Easily identifiable 
CBD Not seen Not seen Not performed Easily identifiable 
LHD Not seen Not seen Not performed Easily identifiable 
RHD Not seen Not seen Not performed Easily identifiable 











Time interval 0:33 0:46 0:52 n/a 
CD Easily identifiable Easily identifiable Easily identifiable 
n/a 
CHD Partially seen Easily identifiable Easily identifiable 
CBD Partially seen Easily identifiable Easily identifiable 
LHD Not seen Not seen Not seen 
RHD Not seen Partially seen Partially identifiable 
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CA Not seen Easily identifiable Easily identifiable 
 
Participant 8 
    
23y female 
BMI 25.7 kg/m2 
Biliary dyskinesia 
Dose: 2.5mg 
Time interval 0:34 0:40 0:52  
CD Easily identifiable Easily identifiable Easily identifiable Easily identifiable 
CHD Easily identifiable Easily identifiable Not seen Easily identifiable 
CBD Easily identifiable Easily identifiable Easily identifiable Easily identifiable 
LHD Not seen Not seen Not seen Easily identifiable 
RHD Not seen Not seen Not seen Easily identifiable 








BMI 33.1 kg/m2 
Biliary colic 
18mg 
Time interval 2:32 2:37 2:38 n/a 
CD Easily identifiable Easily identifiable Easily identifiable 
n/a 
CHD Not seen Easily identifiable Easily identifiable 
CBD Not seen Easily identifiable Easily identifiable 
LHD Not seen Not seen Not seen 
RHD Not seen Not seen Not seen 
CA Not seen Easily identifiable Easily identifiable 






BMI 24.7 kg/m2 
Biliary colic 
15mg 
Time interval 2:28 2:34 2:43 n/a 
CD Easily identifiable Easily identifiable Easily identifiable 
n/a 
CHD Easily identifiable Easily identifiable Easily identifiable 
CBD Easily identifiable Easily identifiable Easily identifiable 
LHD Easily identifiable Easily identifiable Easily identifiable 
RHD Easily identifiable Easily identifiable Easily identifiable 
CA Not seen Easily identifiable Easily identifiable 
   
Participant 11 
    
79y Female 




Time interval 3:11 3:29 3:53  
CD Not seen Not seen Not seen Easily identifiable 
CHD Easily identifiable Not seen Not seen Easily identifiable 
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CBD Equivocal Not seen Not seen Easily identifiable 
LHD Not seen Not seen Not seen Easily identifiable 
RHD Not seen Not seen Not seen Easily identifiable 
CA Not seen Not seen Not seen n/a 
   
Participant 12 
   
n/a 
28y Female 
BMI 30.0 kg/m2 
cholecystitis 
23.5mg 
Time interval 4:07 4:13 4:15 n/a 
CD Not seen Easily identifiable Easily identifiable 
n/a 
CHD Not seen Partially seen Easily identifiable 
CBD Not seen Easily identifiable Easily identifiable 
LHD Not seen Easily identifiable Easily identifiable 
RHD Not seen Easily identifiable Easily identifiable 













Time interval 2:47 2:59 3:14 n/a 
CD Not seen Easily identifiable Easily identifiable Easily identifiable 
CHD Not seen Not seen Not seen Easily identifiable 
CBD Not seen Not seen Not seen Easily identifiable 
LHD Not seen Not seen Not seen Easily identifiable 
RHD Not seen Not seen Not seen Easily identifiable 
CA Not seen Easily identifiable Easily identifiable n/a 
 
Participant 14 
   
n/a 
69y Male 




Time interval 0:33 0:49 0:55 n/a 
CD Partially seen Easily identifiable Easily identifiable 
n/a 
CHD Not seen Equivocal Easily identifiable 
CBD Equivocal Easily identifiable Easily identifiable 
LHD Not seen Not seen Not seen 
RHD Not seen Not seen Not seen 
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20.2mg 
   
Time interval 0:29 0:31 0:34 n/a 
CD Not seen Easily identifiable Easily identifiable 
n/a 
CHD Not seen Not seen Not seen 
CBD Not seen Not seen Not seen 
LHD Not seen Not seen Not seen 
RHD Not seen Easily identifiable Easily identifiable 
CA Not seen Easily identifiable Easily identifiable 
 
Participant 16 
    
47y Male 




Time interval 0:42 0:56 1:03  
CD Not seen Not seen Easily identifiable Easily identifiable 
CHD Not seen Not seen Not seen Easily identifiable 
CBD Not seen Not seen Not seen Easily identifiable 
LHD Not seen Not seen Not seen Easily identifiable 
RHD Not seen Not seen Not seen Easily identifiable 
CA Not seen Not seen Not seen n/a 
 
     
Participant 17 
   
n/a 
39y Female 




Time interval 0:27 0:37 0:41 n/a 
CD Not seen Equivocal Partially seen 
n/a 
CHD Not seen Not seen Not seen 
CBD Not seen Not seen Not seen 
LHD Not seen Not seen Not seen 
RHD Not seen Not seen Not seen 
CA Partially seen Partially seen Easily identifiable 
 
Participant 18 
   
 
37y Male 
BMI 30.8 kg/m2 
Biliary colic 
23.75mg 
Time interval 18:09 18:20 18:31 n/a 
CD Easily identifiable Easily identifiable Easily identifiable 
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CHD Easily identifiable Not seen Not seen 
CBD Easily identifiable Easily identifiable Partially seen 
LHD Easily identifiable Not seen Not seen 
RHD Easily identifiable Not seen Not seen 
CA Not seen Easily identifiable Easily identifiable 
     
Participant 19    
n/a 
67y female 




Time interval 20:49 21:03 21:14 n/a 
CD Easily identifiable Easily identifiable Easily identifiable 
n/a 
CHD Equivocal Partially identifiable Not seen 
CBD Easily identifiable Easily identifiable Easily identifiable 
LHD Not seen Not seen Not seen 
RHD Not seen Not seen Not seen 
CA Easily identifiable Easily identifiable Not seen 
     
Participant 20 






Time interval 17:00 17:13 17:21 n/a 
CD Easily identifiable Easily identifiable Easily identifiable 
n/a 
CHD  Not seen Easily identifiable Easily identifiable 
CBD  Not seen Easily identifiable Easily identifiable 
LHD  Not seen Not seen Not seen 
RHD  Not seen Not seen Not seen 
CA  Not seen Not seen Not seen 
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Table 4: NIR-FC clinical trial intraoperative biliary structure results by individual participant. 
Participant ID, age, indication for surgery, dose of ICG received, time interval from 
administration to fluorescent assessment and surgeon assessment of extrahepatic biliary 
structure fluorescent detection shown. Abbreviations: y – years; CD – cystic duct; CHD – 
common hepatic duct; CBD common bile duct; LHD left hepatic duct; right hepatic duct; CA 









Time interval 22:52 23:06 23:24 OTC 
CD Partially identifiable Not seen Partially identifiable Easily identifiable 
CHD equivocal Not seen Equivocal Easily identifiable 
CBD Easily identifiable Not seen Easily identifiable Easily identifiable 
LHD Not seen Not seen Not seen Easily identifiable 
RHD Not seen Not seen Not seen Easily identifiable 












Time interval 17:47  17:53 OTC 
CD Easily identifiable  Easily identifiable  
CHD Easily identifiable  Easily identifiable  
CBD Easily identifiable  Easily identifiable  
LHD Not seen  Not seen  
RHD Not seen  Not seen  
CA Not seen  Not seen  
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ICG Dose 2.5mg 0.25mg/kg 
Target dosing interval 20-40min 20 - 4min 90min – 3 hours 12 – 36 hours 
N = 22 8 4 5 5 
ICG Dose (mg) (±S.D) 2.5 (±n/a) 21.4 (±1.5) 17.6 (±3.8) 18.5 (±3.5) 
Mean Operation 
length (h:mm) (±S.D) 
1:17 (±0:50) 0:59 (±0:27) 1:07 (±0:27) 1:07 (±0:25) 
Operative length 
range (h:mm) 
0:38 – 2:49 0:24 – 1:18 0:37 – 1:38 0:35 – 1:44 
Interval to 1st 
assessment achieved 
(h:mm) (±S.D) 
0:40 (±0:12) 0:32 (±0:12) 3:01 (±0:41) 19:19 (±2:11) 
Interval to 2nd 
assessment achieved 
(h:mm) (±S.D) 
0:52 (±19) 0:40 (±19) 3:10 (±53) 19:56 (±2:40) 
Interval to 3rd 
assessment achieved 
(h:mm) (±S.D) 
1:05 (±0:27) 0:47 (±0:14) 3:21 (±0:43) 19:40 (±2:17) 
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Structure Visualisation  
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Figure 12: Number of extrahepatic biliary structures (CD, CHD and CBD) graded as clearly 
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Figure 13: Average number of structures clearly delineated at each assessment point for all 
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The number of extrahepatic biliary structures detectable with NIR-FC varied considerably 
between participants and subgroups. The dosing regimen 2.5mg/kg 20-40 minutes prior to 
surgery was the least effective (participants 14 to 19 in Table 4). The dose of ICG was too 
high and the interval to allow accumulation in the bile ducts was too short to produce 
acceptable bile duct mapping. The signal to noise ratio was very low in this subgroup.  
In participants who underwent acute index admission laparoscopic cholecystectomy, there 
was often peri-hilar inflammation and oedema, which might have interfered with the 
penetrance of NIR-FC and its ability to clearly delineate biliary anatomy -  examples shown in 
Table 4, participant ICG010 and ICG012.  
 
On-Table Cholangiogram 
Ten participants (48%) required on-table cholangiogram (OTC). All biliary ductal structures 
were “clearly identifiable” with OTC. The addition of OTC identified distal CD stones for one 
patient, which were not detectable by NIR-FC alone.  
Figure 14 compares the number of extrahepatic ductal structures clearly delineated at the third 
NIHR-FC assessment point to the results of OTC. Paired t-test of mean number of 
extrahepatic biliary structures clearly identifiable at OTC and the third NIR-FC assessment 
point found a significant difference of 2.4 structures (95% C.I. -2.37 to - 0.38, p = 0.01). OTC 
was superior to NIR-FC in the ten participants analysed.  
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Figure 14: NIR-FC compared to OTC. Number of biliary structures reported as “clearly 
identifiable” at each assessment point (structures assessed CD, CBD, CHD, LHD and RHD 
(N = 10). 
 
Factors Adversely Affecting Structure Delineation 
Linear regression was performed to ascertain if there was a clear linear relationship between 
participant factors and fluorescent bile duct mapping. The total numbers of structures identified 
across the three times points were plotted as a function of participant body mass index (BMI), 
pre-operative serum CRP, and serum albumin values. The Goodness of fit, r2 value, was low 
and the p value not significant. The sample size is likely too small and heterogeneous to make 
any more meaningful conclusions of the relationship between these factors and trial outcome.   
96 
  
Name: Gemma Armstrong  
Student No: 201073014 


















































 =  0 . 0 0 9
p  =  0 . 7
9 5 %  C . I  - 0 . 3  t o  0 . 5


















































b i l i a r y  s t r u c t u r e s
N  =  7
R
2
 =  0 . 2 5
p  =  0 . 2 5
9 5 %  C . I  - 0 . 0 4 9  t o  0 . 0 1 6














































b i l i a r y  s t r u c t u r e s
R
2
 =  0 . 0 2 5
p  =  0 . 5
9 5 %  C . I  - 0 . 2 4  t o  0 . 1 2
















































 =  0 . 0 3
p  =  0 . 4 3
9 5 %  C . I  - 0 . 1 8  t o  0 . 4 1
b i l i a r y  s t r u c t u r e s
 
Figure 15: linear regression of participant factors and an average number of extrahepatic biliary structures visualised with NIR-FC. N = 22 for 
BMI, ICG dose and serum Albumin pre-operatively, N = 7 for pre-operative CRP value. All p values not significant
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Optimum Dosing Interval  
Exploration of the dosing intervals found 0.25mg/kg more than 12 hours before surgery to be 
the optimum regimen. Four participants received this regimen. Participant 20 (Table 4) 
received a weight-adjusted dose of ICG 17 hours prior to surgery. This allowed ICG loaded 
bile to accumulate in the biliary tree and aid delineation. The bifurcation of the cystic duct and 
common hepatic duct was clearly identified through the surrounding tissue. This was not seen 
with other dosing intervals. 
Administration of ICG more than 20 hours appears to exceed the optimum window for imaging 
of bile ducts with NIR-FC. Participant 19 and 21 (Table 4) received ICG more than 20 hours 
before surgery and their NIR-FC signal was weak. Participant 19 shows limited accumulation 
of ICG in the biliary system and poor fluorescent signal was obtained. This may be individual 
participant specific or a detectable trend in the group. The surgeon satisfaction questionnaire 
also concluded 0.25mg/kg 12 to 36 hours prior to surgery was the optimum dosing regimen.   
 
Operative Length 
The mean operative procedure length, defined as duration from introduction of umbilical port 
to closure of laparoscopic port sites, is shown in Table 5. The heterogeneity of the subgroups 
and the wide range of operative times has skewed the data and precludes meaningful 
statistical analysis at interim and final review.   
 
Secondary Review 
Two consultant hepatobiliary surgeons at LTHT reviewed the anonymised NIR-FC videos and 
OTC for the first 21 trial participants. The reviewers used the same semi-quantifiable scale to 
quantify the number of biliary structures clearly delineated with the addition of NIR-FC bile 
duct mapping.  
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There was considerable variance between the initial NIR-FC intraoperative assessment and 
the secondary review result, and a degree of variance between the two assessors. Figure 16 
compares the number of structures defined as easily identifiable intraoperatively at each 
assessment point against the score provided by the reviewing surgeons.  
The secondary reviewers consistently reported less structures as “easily identifiable” with NIR-
FC compared to the intraoperative result at all three of the assessment points (p value = < 
0.0001, 0.003 and 0.009 respectively).  The exact cause of this variance is uncertain; however, 
it may be attributed to the lack of white light visual information provided. The reviewers were 
only shown short edited NIR-FC videos and they specifically assessed if the structures were 
clearly delineated in NIR-FC mode only. The reviewers were more strongly influenced by the 
noise to signal ratio created by strongly background liver fluorescence with some of the dosing 
regimens. 
The intraoperative assessment and the secondary review confirmed OTC was superior to NIR-
FC for the detection of biliary structures. OTC was performed on 10 occasions and for every 
participant the reviewers confirmed the intraoperative grading, deeming the key biliary 
structures as “easily identifiable” (p = 0.01).  
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Figure 16: Secondary review by assessment point on individual participant level. The 
number of structures classified as “easily identifiable” (CD, CBD, and CHD). One-way 
ANOVA analysis of variance performed. N = 21.  
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Interim Analysis 
Surgeon Satisfaction  
After each case, participating surgeons completed a Likert score of their experience using the 
NIR-FC technique. They found the Novadaq Pinpoint® Near Infrared Laparoscopic System 
easy to use and adequate for the procedure, the option “strongly agree” or “agree” was 
selected for all cases appraised. 
Table 6 shows the response to each question by dosing subgroup. The individual subgroups 
are small and differing in size, therefore calculation of percentage of total and statistical 
analysis cannot be performed. However, the addition of ICG was considered to aid 
identification of extrahepatic biliary structures with greatest certainty at a dose of 0.25mg/kg 
more than 12 hours before surgery. It was also the only regimen felt to make “the surgical 
procedure easier” and to increase surgeon “confidence in biliary structure identification” in all 
cases.  
It was reassuring to see that background liver fluorescence produced with ICG was not felt to 
hinder the operative procedure. At the short dosing interval, surgeons could use a proprietary 
feature of the Novadaq® NIR laparoscopic system, the CSF mode, to artificially colour and 
semi-quantify areas of maximal fluorescence demonstrated in Table 4, to delineate structures 
from background. The prolonged dosing interval (0.25mg/kg 12 to 36 hours prior to surgery) 
did not require the CSF mode owing to reduction in background hepatic fluorescence.  
NIR-FC was not felt to produce comparable results to OTC or be able to replace OTC at any 
of the dosing regimens explored. Free text data from surgeons clarified the reason for this; 
NIR-FC could not identify intraductal stones or demonstrate free flow of contrast into the 
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12 – 36 hr 
8 4 5 4 
The addition of ICG aided the 
identification of extrahepatic biliary 
structures during laparoscopic 
cholecystectomy   
3 
(37.5%) 
2 (50%) 3 (60%) 4 (100%) 
The background liver fluorescence 
produced with ICG hindered the 
operative procedure  
0 (0%) 0 (0%) 1 (20%) 0 (0%) 
The addition of ICG made the surgical 
procedure easier and increased my 
confidence in biliary structure 
identification  
2 (25%) 0 (0%) 1 (20%) 4 (100%) 
NIR cholangiography provided 




0 (0%) 0 (0%) 0 (0%) 
In the future, NIR cholangiography 
could replace standard radiological 
OTC in my operative practice 
0 (0%) 0 (0%) 1 (20%) 0 (0%) 
Using ICG could help to reduce 
intraoperative complications including 
bile duct injuries 
7 
(87.5%) 
2 (50%) 2 (40%) 3 (75%) 
ICG should be reserved for technically 
difficult and/or acute laparoscopic 
cholecystectomies only  
0 (0%) 0 (0%) 0 (0%) 0 (0%) 
I am keen to use ICG in laparoscopic 
cholecystectomy surgery again  
8 
(100%) 
4 (100%) 5 (100%) 4 (100%) 
 
Table 6: Participating surgeon NIR-FC laparoscopic cholecystectomy operative feedback 
results. Number of “strongly agree” or “agree” responses given to each question and as 
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Final Analysis 
The interim analysis defined 0.25mg/kg of ICG 12 – 36 hours prior to surgery as the optimum 
dosing regimen. Therefore, this regimen was assessed in more detail at final analysis. 
Following recruitment of the final participant (participant 22) the feasibility, optimum dose and 
safety of the intervention were assessed.  
 
Safety  
Participants received trial specific follow up at 30 days post operation.  There were no Serious 
Unexpected Serious Adverse Reaction (SUSARS) reported. There were two Serious Adverse 
Events (SAEs) observed. Causality was assessed promptly, and neither were deemed related 
to the trial specific intervention. One participant returned to theatre on post-operative day 3 
and was found to have a slow bleeding ooze in the gallbladder fossa, and one participant was 
re-admitted to investigate the possibility of pulmonary embolism, which was excluded with CT 
pulmonary angiography (CTPA) in the weeks following surgery.  
Specifically, in relation to the secondary safety endpoints of the trial, there were no bile duct 
injuries, no incidences of vascular injury and no intraoperative conversions to open 
cholecystectomy. The sample size was too small to draw any further conclusions or perform 
statistical analysis on SAE causation.  
The minor post-operative adverse events were expected complications of umbilical port-site 
infection reported in two participants. The surgical site infection responded to oral antibiotics 
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Feasibility of NIR-FC in Laparoscopic Cholecystectomy Clinical Trial  
The inclusion criteria for the trial were adequate for the purposes of recruitment ( 
Figure 11). Only 28 individuals screened were ineligible to participate (15.9%). Of these, 26 
were excluded due to pre-existing medical conditions, most commonly renal dysfunction, and 
hyperthyroidism. One individual was excluded as they lacked capacity to consent and one 
individual had limited understanding of English and we lacked facilities to translate trial 
documents. Only 23 (13.1%) of those approached declined to participate in the trial, further 
details of reason for this decision were not captured.  
The greatest barrier to recruitment was the availability of the NIR equipment and research 
staff able to facilitate the trial intervention in theatre and the number of participating surgeons. 
Seventy-seven (43.8%) of eligible individuals screened were excluded because they were 
undergoing surgery under the care of a surgeon not participating in the trial. Only 5 
Hepatobiliary consultant surgeons at Leeds participated in the trial, limiting the number of 
cases that could be recruited during the study period. Also, LTHT has only one NIR 
laparoscopic system and this is shared with several surgical specialties limiting access to the 
equipment needed to perform the surgery.  
The trial was able to achieve the target dosing interval for each regimen. The average time 
taken from administration of ICG to introduction of the umbilical port was 32 minutes for the 
2.5mg given 20 to 40 minutes beforehand group; 29 minutes for the 0.25mg/kg 20 to 40 
minutes subgroup; 2 hours and 55 minutes for 0.25mg/kg 90 to 180 minutes subgroup, and 
19 hours 34 minutes for the 0.25mg/kg 12 to 36 hours prior to start of surgery subgroup. The 
90 to 180-minutes dosing subgroup was the most difficult interval to coordinate. It was 
extremely difficult to accommodate delays in theatre lists and ensure the ICG was 
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Optimum Dosing Regimen 
A composite score of the average number of extrahepatic structures considered easily 
identifiable at the first and third assessment time points was generated to compare the dosing 
intervals. The standard deviation was also calculated Figure 17. The optimum dosing regimen 
was ascertained at 0.25mg/kg 12 to 26 hours prior to laparoscopic cholecystectomy.  
A v e r a g e  n u m b e r  s t r u c t u r e  v i s u a l i s a t i o n  a t  f i r s t  a n d  t h i r d  t i m e  p o i n t  ( S . D )


















































































Figure 17: the average total number of extrahepatic biliary structures visible at the first and 
third assessment point for participants allocated to each of the dosing interval subgroups 
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Trial Closure  
The trial endpoint was defined as the LVLS. This was performed on 31st December 2018. The 
trial closed to recruitment on 22nd January 2019. The Declaration of End of Study (Declaration 
of End of Study non-CTIMP v1.3, August 2014) was submitted to the REC North East on 28th 
February 2019.   
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2.4  DISCUSSION 
Limitations of NIR-FC 
Iatrogenic Gallbladder Perforation  
When the gallbladder was opened during laparoscopic cholecystectomy, the spillage of bile 
contaminated the operative field with ICG loaded bile. This is demonstrated in participant 11 
(Table 4), and prevented delineation of any biliary structures with NIR-FC. This is a limitation 
of NIR-FC technology not discussed in the previously published literature. 
 
Tissue Penetrance with Peri-Hilar Inflammation 
This trial did not fully explore NIR-FC in the acute setting. Index admission laparoscopic 
cholecystectomy is the gold standard treatment, but there is significant variance across 
centres, and with presenting complaint. These patients often have significant peri-hilar 
inflammation with dense adhesions and oedema. The depth of tissue penetrance with NIR-FC 
is limited and may be insufficient to overcome the inflammatory tissue seen in emergency 
hepatobiliary surgery. Participants 5 and 6 in Table 4 demonstrate the dense adhesions that 
make this surgery technically more challenging.  
The necessary planning required to administer ICG the day prior to surgery precluded 
enrolment of many emergency admission patients into the prolonged dosing sub-group, 
despite this being deemed the most effective at interim analysis. Currently, LTHT does not 
have “hot” cholecystectomy operating lists. The availability of these theatre lists, as seen in 
other hospitals, may have allowed operative planning and recruitment of patients admitted 
acutely with biliary pathology.  
The dosing regimen of 0.25mg/kg more than 12 hours prior to surgery is likely to be the most 
effective for delineation of biliary structures. This allows sufficient time for the ICG to 
accumulate in bile and increases the signal to noise ratio – there is reduced or absent liver 
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fluorescence at this dosing interval. It also allows the operation to be performed with the 
fluorescent overlay mode and does not require the artificial coloration mode (CSF mode) to 
delineate structures. Only five participants were enrolled into this subgroup and there was 
variability in the timing of the dose. For the participant who received their dose more than 18 
hours prior to surgery, the fluorescent signal was weak. This may relate to individual 
participant factors, for example gallbladder/sphincter dysfunction allowing rapid transit of ICG 
loaded bile into the duodenum or confirm a generalisable finding of the maximum dosing 
interval for NIR-FC. The subgroup is too small to perform meaning statistical analysis of time 
of administration and biliary structure identification by means of logistical regression 
modelling. Further to this, structure identification may be impaired by Sphincter of Oddi 
dysfunction and or previous ERCP therapy. This data was not captured for trial participants 
but is likely to have affected retention of ICG loaded bile in the biliary system and therefore 
operative fluorescent signal detected.  
The results of this feasibility study contrast previously published studies of NIR-FC in 
laparoscopic cholecystectomy. The majority of previously published trials have used a 
standardised dose of 2.5mg ICG immediately pre-operatively. Our experience of NIR-FC is 
that this dose is inadequate to consistently saturate the bile with ICG and allow NIR assisted 
bile duct mapping in the elective setting.  
This concurs with Zarrinpar et al’s conclusion of the optimum ICG dose but challenges the 
timing of its administration. A dose of 0.25mg/kg is within the maximum safe dose of ICG 
permitted and appears to allow ICG to accumulate in the extrahepatic bile ducts more 
consistently. However, Zarrinpar et al concluded 45 minutes was an acceptable dosing 
interval(123). In our experience, this was the least effective interval. Intravenous 
administration of 0.25mg/kg of ICG on average 32 minutes prior to assessment had very poor 
signal to noise ratio and visualisation of the bile ducts was hindered by limited ICG 
accumulation in the ducts and strong background liver fluorescence. A prolonged pre-
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operative dosing interval, possibly 12 to 18 hours, appears to increase signal to noise ratio 
with low background liver fluorescence and demonstrates the greatest tissue penetrance.  
Overall, participating surgeons were satisfied with the image quality of the Novadaq® NIR 
laparoscopic system and found it easy to use. However, the unanimous opinion was that NIR-
FC was inferior to standard OTC and could not replace radiological assessment of the bile 
ducts intraoperatively. In cases were OTC was performed, NIR-FC was inferior in its ability to 
delineate extrahepatic bile duct structures. The prolonged dosing interval (0.25mg/kg 12 to 36 
hours before surgery) was the only subgroup where surgeons felt NIR-FC increased their 
confidence in structure identification in all cases performed.  
There is also considerable variance in the interpretation of NIR-FC results not seen with 
radiological OTC. The secondary review of intraoperative NIR-FC videos at the interim 
analysis showed a significant difference of opinion between the intraoperative assessment of 
structure visualisation and to some degree between the two reviewers. Overall, at secondary 
review NIR-FC was felt to be less effective at delineating biliary anatomy. The reviewers 
agreed that the prolonged dosing interval (0.25mg/kg 12 to 36 hours prior to surgery) was 
likely to be the most effective. To confirm this hypothesis, the sample size needs to be 
increased and the ICG should be administered less than 18 hours prior to the start of surgery.   
NIR-FC may be considered a useful adjunct to standard care in laparoscopic cholecystectomy. 
It has been proven safe and feasible to explore the optimum dosing regimen in a mixed patient 
population in a tertiary referral hepatobiliary unit. However, as yet, we have not conclusively 
proved NIR-FC is effective in delineating biliary structures or in reducing serious intraoperative 
complications. Compared to OTC, NIR-FC appears inferior, so the additional cost of the 
technology and burden of ICG administration may not be cost-effective in the longer term.  
In the future, a dedicated trial of NIR-FC in the acute setting is needed. This trial would need 
specific eligibility criteria to identify patients with acute cholecystitis and likely peri-hilar 
inflammation. This may include elevated CRP and deranged LFTs on admission blood tests, 
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treatment with IV antibiotics, and radiological evidence of acute cholecystitis on ultrasound 
scan. This trial would need a much larger sample size to analyse the effect of NIR-FC on 
operative outcomes.  
The trial conducted was underpowered to determine the effect of NIR-FC on iatrogenic bile 
duct injury. The highest level of evidence remains a randomised controlled trial of an 
intervention. Bile duct injury is a rare but serious complication of cholecystectomy. If we 
assumed a conservative bile duct injury rate is 0.4% with laparoscopic cholecystectomy, and 
75% reduction bile duct injury rate as the dichotomous endpoint in the study population, with 
an equal 1:1 randomisation to control and intervention arms, and with a two-sided 5% level of 
significance and 80% power, a sample size of 8696 participants would be require. If we were 
to settle for comparing a single study cohort against the published literature incidence, 
negating the need for a control arm, and assuming a literature bile duct injury rate of 0.4% and 
study population rate of 0.2%, we would still need to recruit 6505 patients for a two-sided 5% 
level of significance and 80% power to confirm the efficacy of NIR-FC in reducing iatrogenic 
bile duct injuries(222). A trial of this magnitude would be extremely costly and time-consuming 
to conduct. It is also unfeasible to conduct a trial of this size in a single centre and would 
require collaboration with multiple centres. 
This single centre, phase IIa, feasibility study has shown that NIR-FC is feasible and safe. The 
dosing regimen optimisation aim of this study successful identified 0.25mg/kg of ICG 
administered intravenously 12 to 36 hours prior to surgery as the optimum regimen to 
delineated extrahepatic biliary anatomy. This regimen was favoured by the operating surgeons 
and yielded identification of a greater number of biliary structures compared to the shorter 
dosing intervals. NIR-FC appears inferior to OTC in patients who undergo radiological 
intraoperative bile duct mapping.  Further exploration of NIR-FC in the acute index admission 
laparoscopic cholecystectomy setting is required. These are the most technically challenging 
cases and would benefit the most from a real-time dynamic method of performing 
intraoperative bile duct mapping.   
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3. CHAPTER THREE 
EXPLORATION OF EMI-137 AS AN IMAGING AGENT IN 2D AND 3D 
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3.2 AIMS AND OBJECTIVES  
1. To confirm the spectral properties of EMI-137 at various concentration dilutions.  
2. To explore a novel c-Met targeted fluorescent molecule (EMI-137) to detect primary 
colon cancer and metastases. 
a. To determine the colorectal cancer cell line with highest c-Met protein 
expression 
b. To confirm the c-Met receptor specificity of EMI-137 by means of mRNA 
silencing in a selected colorectal cancer cell line.  
c. To compare EMI-137 as an optical imaging agent against standard indirect 
immunofluorescence.  
3. To develop an animal model of colorectal cancer.  
a. To assess the specific binding of EMI-137 in an animal model of colorectal 
cancer and explore the renal excretion of the compound. 
4. To assess c-Met expression by methods of immunohistochemistry in anonymised 
donor colorectal cancer tissue.  
5. To map and quantify c-Met expression in tissue microarrays from a defined colorectal 
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3.3  MATERIALS AND METHODS 
EMI-137 Supply 
The investigational medical product EMI-137 was kindly supplied by our research 
collaborators at Edinburgh Molecular Imaging Ltd, Nine Edinburgh Bioquarter, 9 Little France 
Road, Edinburgh, UK. EMI-137 was supplied as a blue dry powder in individual vials. It was 
stored at 4̊C in a temperature controlled and monitored refrigerator and shielded from light. 
 
EMI-137 Spectral Properties Assessment 
The photophysical properties of EMI-137 were confirmed using the NanoDrop 3300 UV-Vis 
spectrophotometer. A serial dilution of EMI-137 was prepared with Dulbecco's Phosphate-
Buffered Saline (DPBS). The concentrations ranged from 20,000nm to 1,000nm and were 
shielded from light. A single 1µL drop of EMI-137 was loaded into the nanodrop and excited 
with the white light emitting diode (LED) (excitation maxima 460 to 650nm). Results were 
normalised to a phosphate buffer control solution. This ascertained the peak absorbance 
wavelength for EMI-137 across the range of concentrations.  
 
3.3.1 In Vitro 2D Model of Colorectal Cancer 
3.3.1.1  Western Blotting 
Mammalian Cell Lines 
Several CRC cell lines were strategically selected for evaluated to find a c-Met in CRC 
representative cell line. The colorectal adenocarcinoma cell lines were selected for expected 
high expression of c-Met protein with the aim of identifying a single cell line for further research 
and development of an in vivo xenograft mouse model. Breast adenocarcinoma MCF-7 was 
used as a predicted low expressing adenocarcinoma line, whilst HFFF-2 was used as a non-
cancerous normal human fibroblast control cell line. c-Met expression by HFFF-2 was 
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expected to be low because c-Met is normally expressed by cells of epithelial origin. HGF 
secretion is restricted to cells of mesenchymal origin, such as fibroblasts. The immortal murine 
fibroblast cell line 3T3, was used to confirm the selectively of the antibody for human c-Met 
prior to commencing any murine xenograft work.  
 
Primary Cell Culture 
All cell lines were obtained from European Collection of Authenticated Cell Cultures (ECACC) 
(Salisbury, England) and cultured in the appropriate medium enriched with 10% (v/v) Foetal 
Bovine Serum (FBS) (Sigma-Aldrich, Dorset, UK; Cat. No. F7524) and incubated at a constant 
temperature of 37°C with 5% carbon dioxide. Regular passage of the cell lines was performed 
in a class II laboratory cabinet as per usual laboratory technique to maintain viability. Cell lines 
routinely tested for mycoplasma infection.  
Human colon adenocarcinoma cells lines, SW480, HCT-116, HT-29 and Caco-2 cells were 
cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium + GlutaMAX™-I (Gibco® by 
Life Technologies™, Paisley, UK; Cat. No. 11875093). The human colon adenocarcinoma 
LoVo cell line was cultured in F-12 Nutrient Mixture + GlutaMAX™-I Medium (Gibco® by Life 
Technologies™, Cat No: 31331-028). The human breast adenocarcinoma Michigan Cancer 
Foundation-7 (MCF-7), the Human Foetal Foreskin Fibroblast HFFF-2, and the mouse 
embryonic fibroblast 3T3 cell line were cultured in Dulbecco’s Modified Eagles Medium 
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Protein Extraction and Quantification 
The selected cell lines were grown to a confluent state. The media was removed, and the cells 
washed in ice cold Dulbecco’s Phosphate-Buffered Saline (DPBS) (1X), (Gibco® by Life 
Technologies™; Cat. no. 14190094) solution before 4ml of protein lysate buffer was added for 
10 minutes and maintained at 4C. The protein lysate buffer was prepared from equal 
quantities of radio-immunoprecipitation assay (RIPA) buffer (100mM Tris HCL pH 7.4; 300mM 
NaCl; 10% NP40 and diH2O) and complete protease inhibitor cocktail tablets. The cells were 
scraped from the flask, and the supernatant prepared for storage at -80̊C.   
The protein concentration was determined using the BIO-RAD DC colorimetric assay kit with 
Bovine Albumin Serum (BSA) as the known protein standard. Serial dilutions of BSA control 
and BSA with protein lysate were prepared and the optical density (OD) read at 620nm on a 
fluorescence microplate reader. The standard was used to construct a standard curve in 
Microsoft Excel 2013.   
 
Protein Gel Electrophoresis and Transblotting 
Standardised volumes of protein lysate dissolved in loading buffer and diH2O were loaded into 
individual wells of a protein gel. Proteins were resolved by electrophoresis at 180 volts for 1 
hour 45 minutes. Equal quantities of two western protein standards were used as a molecular 
marker. The resolved proteins were then transferred to an activated PVDF membrane with an 
appropriate transfer buffer solution.  All reagents and equipment are described in Table 7. The 
membrane was blocked in 5% and 1% skimmed milk solution. 
The membrane was then probed for the primary antibody with a Horseradish Peroxidase 
(HRP) enzyme conjugated secondary immunoglobulin. Anti-β Actin and anti-α-Tubulin were 
used to probe for the loading control. All concentrations described were achieved by diluting 
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the antibody in 1% skimmed milk solution in TBST (mixture of DPBS, tris-buffered saline and 
Tween-20%).  
 
Membrane Imaging  
The PVDF membrane was imaged using the Gel Doc™ XR+ Gel Documentation System (Bio-
Rad Laboratories, Inc; Hertfordshire, UK). Immunoreactive protein bands with HRP-
conjugated substrate were detected by application of ECL; West Femto high sensitivity 
chemiluminescence substrate was used to detect the c-Met protein and West Pico was used 
to detect the loading control ( 
Table 8).  
 
Relative Quantification of Western Blot Bands  
The image processing program ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of 
Health, Bethesda, Maryland, USA) was used to analyse the Western Blot images. To quantify 
the bands, the mean gray value was calculated for the protein band, the loading control band, 
and a neighbouring negative control band for each cell line. The pixel density was inverted, 
and the net value of the band compared to its matched control was calculated. This allowed 
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Product Full Product Name Supplier/Manufacturer Product Code 
Protease Inhibitor complete protease inhibitor cocktail tablets 
Roche diagnostics GmbH 
Ltd. 
Cat No: 11697498001 
Colorimetric 
protein assay kit 
DC Protein Assay Reagents Package 
1. DC™ Protein Assay Reagent A (SDS) alkaline copper tartrate 
2. DC™ Protein Assay Reagent B (SDS) Folin reagent 
3. DC™ Protein Assay Reagent S (SDS) surfactant solution 




Mithras LB 940 Multimode Microplate Reader with MikroWin 2010 v5.21 
Berthold Technologies 
GmbH & Co. KG 
n/a 
Loading control NuPAGE™ Sample Buffer (4X) 
Invitrogen™ - Thermo 
Fisher Scientific Inc 
Cat No: NP0007 
Protein Gel NuPAGE™ 12% Bis-Tris Protein Gels, 1.0 mm, 10-well 
Invitrogen™ - Thermo 
Fisher Scientific Inc 
Cat No: NP0341BOX 
Running Buffer NuPAGE™ MOPS SDS Running Buffer (20X) 
Invitrogen™ - Thermo 
Fisher Scientific Inc 
Cat No: NP0001 
Transfer Buffer NuPAGE® Transfer Buffer (20X) 
Invitrogen™ - Thermo 
Fisher Scientific Inc 
Cat No: NP00061 
Western standard 
marker 1 
SeeBlue™ Plus2 Pre-stained Protein Standard 
Invitrogen™ - Thermo 
Fisher Scientific Inc 
Cat No: LC5925 
Western standard 
marker 2 
MagicMark™ XP Western Protein Standard 
Invitrogen™ - Thermo 
Fisher Scientific Inc 
Cat No: LC5602 
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PVDF Membrane Polyvinyl Difluoride (PVDF) Transfer Membrane, 0.45 µm, 26.5 cm x 3.75 m Thermo Fisher Scientific Inc Cat No: 88518 
Milk powder Marvel Dried Skimmed Milk Powder 340g Premier Foods Group Ltd n/a 
chemiluminescence substrate 
(ECL) 
1. SuperSignal™ West Femto Maximum Sensitivity Substrate 
2. SuperSignal™ West Pico PLUS Chemiluminescent Substrate 
Thermo Fisher Scientific Inc 
 
Thermo Fisher Scientific Inc 
Cat No: 34095 
 
Cat No: 34580 
Gel Imaging system Molecular Imager® Gel Doc™ XR+ System with Image Lab™ Software Bio-Rad Laboratories, Inc Cat No: 1708195 
 Table 7: Western Blot equipment and reagents  
 
Table 8: Western Blot Antibodies. Abbreviations: RT - room temperature. HRP - Horseradish peroxidase
Antibody Origin Product code Commercial Source Dilution Incubation time Temperature 




Goat Polyclonal P0448 
Dako - Agilent 
Technologies Ltd 




Rabbit Polyclonal P0260 
Dako - Agilent 
Technologies Ltd 
1:2000 30 minutes RT 
Alpha (α) tubulin Mouse monoclonal T516 Sigma Aldrich 1:20,000 60 minutes RT 
118 
 
Name: Gemma Armstrong  
Student No: 201073014 
3.3.1.2 Temporary silencing of c-Met mRNA transcription 
Temporary messenger RNA (mRNA) suppression was used to confirm expression of c-Met 
by the HT-29 cells line and that EMI-137 specifically binds to the c-Met transmembrane protein 
present. EMI-137 was compared against the same anti c-Met recombinant monoclonal 
antibody used in the western blot described in 3.3.1.1 with an immunofluorescent (IF) specific 
secondary antibody for protein localisation. 
Immediately upon delivery, the concentration of SiRNA was verified. The concentrated SiRNA 
sample was briefly centrifuged and re-suspended in RNAse-free water (ThermoFisher 
Scientific Inc., Cat: AM7001) to achieve a concentration of 20µM. The sample was then mixed 
via continuous agitation at RT for 30 minutes. The concentration of RNA was confirmed using 
the NanoDrop 3300 UV-Vis spectrophotometer at an excitation maxima wavelength of 260nm. 
A total of three repeat sample analyses, each at 1µL were performed to confirm an average 
SiRNA concentration of 1uM =13.3ng/µL. 
 
Transfection of cells  
HT-29 cell lines were grown to 80% to 90% confluence in RPMI media supplemented with 
10% FBS v/v. Sterile microscope glass cover slips (22mm x 22mm) were prepared in 6-well 
flat bottom cell culture plates (Corning Costar Inc., New York, USA; Cat. No. 3516) seeded to 
a density of 1.2x106/well. The cells were allowed to settle overnight before transfection. 
Short interfering Ribonucleic Acid (SiRNA) was used to temporarily silence c-Met mRNA 
transcription and c-Met protein expression in HT-29 cells. Cells were allowed to settle 
overnight and were then transfected with a pooled c-Met SiRNA (Table 9) or a pooled non-
targeted SiRNA control (siGENOME Non-Targeting SiRNA Pool #1; (Dharmacon Inc., 
Lafayette, CO, USA). Cat No: D-001206-13-05) using an appropriate transfection reagent 
(DharmaFECT Transfection Reagent #1; Cat No: T-2001-01 (Dharmacon Inc., Lafayette, CO, 
USA). The SiRNA was diluted to the desired concentration in RNAse-free water and RPMI cell 
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culture media. At 24 hours, an additional 2mL of complete cell media enriched with 10% v/v 
FBS was added to each well to reduce the potential cell toxicity effect. 
When ready, the cells were fixed by incubation with 4% w/v Paraformaldehyde (PFA) for 10 
minutes. Blocking was performed by incubation with 0.5% w/v skimmed milk solution for 5 
minutes at room temperature. Localisation of the protein of interest was performed by either 
direct or indirect labelling methods described in detail below. Between steps, the slides were 
thoroughly washed with an appropriate quantity of DPBS. The control slides were prepared 
by incubating HT-29 cells in RPMI complete cell media for 72 hours in identical controlled 
conditions. The slides were then treated with the imaging agent as described.  
 
 SiRNA component Target Sequence 
1. 












SiGENOME SMARTpool SiRNA D-
003156-12 
GAAACUGUAUGCUGGAUGA 
Table 9: Composition of Dharmacon siGENOME Human MET (4233) SiRNA SMARTpool 5 
nmol (Dharmacon Inc., Lafayette, CO, USA). Cat No: M-003156-02-0005). 
 
Indirect c-Met Protein Expression Detection 
To localise the c-Met protein via indirect labelling methods, selected slides were incubated 
with 100µL/well of the c-Met antibody described in  
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Table 8 at a concentration of 1: 200 prepared in 0.5% w/v skimmed solution for 1 hour, followed 
by 100µL/well of 1:300 Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 488 (ThermoFisher Scientific Inc Cat: A-11001) prepared in 0.5% w/v skimmed 
milk solution for 30 minutes at RT in the dark. To exclude non-specific secondary antibody 
binding, a negative control slide was treated with the fluorescent secondary antibody only.  
 
Imaging 
Slides were mounted on Superfrost Plus Adhesion glass microscope slides (25 x75 x10 mm) 
(ThermoFisher Scientific Inc, Cat: J1800AMNT) with ProLong Diamond Antifade with DAPI 
(4′,6-diamidino-2-phenylindole) mountant (ThermoFisher Scientific Inc Cat: P36962) and 
cured overnight at RT. Imaging was performed at x63 and x40 magnification under oil 
immersion using the Zeiss Axioimager fluorescent microscope (Carl Zeiss, Hertfordshire, UK). 
c-Met protein was imaged with the FITC (fluorescein isothiocyanate) fluorescent light channel. 
Nuclear staining was performed with the DAPI channel light filter.  
The Advanced Microscopy Group (AMG) EVOS™ FL Imaging System inverted fluorescent 
microscope using the DAPI and Cy5 filters (Life Technologies, Loughborough, UK) at x40 
magnification was used to image EMI-137 stained slides. The DAPI filter confirmed nuclear 
staining. Direct staining of the protein of interest with EMI-137 was performed with the Cy5 
filter (excitation 628±40nm and emission 692±40nm). The images were analysed and an 
overlay image created where necessary using ImageJ (Rasband, W.S., ImageJ, U. S. National 
Institutes of Health, Bethesda, Maryland, USA) software. This determined location of staining 
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Optimisation of SiRNA Concentration 
To determine the lowest concentration of c-Met targeted SiRNA required to produce 
detectable c-Met protein suppression with immunofluorescent microscopy with the fewest off-
target effects, HT-29 cells were transfected with SiRNA at a concentration of either 25nM, 
37.5nM or 50nM and incubated in controlled conditions for 72 hours.  
 
Optimisation of EMI-137 Concentration 
The optimum concentration of EMI-137 to detect c-Met protein expression in HT-29 cells was 
determined. HT-29 cells grown to confluence on sterile glass cover slips for 72 hours as 
described above. A serial dilution of EMI-137 diluted in DPBS was prepared to yield final 
concentrations of 1000nM, 500nM, 250nM, 125.nM, and 62.5nM.  Each plate was then 
incubated with 100µL/well of EMI-137 for one hour at RT in the dark. Untreated HT-29 cells 
stored in DPBS until imaged were used as negative control.  
 
EMI-137 Specificity for c-Met 
To determine the utility of EMI-137 as a molecular targeting agent in CRC, the expression of 
c-Met protein was investigated using temporary mRNA silencing in HT-29 as a representative 
CRC cell line. HT-29 cells were transfected with a range of concentrations of c-Met SiRNA or 
the non-targeted SiRNA control (05nM, 15nM or 25nM) and treated with a fixed concentration 
of EMI-137 (500nM) or the anti c-Met combination described above. The concentration of EMI-
137 and SiRNA used was defined by previous experimental results described above.   
HT-29 cells were cultured and transfected with pooled c-Met SiRNA or untargeted SiRNA at 
a concentration of 5nM, 15nM or 25nM. The prepared cover slips were then probed with the 
monoclonal c-Met antibody and FITC tagged fluorescent secondary antibody or with 
100µL/well of 500nM of EMI-137 for 1 hour.  
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3.3.2 3D Animal Model of Colorectal Cancer 
Experiments were conducted at a dedicated animal research facility at the University of Leeds 
under Home Office Project License Number 40/3291 held by Dr. L Coletta. The experiment 
was conducted under the supervision of Dr. Nikki Ingham (Home office personal license no. 
40/9070) and Mr. Tom Maisey. Experiments were conducted in accordance with the Animals 
(Scientific Procedures) Act 1986 (ASPA). The ASPA incorporates the European Directive 
2010/63/EU on the protection of animals used for scientific purposes.  
The murine models were developed to analyse EMI-137 excretion and bioaccumulation in live 
tissue. The xenograft was used to analyse c-Met protein expression and EMI-137 binding to 
tumour expressed c-Met in a 3D model of colorectal cancer.  
 
Xenograft Preparation  
Low passage number HT-29 human colorectal cells were grown to a confluent state (70% to 
80% confluence) in complete RPMI media with FBS 10% (v/v) supplementation. The HT-29 
cells were washed, typsinised and then re-suspended in serum-free RPMI media to yield a 
final concentration of 1x107 HT-29 cells per ml in accordance with standard laboratory 
procedures.  
Twelve female BALB/c nude athymic mice were purchased Charles River UK, Ltd (Margate, 
UK) and raised in protected conditions. When the mice were six weeks old, twelve individual 
mice of 20g in weight were selected for experimentation. The mice received a subcutaneous 
injection of 1x106 HT-29 cells in a volume of 100µL of media into the right flank without 
anaesthesia. The xenograft tumour was allowed to develop for 14 days and achieved a 
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EMI-137 Administration 
The athymic mice were restrained and injected with 0.18mg/kg of EMI-137 reconstituted in 
100µL of sterile DPBS via the tail vein. The control mice received 100µL of sterile DPBS 
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Biodistribution Visualisation 
At each of the specified time points (1 hour, 4 hours and 6 hours post-injection of EMI-137) 
the female BALB/C nude athymic mice were anaesthetised by inhalation of vaporised 
Isoflurane and immediately humanly sacrificed. The mice were dissected and solid organs - 
heart, liver, lungs, spleen, brain, and kidneys, and tumour xenografts were retrieved and 
orientated for imaging using IVIS Spectrum In-Vivo Imaging System (PerkinElmer Inc. Seer 




The mouse organs were immediately individually preserved in 4% PFA. A sample of the 
xenograft from each animal was also snap-frozen with the aid of dry ice. The sample was 
embedded in Optimal Cutting Temperature (OCT) compound (Bright Cryo-M-Bed Embedding 
Compound, Bright Instrument Company Ltd, Cambridgeshire, UK) and frozen with the aid of 
dry ice. Samples were stored at -80̊C in a HTA approved facility for future use.  
 
 Fluorescent Microscopy 
Ten-micron (10µm) thickness slices of frozen xenograft tissue were sectioned using the Leica 
GeoSystems CM3050 S cryostat (Leica Geosystems Holdings AG; St. Gallen, Switzerland) in 
preparation for imaging by fluorescent laser scanning microscopy. Xenograft tissue was 
sectioned at -45̊C and renal tissue at -28̊C. Tissue slices were mounted on to Superfrost Plus 
Adhesion glass microscope slides (25 x75 x10 mm) using ProLong Diamond Antifade with 
DAPI mountant with a glass coverslip. Slides were shielded from light and allowed to cure at 
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Tissue Imaging  
The tissue was imaged using the Nikon Eclipse Ti inverted microscope mounted on Nikon 
A1R Confocal Laser Scanning Microscope (Nikon Instruments UK Ltd; Kingston-Upon-
Thames, Surrey, UK) at x60 magnification with Apo-oil immersion. Image acquisition settings 
were standardised for the tissue type. EMI-137 staining was detected with Cy5 laser filter 
settings and nucleus localisation was performed with DAPI laser filter settings. An image 
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3.4  IN-VITRO RESULTS 
3.4.1 Spectral properties of EMI-137 
The peak absorbance was detected at 650nm wavelength across the sample range. This 
confirmed Cy5 nature of the fluorescent peptide coupled to the c-Met peptide and guided filter 
selection for fluorescent microscopy (Figure 18).  
 
Figure 18: EMI-137 peak absorbance at variable concentrations (20,000nm to 1,000nm) and 
DPBS control. Left to right; top row DPBS and 1000 NM. Middle row 2000nM and 5000nM. 
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Assessment of spectral properties of EMI-137 confirmed the excitation and emission 
wavelength as described in the Investigator’s Brochure from EM Imaging Ltd and in Burggraaf 
et al’s research(218,220) (excitation 653nm and emission at 675nm). As expected, there was 
an increase in detectable absorbance signal with an increase in concentration of EMI-137. It 
also confirmed there was a consistently detectable signal from EMI-137 at the likely predicted 
concentrations required for in vitro clinical research in primary tissue culture and in a murine 
model of CRC.   
 
3.4.2 C-Met Protein Expression Quantification by Western Blot 
Western Blot Protein Quantification  
The average relative protein concentration for each cell line was calculated with BSA as the 
known standard. The gradient of the straight line was calculated to yield an R² value of 0.9959 
(Table 10 and  
Figure 19). 
CELL LINE 
RUN HT-29 CACO-2 LOVO SW480 HCT-116 MCF-7 HFFF-2 3T3 
1 0.271 0.128 0.106 0.257 0.206 0.133 0.143 0.137 
2 0.296 0.135 0.117 0.264 0.215 0 0.14 0.16 
3 0.302 0.145 0.113 0.251 0.221 0.149 0.133 0.135 
AVERAGE 
(AU) 
0.290 0.136 0.112 0.257 0.214 0.141 0.139 0.144 
Table 10: Western Blot Protein Quantification with BSA Standard 
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Figure 19: Western Blot BSA Standard Curve 
 
 
Figure 20: Western Blot –detection of c-Met protein expression with a mouse monoclonal 














































































Figure 21: Relative quantification of c-Met protein band density relative to matched loading 
control. 




















Protein Standard (BSA 2mg/ml to 0mg/ml)
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Protein expression in the selected cell lines was investigated by western blotting. A protein 
band of 190-210kDa corresponding to the c-Met protein was identified ( 
Figure 20) when imaged with high sensitivity chemiluminescence substrate. Equal protein 
loading was confirmed by probing the PVDF membrane with α-tubulin antibody and imaging 
with chemiluminescence substrate. 
Visual inspection of the image obtained, and relative quantification of the band density 
compared to the loading control, identified HT-29 as the cell line consistently expressing high 
levels of c-met protein detectable by means of western blot analysis. This was followed by the 
colorectal cancer cell lines HCT-116 and SW-480. MCF-7 was confirmed as a low expressing 
human cancer cell (Figure 20 and Figure 21). This correlates with previously published data 
of c-Met expression in CRC cell lines by Zeng et al(204).  
 
3.4.3 c-Met Silencing with Short Interfering RNA 
c-Met mRNA Transcription Silencing  
HT-29 cells transfected with pooled c-Met specific SiRNA for 72 hours showed markedly 
reduced c-Met protein expression relative to the untreated positive control and to the matched 
pooled non-targeted control with immunofluorescent microscopy (Figure 22).  The resulting 
image was similar with all concentrations of c-Met SiRNA used. This suggests that 25nM of c-
Met SiRNA is the maximum required concentration to temporary silence c-Met mRNA 
transcription at 72 hours post transfection under these experimental conditions and there is 
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Figure 22: HT-29 cells at variable concentrations of SiRNA. A) Targeted to c-Met SiRNA and 
B) pooled matched untargeted SiRNA. Imaged at x63 magnification using the Zeiss 
Axioimager fluorescent microscope. Top row shows DAPI nuclear staining. Middle row shows 
membrane staining with 1:200 monoclonal rabbit recombinant anti c-Met as primary antibody 
and 1:300 Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody - Alexa Fluor 488 
in the FITC channel. Bottom row shows the merged composite image of DAPI nuclear staining 
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Optimisation of EMI-137 Concentration 
A concentration of 500nM EMI-137 was confirmed as the optimum concentration for 
fluorescent microscopy imaging of c-Met. This concentration provided consistent bright 
fluorescent detection of the transmembrane c-Met protein at standardised image acquisition 
settings. Relative to control, a concentration of 62.5nM and 125nM of EMI-137 demonstrated 
little to no detectable fluorescence, whilst 1000nM demonstrated a degree of non-specific 
binding and excessive fluorescent signal that was prohibitive to accurate delineation of 
structures (Figure 23).  
Figure 23: HT-29 incubated with variable concentrations of EMI-137 for 1 hour. Imaged at 
x40 magnification on the EVOS inverted fluorescent microscope with standardised image 
acquisition settings. Merged DAPI and Cy5 filter images.   
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3.4.4 EMI-137 Specificity for c-Met 
 
Figure 24: HT-29 incubated with 25nm of pooled c-Met targeted SiRNA and untargeted 
SiRNA. C-Met protein located with a) 1:200 monoclonal c-Met antibody and 1:300 Alexa 
Fluor 488 fluorescent secondary antibody. Zeiss fluorescent microscope at x40 
magnification. b) HT-29 incubated with 500nM EMI-137 and imaged using the EVOS 
inverted fluorescent microscope at x40 magnification. 
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The specificity of EMI-137 for the c-Met transmembrane protein in HT-29 cells was confirmed 
via temporary c-Met mRNA transcription suppression. HT-29 cells were transfected with 
pooled c-Met targeted SiRNA for 72 hours at a concentration of 5nM, 15nM, or 25nM or with 
untargeted SiRNA of a matched concentration. C-Met protein expression was detected by 
direct or indirect labelling with the novel fluorophore EMI-137 or with anti c-Met primary 
antibody and a FITC conjugated fluorescent secondary antibody respectively.  
The positive control images in  
Figure 24 show identical cell membrane binding with the two fluorescent combinations (a and 
b). This confirms EMI-137 is selective for the human c-Met protein expressed by HT-29 cells 
and comparable to the monoclonal antibody and fluorescent secondary.  
The untargeted SiRNA treated HT-29 cells showed near identical morphology to their matched 
positive control, confirming the mode of action of the untargeted SiRNA and the continued c-
Met protein expression by these cells. EMI-137 appears to give a brighter fluorescent signal 
at a concentration of 500nM when compared to the antibody combination and showed 
marginally less non-specific background binding. A concentration above 500nM is prohibitive 
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3.5  ANIMAL MODEL RESULTS 
Mouse Model Organ Fluorescent Imaging  
A suitably sized tumour developed on the flank in 11 of the 12 female athymic mice selected. 
Owing to their lack of bladder control and therefore inability to store and concentrate urine, 
blue urine discoloration was not observed if the mice.  
Figure 25 shows the fluorescent signal of each organ dissected from the mice at one, four and 
six hours post intravenous administration of EMI-137. The kidneys and xenograft showed high 
fluorescent signal relative to the control and other organs.  
The lack of fluorescence in control animals excluded this being the result of auto-fluorescence 
only. From the pre-clinical data supplied by EM Imaging Ltd we expected renal excretion of 
EMI-137 and therefore the high renal signal was to be expected. At 6 hours post 
administration, kidneys from treated mice showed very low fluorescent signal, whereas the 
xenograft remained bright. The reducing renal signal relative to kidney indicates EMI-137 is 
specific and shows prolonged binding to the human c-Met protein, whereas kidney 
immunofluorescence represented excretory flow only. With increasing duration from injection, 
there was increased xenograft signal relative to kidney. The lack of signal in the other mouse 
organs confirmed EMI-137 specificity for human c-Met protein.  
 
Immunofluorescence  
Fresh frozen tissue from selected control and EMI-137 treated animals was imaged with 
standardised fluorescent imaging settings at x60 magnification. The composite images show 
bright membranous and cytoplasmic fluorescent signal at the expected wavelength of EMI-
137 excitation/emission, relative to the DPBS-treated negative control ( 
Figure 26). There was maximal fluorescence in the xenograft tissue between one- and four-
hours post-administration, with an overall reduction in signal at six hours post administration. 
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This likely demonstrated clearance of the EMI-137 compound from the tissue and circulation. 
Figure 25 shows continued mouse kidney fluorescence at 6 hours post-administration, 
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Heart Xenograft Liver 
Lungs  Spleen 
Brain  Kidneys 
Figure 25: Dissected organs from each mouse. PBS control versus 
treated with 0.18mg/kg EMI-137 at each time point. Clockwise from top 
left A) One-hour post administration B) Four hours post administration 
and C) Six hours post administration. d) Organ lay-out index map. Imaged 
using the IVIS Spectrum In-Vivo Imaging System.  
   
   







Name: Gemma Armstrong  
Student No: 201073014 
 
 
Figure 26:  HT-29 colorectal cancer xenograft from BALB/C nude mice imaged at various time points post IV administration of 0.18mg/kg EMI-
137. Imaged with Nikon Eclipse Ti inverted microscope mounted on Nikon A1R Confocal Laser Scanning Microscope at x60 magnification 
Four Hours One Hour Six Hours 
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3.6  DISCUSSION 
Colonic cancer is a leading cause of cancer related death in the UK and around the world(140). 
Current methods of detecting pre-operative tumour stage and lymph node status are imprecise 
and this makes planning the radicality of surgery difficult(166,224). The c-Met targeted 
peptide, EMI-137, is a novel potential solution to this problem. Burggraaf et al have 
demonstrated EMI-137 shows high affinity for the c-Met receptor and can significantly increase 
the polyp yield in high risk patients with the addition of fluorescence guided colonoscopy(218). 
The aim of this pre-clinical work was to assess c-Met expression in colorectal cancer and 
explore the ability of EMI-137 to detect and visualise c-Met protein expression.  
 
2D model of c-Met Expression in CRC 
With Western blot, I identified a colorectal cell line that consistently overexpressed c-Met 
protein - the well differentiated cell line, HT-29. I was then able to use HT-29 cells to model 
colorectal cancer for further analysis. Temporary silencing of c-Met mRNA transcription in HT-
29 confirmed that EMI-137 has high specificity for colorectal cancer c-Met receptors and could 
be imaged with fluorescent microscopy.  
The optimum concentration of c-Met SiRNA to achieve detectable c-Met mRNA transcription 
suppression in a monolayer of HT-29 cells was determined as 25nM. Above 25nM there was 
no further reduction in signal, but the potential for off-target effects was higher. The HT-29 
cells treated with the control pooled non-targeting SiRNA continued to show high detectable 
levels of c-Met expression regardless of SiRNA concentration. The optimum concentration of 
EMI-137 for c-Met protein imaging was also determined as 500nM. 
By conducting these experiments, I was able to optimise conditions to compare direct 
immunofluorescence with EMI-137 against the standard two-step indirect 
immunofluorescence method.  
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This research confirms that the HT-29 cell line expresses high concentrations of c-Met protein 
and EMI-137 is selective for the human c-Met protein expressed by HT-29 cells. The results 
appear to show EMI-137 is comparable to the commercially available c-Met monoclonal 
antibody. 
 
3D Murine Model of CRC 
The xenograft models of colorectal cancer developed in female nude athymic mice showed 
that EMI-137 was uptaken preferentially by binding to high c-Met expressing HT-29 cells in 
vivo. The xenograft showed high fluorescent signal relative to other mouse organs and the 
DPBS treated control. The strong kidney fluorescent signal confirmed the rapid renal excretion 
of EMI-137. The signal detected in the control tissue probably represents a degree of 
autofluorescence from the highly vascularised liver tissue due to the automatic settings of IVIS 
microscope which could not be optimised further.  
Similar results were also found in immunofluorescent imaging of fresh frozen samples of EMI-
137 and DPBS treated mouse kidney and xenograft. The differing pattern of fluorescent signal 
seen between the two tissue types and the control may represent membrane binding and/or 
internalisation of the EMI-137 probe by the c-Met expressing xenograft, whilst the renal tissue 
is likely to represent tubular clearance only.  
 
Limitations  
Primary tissue culture produces a homogenous monolayer of identical cells. They have equal 
access to nutrients and demonstrate similar cell-to-cell adhesions properties. Although 2D 
culture is extremely useful in clinical research, it has its limitations and does not fully replicate 
the tumour micro-environment. The HT-29 cell line used is a low grade, well differentiated line. 
This might not replicate the typical nature of colorectal cancer encountered in clinical practice. 
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It also contradicts the findings of multiple previous studies which have found c-Met expression 
is directly related to tumour advanced stage and is a prognostic indicator of advanced disease 
and vascular invasion(204,206,207).  
I have compared direct and indirect immunofluorescence with SiRNA silencing techniques in 
section Error! Reference source not found. and section 3.4.3. These techniques are not 
always directly comparable and should be interpreted with caution. For greater understanding 
and accuracy, I would have explored the propriety c-Met peptide and fluorescent tag 
developed by EM Imaging Ltd separately and compared the results to the combined peptide 
and the indirect immunofluorescence. Exploration of the fluorescent tag coupled to an 
untargeted peptide would have been extremely useful. However, these components have not 
been made available to the research group at Leeds and only the combined molecule could 
be evaluated.  
Mouse xenografts are a 3D model and therefore can demonstrate the altered cellular 
metabolism and protein expression in response to variable access to oxygen and vital 
nutrients we see with human in vivo colorectal cancer. Colorectal tumours are highly 
heterocellular systems composed of cells of epithelial, mesenchymal, and lymphoid origin. 
However, this xenograft was composed of a single cell type. HT-29 cells form a well 
differentiated adenocarcinoma model of colorectal cancer. This homocellular malignant 
proliferation model may not accurately represent the heterogeneous nature of a colorectal 
tumour in vivo.  
The immunohistochemistry performed on the FFT samples confirms the technique has been 
optimised and c-Met can consistently be detected in human colonic tissue samples, even after 
long periods of storage at -80̊c. However, the small number of FFT samples available and lack 
of information regarding the tumour stage and pre-morbid patient state limits the wider 
interpretation of the IHC performed.  
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This pre-clinical research using 2D and 3D models has confirmed c-Met is a feasible target in 
colorectal cancer fluorescent guided imaging. I have established consistently high levels of c-
Met expression in HT-29 cells with western blot and was able to confirm that EMI-137 shows 
high specificity for the human c-Met receptor in colorectal cancer with immunofluorescence. 
The animal xenograft model of colorectal cancer further confirmed that EMI-137 is highly 
specific for human c-Met and can be imaged with our IVIS imaging system.  
The next stage of this research was to define c-Met expression in a large sample of human 
colorectal cancer tissue via immunohistochemistry and to progress to a small phase IIa clinical 
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4. CHAPTER FOUR 
C-MET PROTEIN EXPRESSION QUANTIFICATION IN A COLORECTAL 
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4.1 AIMS & OBJECTIVES 
i. To optimise the method of quantification of c-Met expression in colorectal and normal 
tissue with immunohistochemistry. 
ii. To correlate c-Met IHC expression scores with final pathological stage (TNM v5.0) in 
CLASICC cohort.  
iii. To explore c-Met as diagnostic biomarker of colorectal cancer (CRC) 
a. To develop and utilise a semi-quantifiable grading system to examine the 
average c-met protein expression in human CRC tissue relative to matched 
normal control tissue 
b. To determine the sensitivity and specificity of c-Met as a diagnostic marker of 
CRC. 
c. To determine the IHC cut-off threshold for c-Met as a diagnostic marker of 
CRC. 
d. To determine the Area Under Curve and predictive likelihood of c-Met as a 
diagnostic marker in CRC.  
 
4.2  METHODS 
The antibody used (Rabbit monoclonal anti c-Met antibody (ref: ab51067) Abcam Plc) had 
been validated in mouse and human tissue for IHC and immunofluorescence. The antibody 
was used at dilution concentration of 1:250 throughout. Reagent batch numbers and timings 
were recorded for each run of IHC performed and stored securely in the trial specific laboratory 
folder. The method was optimised and validated in control fresh frozen tissue obtained from 
the Leeds Multidisciplinary Research Tissue Bank prior to undertaking the CLASICC tissue c-
Met quantification process.  
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Control Samples 
Fresh Frozen Tissue (FFT) samples of colonic tumour, normal tissue and colonic adenomas 
(polyps) were obtained from two anonymised patients (c0007 and c0008). The tissue was 
obtained from the Leeds Multidisciplinary Research Tissue Bank (RTB) held under active 
project license from Prof D Jayne and with support of laboratory RTB manager S Perry.  
Analysis of these samples explored c-Met expression in early and pre-cancerous lesions as 
compared to the late cancerous lesions obtained in the trial. It also assessed the impact of 
formalin fixation on background staining and possible auto-fluorescence on imaging results 
obtained.  
 
Control Slide Preparation  
The tissue was embedded in Optimal Cutting Temperature Compound (OCT) and snap frozen. 
Samples had been stored at -80̊C in a HTA approved facility at the University of Leeds, UK. 
Ten-micron (10µm) thickness sections of frozen tissue were produced using the Leica 
GeoSystems CM3050 S cryostat (Leica Geosystems Holdings AG; St. Gallen, Switzerland) at 
-28̊C. Sections were mounted on to Superfrost Plus Adhesion glass microscope slides 
(Thermo Fisher Scientific, Altrincham, UK) and returned to -80̊C. Immediately prior to use, the 
slides were slowly defrosted at RT for 30 minutes and rehydrated in PDS solution.  
 
CLASICC Tissue Samples  
The Medical Research Council (MRC) CLASICC randomised controlled trial was a superiority, 
parallel group, randomised controlled trial of laparoscopic assisted versus conventional open 
surgery in the treatment of colorectal cancer (Trial Number ISRCTN74883561). CLASICC 
recruited 794 patients from 27 UK centres undergoing CRC surgical resection surgery 
between 1996 and 2002. Consent was obtained from participating patients for biopsies of 
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normal colonic epithelium and CRC to be stored for future research. The study aimed to 
compare completeness of oncological resection, peri-operative mortality, patient-reported 
quality of life outcome measures and long term survival between the two surgical 
approaches(152,153,155). Final pathological staging of the resected CRC specimen was 
reported according to the contemporary American Joint Committee on Cancer (AJCC) TNM 
Classification of Malignant Tumours, Fifth Edition (1997)(225).  
 
CLASICC Tissue Microarray (TMA) Preparation 
Formalin Fixed Paraffin Embedded (FFPE) colorectal cancer and matched normal colorectal 
mucosa tissue core samples deemed most representative at Hematoxylin and Eosin (H&E) 
staining, provided by a representative sample of 280 patients recruited in to the CLASICC trial, 
were incorporated in to seven anonymised Tissue Microarrays (TMA) (Ethics London-Dulwich 
Committee - 12/LO/1327, approval granted in 2012) by S Yeluri previously. Each TMA 
contained three 0.6mm core tumour samples and three matched normal tissue samples from 
each of the 280 participants. Control normal tissue archival samples of placenta, ovary, 
prostate, kidney, epididymis, liver, gallbladder, stomach, oesophagus, pancreas, small bowel, 
lung and muscle held within the University of Leeds archive were incorporated into the TMA 
margins for comparative and orientation purposes. Comprehensive TMA block indexes were 
produced and stored securely at the University of Leeds and utilised during sample analysis.  
 
CLASICC Slide Preparation  
Five-micron sections from the TMA blocks were prepared with the Leica RM2235 Manual 
Rotary Microtome (Leica Microsystems (UK) Ltd, Milton Keynes, UK), mounted on SuperFrost 
AdhesivePlus glass slides with the aid of a thermostatic water bath maintained at a constant 
temperature of 47̊c and dehydrated overnight in a drying cabinet. To ensure resistance to 
mechanical manipulation, slides were heated at 78̊c for 10 minutes on the Leica HI1220 
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flattening table (Leica Microsystems (UK) Ltd, Milton Keynes, UK) and allowed to cool at RT. 
The prepared slides were then de-paraffinised in xylene and 99.8% v/v ethanol and rehydrated 
in water according to laboratory SOP in preparation for specific antibody probing and imaging. 
 
4.2.1 Immunohistochemistry 
Antigen Retrieval  
The FFPE CLASICC trial TMA tissue required antigen retrieval prior to immunohistochemical 
processing. The fresh frozen control tissue from the RTB did not require this step. Heat 
induced antigen retrieval was performed by placing the slides into citric acid buffer solution 
adjusted to pH6.2, and into a microwave for 10 minutes at 900W. The slides were allowed to 
cool at RT then washed for 5 minutes in running cold water.   
 
c-Met Expression Immunohistochemistry  
The monoclonal recombinant anti-Met (c-Met) antibody ([EP1454Y], Abcam PLC, Cambridge, 
UK) concentration and protein detection conditions were optimised with human appendix and 
tonsil tissue obtained from stored samples held on behalf of the research group in accordance 
with Human Tissue Act (HTA) guidance prior to conducting the experiments described below 
(data not shown).  
Slides were incubated with 1:250 Recombinant Anti-Met (c-Met) primary antibody [EP1454Y] 
for one hour at room temperature in a humidified chamber. Next, a rabbit specific labeled 
Horseradish Peroxidase (HRP) immunoenzymatic antigen detection system was used for 
protein detection and chromogenic visualisation. Slides were incubated with 100µL of HRP 
containing Equilibrate SignalStain® Boost IHC Detection Reagent (Cell Signalling Technology 
Inc, Leiden, The Netherlands. Cat: 8114S) as the secondary antibody for 30 minutes in a 
humidified chamber. Slides were repeatedly washed in TBS solution. Enzymatic chromogenic 
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detection was performed with the SignalStain® 3,3'-diaminobenzidine (DAB) Substrate Kit 
(Cell Signalling Technology Inc, Leiden, The Netherlands. Cat: #8059S). Slides were 
incubated with 100µL of the prepared chromogen reagent for 10 minutes in a humidified 
chamber at RT. Development of brown tissue colouration was observed. In between each 
incubation step, the slides were washed repeatedly in a pre-prepared dilute tris-buffered saline 
(TBS) solution.  
A control slide of tissue was prepared in an identical manner except for incubation with the 
primary anti-c-Met antibody. The control slide was used to exclude background staining or 
oxidation.   
 
Counterstaining  
Counterstaining was performed according to local laboratory protocol. Prepared tissue slides 
were incubated with Meyer’s Hematoxylin solution (Sigma-Aldrich Scientific Inc., Cat: H9627-
25G) for 60 seconds and washed under running tap water before incubation with Scott’s tap 
water (laboratory stock reagent). Slides were dehydrated in gradient concentrations of ethanol 
and cleaned in xylene, then mounted on to glass cover slides with DePeX Mounting Medium 
for histology and allowed to cure overnight at RT.  
 
Imaging  
CLASICC Tissue Imaging 
The CLASICC slides were imaged at x40 magnification and digitalised with the Leica 
BioSystems Aperio AT2 whole slide scanner (Leica Microsystems Ltd, Milton Keynes, UK) 
and proprietary microscopic imaging platform software by Mr. M Hale in the Virtual Pathology 
team within the Division of Pathology and Data Analytics at the Leeds Institute of Medical 
Research at St. James’s. Slide images were uploaded to the virtual pathology website portal 
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(https://www.virtualpathology.leeds.ac.uk/). The slides were viewed with Aperio ImageScope 
v12.4.0.5043 (Leica BioSystems Pathology Imaging Ltd, Milton Keynes, UK).  
 
RTB Control Tissue Imaging  
Bright-field microscopy imaging of prepared slides was performed using the Nikon Eclipse 
MicroscopyU E1000 automated microscope (Nikon Instruments Inc., New York, USA) at x20 
magnification.  
 
4.2.2 c-Met Expression Scoring 
A semi-quantified scale used to score CRC biomarker expression developed by J. Tiernan 
within the research group in 2014(226),(227) was adapted and applied to score the c-Met 
expression in the CLASICC tissue samples. The system utilised previously established and 
validated protein expression grading systems(228–231). c-Met protein immunopositivity in 
epithelial cell membranes from each tissue core was scored. The intensity of the chromogenic 
reaction was quantified with a numerical scale between 0 and 3 (0 = no detectable expression, 
1 = mild expression, 2 = moderate expression and 3 = strong expression). The distribution of 
membranous c-Met immunopositivity was determined by calculating the percentage of tumour 
or normal epithelial cells deemed positive as a percentage of all of the tumour/normal epithelial 
cells in the core total area. For tumour cores, non-cancerous tissue was excluded from the 
analysis. The intensity and distribution scores generated were multiplied to provide a 
compound c-Met expression score, with a maximum score of 15 (Equation 1).  
The intensity and distribution measurements were done in triplicates for each tissue sample. 
Cores with insufficient mucosal (epithelial) tissue, for example core samples lost through 
processing, were discounted. In total, 263 tumour and 253 normal epithelium core triplicates 
(or pairs if single core not assessable) were suitable for analysis and 242 matched tumour-
normal tissue paired samples (86.43% of pairs) were included in the final analysis. 
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𝑻𝒐𝒕𝒂𝒍 𝒄 − 𝑴𝒆𝒕 𝒆𝒙𝒑𝒓𝒆𝒔𝒔𝒊𝒐𝒏 𝒔𝒄𝒐𝒓𝒆 =  𝒊𝒏𝒕𝒆𝒏𝒔𝒊𝒕𝒚 × 𝒅𝒊𝒔𝒕𝒓𝒊𝒃𝒖𝒕𝒊𝒐𝒏 
Equation 1: Equation to calculate total c-Met expression scores of TMA specimens 
 
The scoring criteria was appraised and approved by several colleagues with experience of 
IHC and grading IHC immunopositivity at consensus meeting prior to initiating the scoring 
process. Representative examples of c-Met expression at each distribution score (0 to 5) and 
intensity score (0 to 3) were approved by the group and available for reference throughout the 
scoring process. 
 
Statistical Analysis  
Microsoft Excel and GraphPad Prism 7 (GraphPad V7.04 Software, Inc., California, USA) were 
used for all data handling and statistical analyses. A D'Agostino-Pearson test was performed 
to determine the normality and skewness of the data. This confirmed the data was not from a 
normal Gaussian distribution and guided the selection of non-parametric statistical tests. 
A Wilcoxon matched-pairs signed-rank test was used to compare the median rank between 
the two matched TMA populations, tumour and normal tissue. The Interquartile Range (IQR), 
and two- tailed p value is reported. A statistical significance threshold of p = <0.05 was applied. 
The Wilcoxon matched-pairs signed-rank estimate of the 95% confidence interval (95% C.I) 
of the ranked median population score for both tissue types and the median difference bound 
by the IQR is also quoted. This method used binominal probabilities to predict the 95% C.I 
around the median and is therefore asymmetrical around the median value provided(232). 
The likelihood ratio, an alternative measure of diagnostic accuracy, is also quoted. In clinical 
practice, a likelihood ratio of 2 increases the probability of the disease or condition being 
present by around 15% compared to a negative result(233). A Spearman test assessed the 
correlation in the matched pair results and provided an overall R value. To account for 
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uncertainty in the data caused by missing core samples pairs, a sensitivity analysis assuming 
the highest c-Met expression (compound score 15) for all missing data fields was performed. 
To determine the relationship between the final pathological stage (AJCC TNM v5.0) and the 
c-Met expression observed with IHC, the median c-Met IHC expression for tumour, normal 
and the difference between the values (tumour minus normal score), for each Tumour (pT) 
and Nodal stage (pN) (TNM v5.0) was calculated. The Spearman rank correlation between 
the pT stage, pN stage and difference between tumour and normal tissue score and TMA c-
Met expression score was obtained. A Chi-Squared test of trend analysed the relationship 
between pT stage and pN stage median tumour c-Met IHC expression score to generate a p 
value to determine significance.   
A Receiver Operating Characteristic curve (ROC curve) was plotted to determine the 
diagnostic capability of c-Met protein as a biomarker of CRC and potential intraoperative 
differentiator of normal from malignant colonic tissue. The sensitivity of c-Met as a predictive 
CRC biomarker (true positive) rate was plotted as a function of the specificity (true negative) 
and used to calculate varying decision cut-off thresholds and the relevant 95% C.I. The Area 
Under Curve (AUC) was calculated to numerically quantify the diagnostic capability of c-Met 
in discriminating malignant from normal colorectal tissue.  
 
4.3  RESULTS 
Method Optimisation 
Control RTB Tissue 
C-Met expression in fresh frozen tissue samples from two donor patients were analysed with 
IHC. The three tissue types (normal, tumour and pre-malignant polyp) all showed areas of 
high levels of c-Met expression relative to negative (untreated) control tissue ( 
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Figure 27). These results were used to confirm the required antibody protocol described below 
and exclude background non-specific chromogenic staining inference. The results also guided 
the development of the c-Met grading system described. The CLASICC participant samples 
were compared to the fresh frozen tissue samples. The comparison excluded interference in 




Name: Gemma Armstrong  
Student No: 201073014 
 
Figure 27: IHC optimisation results. Fresh frozen colorectal malignant, normal and polyp 
tissue from two donor patients. Immunohistochemistry analysis of c-Met protein expression 
(antibody concentration 1;250) relative to matched negative control tissue. Imaged at x20 
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CLASICC Population Demographics 
The key demographic and clinicopathological characteristics of the CLASICC trial 280 patient 






Table 11 (adapted from Tiernan et al (2014), Guillou et al (2005) and Jayne et al 
(2005)(152,153,227)). Forty-six (46/560; 8.2%) individual tissue samples were deemed 
ungradable (18/280 tumour and 28/280 normal tissue samples). There was an expected pT3 












Table 11: Key clinical and pathological features of CLASICC patient cohort. Adapted from 
Jayne et al (2007) and Guillou et al (2005) (152,153) 
Characteristic 
Number of cases (%) 
N = 280 
Age range: 33 - 93 years 
Mean age: 68.9 years 
Gender  
Male 144 (51.4%) 
Female 136 (48.6%) 
pT stage  
1 10 (3.6%) 
2 54 (19.3%) 
3 161 (57.5%) 
4 52 (18.6%) 
Unknown 3 (1.1%) 
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CLASICC c-Met Expression 
The c-Met immunopositivity of epithelial cells varied considerably throughout the normal and 
tumour tissue population; examples of very low and low expression were observed in both 
populations as shown in Figure 28.  
The D'Agostino & Pearson normality test confirmed the populations were not sampled from a 
normal distribution and a non-parametric test was required; skewness -0.6 and 0.3 and 
kurtosis -1.1 and -1.3 for tumour and normal tissue respectively (p = <0.0001). 
Variable c-Met levels detected with chromogenic techniques were observed across the 
matched specimens. CRC cancers frequently demonstrated stronger c-Met protein expression 
as compared to normal tissue. High expression was defined as an overall c-Met expression 
intensity score of 15 and was found in 30.80% (81/263) of CRC samples as compared to 
12.25% (31/253) in normal tissue samples (p<0.0001). No detectable c-Met expression with 
a composite c-Met expression score of 0 was found in 7.90% (20/253) of normal colorectal 
tissue samples versus 3.42% (9/263) in matched tumours (p<0.0001). Representative 
examples of c-Met expression are shown in Figure 28 and Figure 29.  
Wilcoxon matched-pairs signed-rank test showed a significant difference between the median 
expression scores of normal colonic epithelium and colon cancer. Median c-Met IHC 
expression scores of 12.0 (95% C.I 10.0 to 13.0; IQR 6.0 to 15.0) and 6.0 (95% C.I 5.0 to 7.5; 
IQR 2.7 to 12.0) for tumour and normal tissue respectively. The sum of signal rank W score 
was -133 (p = <0.0001). The median differential expression score (tumour – normal) was 2.3 
(95%C.I 1.0 to 3.5 and IQR -0.25 to 7.7; p = <0.0001) (Figure 30).  
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Figure 28: Representative examples of TMA c-Met immunohistochemical chromogenic 
visualisation. 
 
Figure 29: Example of high c-Met expression in normal and colorectal cancer tissue at x13 
and x40 magnification. 
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 Tumour Normal Difference 
Number of pairs 242  
Minimum 0.0 0.0 -14.0 
25% Percentile 6.0 2.8 -0.25 
Median 12.0 6.00 2.3 
75% Percentile 15.0 12 7.7 
Maximum 15.0 15.0 15.0 
Wilcoxon Matched Pairs Signed Rank Test 
p value (two tailed) < 0.0001 < 0.0001  
95% C.I of median difference  1.0 to 3.5 
IQR median difference  -0.3 to 7.7 
Sum of signed ranks (W) 15397  
Sum of positive rank 22274  
Sum of negative rank -6877  
Figure 30: Summary of statistical analysis of TMA c-Met expression by IHC tumour 
versus normal tissue. CLASICC TMA c-Met expression median score and interquartile 
range. Median difference Tumour – normal tissue 2.33 (95%C.I 1.0 to 3.5). 
M e d i a n  c o m p o u n d  s c o r e  t u m o u r  v e r s u s  n o r m a l  w i t h
i n t e r q u a r t i l e  r a n g e  ( I Q R )






























T u m o u r
N o r m a l
157 
 
Name: Gemma Armstrong  
Student No: 201073014 
Correlation Tumour & Normal Tissue Score 
The correlation between normal and tumour tissue c-Met expression was statistically 
significant but yielded a weak overall association between the matched samples; Spearman 
R value 0.3 (95% C.I 0.2 to 0.4; p = < 0.0001). We cannot assume a linear relationship 
between normal and tumour tissue expression. There was a potential for a strong detectable 
noise to signal ratio with c-Met as the target for intraoperative optical imaging and 
differentiation of tissue types.  
 
S p e a r m a n  R  c o r r e l a t i o n  t e s t  o f  m a t c h e d  t u m o u r  a n d  n o r m a l  t i s s u e  p a i r s
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9 5 %  C . I :  0 . 2  t o  0 . 4
 
Figure 31: Spearman correlation of c-Met expression. Intensity of tumour tissue plotted as 




Name: Gemma Armstrong  
Student No: 201073014 
Correlation with TNM stage 
T stage N 
Median tumour c-Met 
IHC expression score 
S.D IQR 
1 9 (3.5%) 13.3 3.2 4.0 
2 51 (20.0%) 11.0 5.8 13.0 
3 149 (58.5%) 11.7 4.9 9.0 
4 46 (18%) 13.0 5.2 8.0 
P value 0.2 
N Stage 
0 146 (57.3%) 11.5 5.2 9 
1 67 (26.3%) 11.5 5.0 9 
2 42 (16.4%) 13.3 5.1 8 
P value 0.2 
Total  255 (91.1%) 
Table 12: Median tumour sample c-Met immunohistochemistry expression score of 
CLASICC TMA by final pathological Tumour (pT) and Nodal (pN) stage (TNM v5.0) with 
percentage of total, standard deviation and interquartile range shown, 255/280 TMA tumour 
samples were suitable for assessment and had TNM stage data available for correlation. 
 
 
Figure 32: Box and whisker plot of CLASICC TMA median tumour c-Met IHC expression 
score by tumour (pT) and node (pN) stage with IQR and range shown.   
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Normal IHC average 
Difference (tumour-
normal) 
R 0.04 0.13 -0.14 
95% C.I of R -0.08 to 0.2 0.004 to 0.3 -0.3 to -0.01 
P value 0.5 0.04 0.03 
Table 13: Final tumour (pT) pathological stage (TNM v5.0) and Spearman correlation with 
Median c-Met immunohistochemistry expression score of CLASICC TMA with difference 
between tumour and normal tissue expression score. N = 255 pairs. 






























Figure 33: Spearman rank correlation of p stage (ranked from pT1 to pT4) and difference 
between tumour and normal c-Met IHC expression score in CLASICC TMA cohort samples. 





Normal IHC average 
Difference (tumour-
normal) 
R 0.05 0.14 -0.11 
95% C.I of R -0.08 to 0.17 0.01 to 0.3 -0.2 to 0.02 
P value 0.5 0.03 0.09 
Table 14: Final lymph node (pN) pathological stage (TNM v5.0) and Spearman correlation 
with Median c-Met immunohistochemistry expression score of CLASICC TMA with difference 
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The final pathological TNM (v5.0) stage and intact TMA triplicates suitable for scoring were 
available for 255 patients (91.1%) from the CLASICC cohort. Forty-four percent of pT1 (4/9 
44.4%) tumour samples had an average tumour IHC c-Met expression score of 15, compared 
to 24% (13/53) of pT2, 31.4% (49/156) of pT3, and 28.6% of pT4 (Chi Squared test of trend p 
= 0.09).  
The median tumour c-Met IHC expression score was higher for pT1 and pT4 tumours, 13.3 
and 13.0 respectively (Table 12), although the trend was not statistically significant (p = 0.2). 
Figure 32 shows the wide spread of data with a broad IQR observed at each tumour stage.  
Spearman rank correlation confirmed there was no evidence of a monotonic relationship 
between the pT or pN stage and the normal tissue c-Met expression score or the difference 
between tumour and normal tissue IHC c-Met expression score in the CLASICC cohort (Table 
13 and Table 14). The correlation coefficient R is very close to the neutral zero value for pT 
stage and pN stage, -0.14 (p = 0.03) and -0.11 (p = 0.09) respectively. Figure 33 is a visual 
representation of the spread of data for pT stage and differential c-Met expression score. 
There does not appear to be any trend in the data or evidence of a relationship between 
tumour stage and c-Met expression observed with IHC. The p value for pT stage and pN stage 
and median tumour IHC score did not reach statistical significance, p = 0.5 and 0.5 
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Accuracy of c-Met as a Colorectal Cancer Diagnostic Biomarker  
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Figure 34: Receiver Operating Characteristic (ROC) curve and Area under Curve (AUC) for 
c-Met. Sensitivity plotted as function of specificity at various decision thresholds for c-Met as 
a diagnostic biomarker in colorectal cancer detection. 
 
Receiver Operating Characteristic (ROC) Curve 
The Receiver Operating Characteristics (ROC) curve of the sensitivity and specificity of c-Met 
IHC expression at various thresholds for the diagnosis of CRC is shown in Figure 34. The 
ROC-AUC score yielded an overall predictive probability likelihood of 0.66 (CI: 0.61 to 0.7; p 
= <0.0001). The 95% C.I indicates the results from the CLASICC study population are likely 
very close to the actual population diagnostic accuracy value.  
A total c-Met expression score of ≥14.5 yielded a high sensitivity of 85.3% (C.I. 80.3% to 
89.5%), but there was a substantial trade-off with specificity of only 30.9% (C.I. 25.4% to 
36.9%), with a likelihood ratio of 2.1. A combined score of the total sensitivity and specificity 
from each cut-off generated by the ROC curve was also calculated. This determined the 
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greatest sensitivity and specificity ratio for c-Met as a CRC detection marker. An overall cut-
off expression score of ≥11.6 yielded the greatest combined true positive and true negative 
rate with a sensitivity for CRC of 55.7% (95% C.I 49.5% to 61.8%) and specificity rate of 71.8% 
(95% C.I 65.8% to 77.3%); likelihood ratio 2.0. The highest likelihood ratio, 2.3 was observed 
with a c-Met expression score of ≥13.2; sensitivity 40.8% (95% C.I 34.8% to 47.1%) and 
specificity 82.1% (95% C.I 76.9% to 86.7%).  
 
Sensitivity Analysis 
The sensitivity analysis assumed the highest level of c-Met expression for all missing data 
(compound score 15). This again confirmed a significant difference in median score between 
the matched tissue samples, 12.3 (IQR 7.6– 15.0) and 10.0 (IQR 6.0 – 13.3) respectively, with 
a median difference of 1.0 (IQR -2.0 to 5.0; 95% C.I 0.33 to 1.67; p = <0.0001). Similarly, the 
ROC-AUC analysis showed an AUC value of 0.6 (95% C.I 0.55 to 0.64; p = < 0.0001). 
However, assumed intense c-Met immunopositivity (expression score ≥14.5) yielded a slightly 
lower CRC predictive value specificity of 78.5% (95% C.I 73.1% to 83.2%) and sensitivity of 
33.9% (95% C.I 28.4% to 39.9%), likelihood ratio 1.2. 
 
4.4  DISCUSSION 
Oncogenic activation of the transmembrane c-Met protein has been reported to induce 
multiple intracellular changes leading to the development and progression of 
cancers(197,200,207,234,235). Overexpression of c-Met has been reported in several 
gastrointestinal malignancies, including colorectal cancer(236). Previous studies have 
identified the overexpression of c-Met in CRC as a predictor of poor prognosis and poor overall 
and progression-free survival(203).  
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I quantified the expression of c-Met protein using IHC in matched tumour and normal epithelial 
tissue samples from participants involved in the MRC CLASICC trial. This analysis of TMA 
tissue from matched tumour and normal tissue samples confirmed the median c-Met protein 
expression score in a large population of UK colorectal cancer patients who underwent surgery 
between July 1996 and July 2002. With the adapted grading system applied, I demonstrated 
that total c-Met transmembrane protein expression was significantly increased relative to 
matched normal tissue (p = <0.0001). The median expression score was significantly higher 
in tumour compared to normal colorectal tissue, 12.0 and 6.0 respectively. There was poor 
correlation between normal and tumour tissue and a non-linear relationship (Figure 31). This 
suggests there is potential for a high signal to noise ratio between tumour and normal tissue 
if c-Met is used as an intra-operative tumour and metastatic lymph node detection agent.  
The ROC curve and AUC confirm c-Met could be a potential biomarker for CRC detection. In 
practice, a score of 12 or over, composed of maximal intensity score (intensity graded as 3 
high) in over 60% of epithelial-type cells yields the greatest combined specificity and sensitivity 
for the detection of colorectal cancer, 76.2% and 52.3% respectively. A total score of 15, 
composed of maximal expression intensity in more than 80% of cells is highly sensitive, 85.3% 
but there is a significant trade-off with specificity of only 30.9%. At this threshold the false 
negative rate is low, but at the expense of a high false positive rate. The likelihood ratio at this 
decision threshold was 2.1. This translates to the presence of a c-Met expression score ≥14.5 
increasing the likelihood of colorectal cancer by little more than 15%. 
Overall, 96.6% of all tumour cores analysed demonstrated detectable c-Met expression at 
IHC. These results correlate with previous research that has shown c-Met is upregulated and 
overexpressed in gastrointestinal cancers (206,237,238). Esfahani et al confirmed c-Met 
positivity in 81% of 163 CRC samples analysed using a TMA and IHC techniques and 
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IHC assessment of protein expression in TMA tissue allowed rapid quantification of c-Met 
levels in a systematic manner. It required a relatively small amount of tissue from the precious 
and finite CLASICC tissue resource and the permanency of prepared slides allowed review of 
results to confirm accuracy and fidelity.  
Assessment of colorectal cancer tissue samples from small observational studies, such as 
Gayyed et al, found a strong positive correlation between c-Met expression levels and clinical 
pathological characteristics(239). However, my analysis of c-Met expression in CRC TMA 
samples obtained within the rigors of a large randomised controlled trial discredit this. I did not 
find any evidence of a monotonic relationship between pT or pN stage and differential c-Met 
expression scores at IHC in the samples analysed. The c-Met protein is consistently 
overexpressed in CRC relative to matched normal tissue and c-Met has the potential to be a 
useful tissue biomarker but its expression does not correlate with disease stage (Figure 33, 
Table 13 and Table 14). This work suggests c-met is present at all stages of disease in variable 
quantities. Fluorescent detection of c-Met may aid intra-operative navigation for both early and 
advanced tumours at laparoscopic resection surgery.  
 
Limitations  
There are limitations to this experiment and the subsequent inferences of the efficacy of c-Met 
as potential biomarker of CRC in laparoscopic resection surgery with EMI-137. The TMA 
tissue samples were obtained from the “most representative” area of tissue in the tumour and 
normal tissue provided by individual participants. The exact location of the sample was not 
provided. The samples are most likely a mix of central and peripheral tissue. The tumour 
microenvironment is highly heterogeneous and hypoxia upregulates expression of c-Met 
protein(202). Central tumour samples obtained from areas of reduced oxygen delivery could 
potentially show an increase in c-Met expression relative to peripheral samples from areas of 
tumour with adequate oxygenation.  
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Immunohistochemistry only allows a semi-quantitative assessment of protein expression. The 
grading system applied was at risk of subjectivity bias and there were a limited number of 
scoring combinations possible. An alternative method, such as real-time quantitative 
polymerase chain reaction (q-PCR), would have provided continuous numeric data of c-Met 
DNA transcription and may have been a more objective measure.  
The data supports the results of smaller studies and is the largest cohort of patients samples 
obtained within the confines of an RCT. Tiernan et al confirmed the potential of 
Carcinoembryonic Antigen (CEA) as a biomarker in CRC and used a very similar scoring 
method to this study(228). They identified increased CEA expression in CRC tissue when 
compared to corresponding normal tissue. c-Met expression levels in my study were inferior 
to CEA, but it outperformed the other common cancer biomarkers explored by Tiernan et al: 
Epidermal Growth Factor Receptor (EGFR), Folate Receptor Alpha (FRα) and Tumour-
Associated Glycoprotein 72 (TAG-72)).  Previous research suggested a possible link between 
c-Met amplification and resistance to EGFR inhibitors in metastatic CRC(213,214). A possible 
area of further research would include co-expression of c-Met and EGFR and the crosstalk 
between these signalling pathways in CRC.  
The investigational medical product, EMI-137, explored during this thesis is known to be 
internalised in the presence of the ligand HGF(221). In trial participants, with endogenous HGF 
present, I expected the EMI-137 to bind to the tumour and lymph node surface c-Met receptor 
and be internalised. This is likely to increase the overall fluorescence and c-Met targeted 
detection. To date, the intensity of fluorescence and depth of tissue penetrance of EMI-137 
has not been clearly defined. For EMI-137 to function as an intraoperative imaging agent, it 
must bind to the transmembrane receptor and the fluorescent tag must be excited by the 
appropriate wavelength of light. Therefore, the c-Met receptor must not only be accessible to 
the EMI-137 molecule but also in a relatively superficial or peripheral location to allow 
excitation of the Cy5 fluorescent tag and detection of the light emitted. The density, 
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accessibility and location of the c-Met protein is important for the diagnostic yield of EMI-137 
in intraoperative colon cancer mapping and will be explored in a phase IIa trial.  
Immunohistochemical analysis of c-Met expression in human tissue samples showed a 
significant differential expression between matched normal colonic epithelium and colorectal 
cancer. Malignant tissue consistently overexpressed c-Met protein, relative to normal tissue. 
EMI-137 is a c-Met targeted peptide coupled to an inert fluorophore. The presence of 
endogenous HGF may increase the internalisation of the imaging molecule and facilitate clear 
fluorescent tumour and lymph node localisation. These pre-clinical results indicated c-Met was 
overexpressed by CRC tissue relative to background, although results did not correlate with 
disease stage, there was sufficient evidence of a potential therapeutic advantages to warrant 
exploration of EMI-137 in the intraoperative setting for the resection of colonic cancer and 
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5 CHAPTER FIVE 
EMI-137 AS AN OPTICAL IMAGING AGENT IN COLON CANCER: A 
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5.1  AIMS AND OBJECTIVES 
Primary Objectives 
The purpose of this study was to investigate the ability of EMI-137 to produce visible 
fluorescence of colon cancer during laparoscopic surgery. We hypothesised that colon cancer 
and/or metastatic lymph nodes would preferentially uptake the EMI-137 marker due to 
overexpression and/or upregulation of the c-Met receptor and this would allow intraoperative 
localisation of the primary cancer and diseased lymph nodes.  
The pre-clinical research conducted and described in Chapters 2 and 3 supported the 
hypothesis that c-Met was a suitable imaging target in colon cancer and that EMI-137 showed 
the required sensitivity and specificity for human c-Met to facilitate intraoperative delineation 
of colonic tumours and metastatic lymph nodes.  
The primary aim of this trial was to investigate the ability of EMI-137 to produce visible 
fluorescence of colon cancer during laparoscopic surgery.  
 
Secondary Objectives 
1) To investigate the ability of EMI-137 to produce visible fluorescence in regional lymph 
nodes draining the colon cancer.  
2) To investigate the concordance of visible fluorescence in colon cancer with 
histopathological stage and c-MET expression in resected specimens.  
3) To investigate the concordance of visible fluorescence in cancer draining lymph nodes 
with histopathological evidence of metastasis. 
4) To explore the tumour (signal) to background (noise) fluorescence  
5) Investigation of the safety profile of EMI-137 
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6) Exploration of systemic, operative, and patient factors, which adversely affect EMI-137 
fluorescence detection of colon cancer. 
7) Study of in vivo imaging compared to ex vivo fluorescent detection. 
 
5.2  CLINICAL TRIAL METHODS 
The clinical feasibility study of EMI-137 in laparoscopic colonic resections was an early phase 
clinical trial. It explored the feasibility of EMI-137 as an intraoperative imaging agent in patients 
undergoing laparoscopic colonic cancer surgery at LTHT.   
 
5.2.1 Trial Design 
This trial was designed as an unblinded, non-randomised, phase IIa feasibility study. The trial 
was conducted at the single site, St James’ University Hospital in Leeds, with support from 
the University of Leeds. The eligibility criteria are defined in Table 15. 
The primary aim of the study was to investigate the ability of the novel c-Met targeted 
fluorescent imaging agent, EMI-137, to produce visible fluorescence in colon cancer during 
laparoscopic surgery. The planned secondary endpoints included exploration of fluorescence 
in metastatic lymph nodes, dose optimisation, safety, and feasibility outcome measures.  
The intraoperative image obtained with EMI-137 and the ability to detect metastatic lymph 
nodes will be compared to the final pathological stage (TNMv8.0) as the gold standard.  
 
Regulatory Approval  
Ethical approval was granted by the Yorkshire and Humber Leeds West Research and Ethics 
Committee (Y&H REC) (Ref 17/YH/0263) on 27th October 2017. Regulatory approval was 
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granted by MHRA under The Medicines for Human Use (Clinical Trials) regulations 2004.S.I 
2004/131 (Ref 16767/0294/001-0001) 29th August 2017. 
Local approval from Leeds Teaching Hospital Trust (LTHT) clinical directorate of Abdominal 
Medicine and Surgery (AMS) was obtained prior to commencing participant recruitment and 
active data collection. The trial was conducted in accordance with all quality assurance and 
ethical best practice guidelines and there were robust systems in place for reporting of any 
protocol breaches or adverse events to the trial sponsor, the University of Leeds, and the 
regulatory authorities. LTHT Surgical Clinical Trials Unit (CTU) supported the trial and were 
actively involved in participant screening, recruitment, and data collection for the duration of 
the trial.   
Substantial Amendments 
Introduction of the Union for International Cancer Control TNM v8 classification system 
Tumour Node Metastasis (TNM) v8.0 classification system on 1st January 2018 at LTHT 
necessitated a substantial amendment to the trial protocol. Regulatory approval was granted 
for this prior to trial commencement by REC and MHRA on 5th January and 10th January 2018 
respectively.  
The Investigator Brochure (IB) and Investigational Medicinal Product Dossier (IMPD) were 
updated twice by the Industrial Partner and drug supplier (EM Imaging Ltd) to incorporate 
batch re-test results and new safety information discovered. This facilitated shelf-life extension 
of the EMI-137 batch supplied to LTHT. MHRA approved the first substantial amendment to 
these supporting documents in March 2018 and in March 2019. 
 
Non-Substantial Amendments  
Non-substantial amendments to the protocol was approved locally by the University 
Leeds/LTHT Quality Assurance (QA) team: 
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1. Incorporated a change to external pharmacovigilance reporting processes. This was 
approved on 14th February 2018.  
2. The expected recruitment period was extended by a further six months. This was 
approved on 4th September 2018. 
3. The expected recruitment period was extended by a further six months. This was 
approved on 15th February 2019.  
 
Participants 
The trial recruited 10 participants with a diagnosis of colon cancer at the single LTHT site – St 
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5.2.2 Eligibility Criteria 
The eligibility criteria are listed in Table 15.  
Inclusion criteria Exclusion criteria 
• Age ≥18 years. 
• Patients with a diagnosis of colonic 
cancer (the disease can be of any 
radiological TNM stage and be located 
anywhere from the caecum up to but not 
including the rectosigmoid junction) 
• Patients with or without distant visceral or 
lymphatic metastatic disease.  
• Patients with synchronous colon cancers 
or polyps can participate. 
• American Society of Anaesthesiologists 
(ASA) classification ≤3. 
• Normal hepatic and renal function (eGFR 
≥60 mls/min/1.73m2) and bilirubin within 
institutional limits and/or ALT ≤2.5x upper 
limit of institutional normal value) on 
serum laboratory blood tests performed 
≤30 days prior to EMI-137 administration.  
• Female participants who are surgically 
sterile (documented bilateral 
oophorectomy and/or hysterectomy), 
post-menopausal (cessation of menses 
for more than 1 year), or pre-menopausal 
with two negative urine pregnancy tests 
performed within 24 hours of 
administration of EMI-137 Injection.  
• Pre-menopausal female participants of 
child-bearing potential who agree to 
• Patients who are participating in 
another intra-operative fluorescence study 
or have participated in another fluorescence 
study within 3 months of the planned 
surgical procedure. 
• Received an investigational 
medicinal product at any dose within 28 
days of planned EMI-137 administration  
• Patients with pre-existing 
inflammatory bowel disease. 
• Patients who have undergone 
neoadjuvant chemotherapy to treat the 
colon cancer. 
• Patients with impaired renal function 
(eGFR <60 mls/min/1.73m2).  
• Patients with impaired liver function 
(Bilirubin above institutional limits and/or 
ALT >2.5x upper limit of normal). 
• Pregnant and breastfeeding woman. 
• Pre-menopausal woman planning to 
become pregnant within 90 days of 
receiving EMI-137; or pre-menopausal 
woman of child-bearing potential who refuse 
to use two forms of contraception for at least 
90 days after receiving EMI-137 
• Male patients with a currently 
pregnant partner or male patients who are 
planning to conceive a pregnancy with a 
173 
 
Name: Gemma Armstrong  
Student No: 201073014 
employ two method of contraception (as 
defined in eligibility criteria section 8.2) 
during the study period and for 90 days 
after EMI-137 administration. 
• Male participants with a non-pregnant 
female partner. Male participants with a 
pre-menopausal partner of child-bearing 
potential who agree to use two forms of 
contraception (as defined in section 8.2) 
during the study period and for at least 90 
days after receiving EMI-137. (The only 
permissible exception would be if the 
participant had undergone documented 
bilateral orchidectomy or their female 
partner is post-menopausal (cessation 
menses >1 year) or has undergone 
documented bilateral oophorectomy 
and/or hysterectomy). 
female partner within 90 days of receiving 
EMI-137; or male participants who refuse to 
use two forms of contraception as defined in 
section 8.2 for at least 90 days after 
receiving EMI-137 with their female partner 
of child-bearing potential.  
• Poorly controlled or serious medical 
or psychiatric illness that, in the 
investigator’s opinion, is likely to interfere 
with participation and/or compliance in this 
clinical trial. 
• Previous adverse reaction to 
fluorescent agents 
Table 15: Eligibility Criteria for Intraoperative Imaging of Colon Cancer using a Fluorescent 
peptide (EMI-137) against the c-Met receptor feasibility study 
 
Screening and Recruitment 
Potential participants were identified thorough the LTHT Colorectal Cancer Multi-Disciplinary 
Team (MDT) Meeting, the LTHT theatre booking platform, or during outpatient clinic 
appointments. All participant eligibility screening and recruitment was performed by the clinical 
research fellow and the participating consultant surgeons, with support from the LTHT Surgical 
Research Unit (SRU). 
Screened participants deemed to meet all the eligibility criteria were approached to participate 
either in face-to-face interactions or over the telephone. All participants were provided written 
information in the form of a Participant Information Sheet (PIS) and given verbal information 
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about the trial at least 24 hours prior to involvement. All potential participants were given the 
opportunity to ask questions and provided with the name and contact details of a delegated 
member of the research team if they wished to discuss their involvement further at a later date. 
All members of the research team were experienced in gaining consent for a clinical trial and 
had valid GCP training. It was stressed to all potential participants that their involvement was 
voluntary, they could withdraw at any time, and refusal to participate would not adversely affect 
the care they received in any way. No incentives to participate were offered to participants. 
Patients wishing to participate in the clinical trial were asked to sign a trial specific patient 
consent form prior to receive EMI-137 and undergoing surgery. Their usual General 
Practitioner (GP) was also informed of their trial involvement. Patients were assigned a unique 
trial participant number and baseline preoperative demographics were collected including age, 
gender, Body Mass Index (BMI), pre-operative blood test results, imaging results, 
comorbidities and previous surgical history via a paper preoperative Case Report Form (CRF).  
 
5.2.3 Trial Intervention 
Fluorescent Laparoscope Equipment and Training  
The laparoscope used in this trial was a standard blue light Karl Storz® (KS) fluorescent 
endoscopy system (Karl Storz Endoscopy (UK) Ltd., Slough, Berkshire, UK) with a propriety 
detachable red-light camera head filter that was selected for intraoperative imaging with the 
fluorophore EMI-137. The Clinical Research Fellow and EM Imaging Ltd worked closely with 
KS Research and Innovation (R&I) team in Germany to develop a laparoscopic system 
suitable for use with EMI-137 during the trial development stage. The excitation filter in the 
light source transmitted light from 620 nm to 656 nm, whilst the emission filter transmitted light 
from 663 nm to 738 nm. This was appropriate for the photo-physical properties of EMI-137 
with peak excitation (λmax ex) of 648 nm.  
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The operating surgeons, Research Fellow, and key members of the theatre clinical team 
received thorough training from UK based Karl Storz Ltd (Rotherham UK) representatives on 
safe operation of the fluorescent laparoscope in theatre. An equipment manual was always 
available and the company representative could be contacted during office hours for technical 
advice. The representatives were also present in theatre during the early cases should 
technical support have been required.   
 
Figure 35: Karl Storz® D -Light Fluorescent laparoscopic system (left) and the prototype 
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Investigational Medical Product (EMI-137) 
The Investigational Medical Product (IMP) was supplied by the industrial partner, Edinburgh 
Molecular Imaging Ltd (EM Imaging Ltd, Edinburgh, UK) to the clinical site, LTHT, with trial 
specific labels attached which conformed to the Directive 2001/20/EC and Medicines for 
Human Use (Clinical Trials) Regulation. The IMP was supplied as a dark blue dry powder and 
was stored in a temperature monitored and controlled refrigerator (between 2C and 8C) and 
shielded from light prior to reconstitution and administration.  
Participants received a single weight-adjusted intravenous bolus of EMI-137 (maximum dose 
0.13mg/kg) 1 to 3 hours prior to the planned start of their surgical procedure.  
 
Surgical Procedure 
The surgical procedure was completed as per surgeon usual technique. Participation in the 
trial did not require any deviation from the accepted surgical technique of laparoscopic colonic 




The KS fluorescent endoscopy system was used to perform the intraoperative fluorescent 
assessment for all cases. After establishment of a pneumoperitoneum and any required 
mobilisation/adhesion division, the endoscope was switched to fluorescent mode and an 
assessment of the fluorescent signal achieved with EMI-137 was performed by the operating 
surgeon. The fluorescent signal detected in the tumour, any regional lymph nodes, or any 
suspected or confirmed intra-abdominal metastases was assessed. Any fluorescent nodes 
were marked with a surgical clip to allow correlation with final pathology nodal status 
assessment. The signal to noise ratio was also appraised. The fluorescence was graded using 
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a semi-quantifiable scale and the opinion of the operating surgeon was considered as part of 
the evaluation process. The assessment was made in relation to the background fluorescence 
(signal to noise ratio). Data was directly entered into the CRF in the operating theatre by the 
trial research fellow.  
 
Follow-up 
All trial participants received a single trial-specific follow-up 2 to 3 weeks following discharge 
from hospital. The purpose of this visit was for the assessment of any post-operative 
complications, including adverse events specifically related to the administration of EMI-137. 
This follow-up appointment usually coincided with routine postoperative follow-up to minimise 
participant inconvenience. After this visit, all trial involvement ceased, and no further data was 
collected from participants.  
 
Data Management  
The majority of trial data was captured on trial specific paper CRFs. Digital media data 
including intraoperative videos and resected specimen photographs were also collected. All 
data collected was stored securely on-site at LTHT in paper form, and where necessary on an 
LTHT recoverable network drive. At the trial endpoint all data was sent to be securely archived 
for 15 years. After this date, data will be destroyed confidentially and in adherence to data 
protection regulations. 
 
Trial Oversight and Quality Assurance  
Due to the size and design of the trial, it did not require a dedicated trial steering committee 
or trial monitoring group. Instead, the trial was overseen and monitored by the LTHT/University 
of Leeds Quality Assurance (QA) team. As per the data management plan, the trial was 
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inspected at regular intervals by the QA team. All CRFs were checked against the original 
source data for completeness and accuracy. Any discrepancies were queried and rectified.  
Progress reports were submitted at six monthly intervals to the trial sponsor.  
Regular progress and development meetings were held with EM Imaging Ltd and Karl Storz 
Research and Innovation team in Germany to analyse the early results and discuss potential 
methods of optimisation.   
 
Trial Closure 
Trial recruitment ceased on 29th July 2019. The trial closed on 28th August 2019 following the 
last visit of the last subject as per the schedule of visits and approved trial design. An end of 
notification and end of trial report was submitted to Y&H REC, MHRA and to EM Imaging Ltd 
in due course.  
 
5.2.4 Radiology Assessment  
Dr. Damian J. Tolan (Consultant Gastrointestinal Radiologist) at LTHT performed all trial 
specific radiology assessments. The pre-operative abdominal and pelvic CT scans were 
reviewed according to the criteria outlined in the radiology appendix of the protocol and 
radiology CRF, and any suspected malignant nodes were marked on a Modified Japanese 
staging subgroups diagram. The Union for International Cancer Control TNM v8 classification 
system(149) was used to predict pre-operative radiological stage. 
 
5.2.5 Histopathology Assessment  
Dr. Nick P West, Associate Professor in Molecular & Digital Pathology, and Honorary 
Consultant in Gastrointestinal Pathology at LTHT, performed the trial specific histopathological 
assessments. Participants in the trial consented to the retrieval and storage of tissue for 
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purposes of research as part of the standard trial consent process. Tissue was collected and 
stored in accordance with the approved trial protocol version and the University of Leeds/LTHT 
histopathology trial specific laboratory SOP. The Union for International Cancer Control TNM 
v8 classification system(240) as used for final tumour grade classification.  
The whole fresh tumour specimen was photographed with labels identifying the anterior and 
posterior surface, the tumour, and the vascular high tie. Any lymph nodes that were suspected 
to contain metastatic tumour deposits during surgery were clearly marked. Trial specimen 
photographs were stored securely in individual NHS patient electronic records and 
anonymised copies were transferred to a secure recoverable University of Leeds network drive 
for research purposes and future long-term archiving. 
The trial participant tumour specimens were prepared as per standard local policy. They were 
fixed in formalin and the non-peritonealised surfaces were painted with India Ink. The tumour 
was sliced into 3-4mm slices and all lymph nodes present were mapped according to the 
Modified Japanese staging subgroups diagram (Figure 36). The distance from the tumour and 
the presence of tumour deposits was also recorded. All preoperative radiological and 
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Figure 36: Modified Japanese colorectal lymph node staging subgroups diagram - Pericolic, 
D1 lymph nodes (red); Intermediate D2 lymph nodes (blue); Main, D3, lymph nodes (yellow). 
Adapted from GLiSten trial protocol(172) with N.P West and D.J Tolan. 
 
H&E Staining 
Counterstaining with Hematoxylin and Eosin (H&E) was performed as part of standard care 
by laboratory staff in the LTHT department of histopathology as per departmental SOP. Slide 
images were digitalised and uploaded to the secure virtual pathology portal (Virtual Pathology 
Image Viewer 0.3.02, Section of Pathology and Tumour Biology, Leeds Institute of Medical 
Research, University of Leeds, 2019) and made available to the research team for the duration 
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Immunohistochemistry  
FFPE Tissue from Trial Participants  
FFPE tissue blocks of tumour (x2), normal colonic tissue, and positive lymph node tissue 
where available from each trial participant and transferred from LTHT pathology department 
to a HTA approved storage facility at the University of Leeds as per the trial specific laboratory 
agreement. For consistency, the IHC method described in Chapter 4 was applied to trial 
participant FFPE tissue blocks. The antibody used (Rabbit monoclonal anti c-Met antibody 




Bright-field microscopy imaging of IHC stained and prepared slides was performed using the 
Nikon Eclipse MicroscopyU E1000 automated microscope (Nikon Instruments Inc., New York, 
USA) at x20 magnification. A representative image from each sample was captured for review 
purposes.  
 
Statistical Analysis  
The analysis of the intraoperative results was mainly descriptive. Microsoft Excel and 
GraphPad Prism 7 (GraphPad V7.04 Software, Inc., California, USA) was used for statistical 
analysis. The frequency, mean, range and standard deviation were calculated. Wilcoxon 
matched-pairs signed rank test was used to assess the accuracy of pre-op radiology CT (cT 
and pT) to predict final pathological tumour stage and lymph node status (cN and pN). 
Spearman correlation was applied to assess the relationship between intraoperative 
fluorescence signal (isofluorescent to background or mildly fluorescent) and participant 
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demographic factors and final pathological stage (TNM v8.0 pT stage and pN stage). The 
Spearman R coefficient value (R) and the p value are quoted.  
 
5.3 CLINICAL TRIAL RESULTS 
5.3.1 Participants  
Recruitment and Screening  
 
Figure 37: EMI-137 in laparoscopic colonic resections consort diagram  
(Abbreviations: PI principal investigator; IHC Immunohistochemistry) 
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Figure 37 shows the total number of patients screened, treatment allocation, and participants 
followed up to trial completion. Thirty-six percent (57/158) of all patients screened did not meet 
the eligibility criteria. This is relatively high for a clinical trial and relates to the strict eligibility 
criteria of the trial. This was a phase IIa trial of EMI-137 with limited safety data provided from 
small healthy volunteer studies, which limited inclusion of participants with impaired 
hepatorenal function(218,220). CRC is a disease of advanced age, trial participation required 
normal hepatorenal function which tends to decline with age (Table 15). Only 12.7% of patients 
screened declined to participate showing the trial was acceptable to the majority of patients 
approached. A major barrier to recruitment was availability of research staff and/or the 




The first patient was recruited to the trial on 14th February 2018 with a total of 10 patients 
recruited. The last patient underwent fluorescent guided surgery on 29th July 2019. The last 
visit of the last subject was conducted on 28th August 2019. 
 
Participant Demographics 
Table 16 shows the baseline demographics of the nine participants enrolled into the trial who 
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Table 16: Summary of participant baseline demographics   
(N = 9) Mean average S.D 
Age (years) 72 ± 3.9 
Gender M: F 4: 5   
Body Mass Index (m2) 26.5 ± 4.1 
ASA grade 
1 1   
2 4   
3 4   
Co-morbidities 
Cardiovascular disease Yes: No 6: 3 
  




Respiratory disease Yes: No 3: 6   
Diabetes Yes: No 0: 9   
Pre-op colonoscopy 
Tumour location    
Ascending colon 2   
Transverse colon 1   
Hepatic flexure 1   
Descending colon 1   
Sigmoid colon 4   
Tumour morphology 
Polypoidal 2   
Semi annular 1   
Circumferential (annular) 6   
Colorimetric tattoo applied 9: 0   
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Table 17: Key characteristics of trial participants. Abbreviations: pT pathological Tumour stage; pN pathological node stage; M male; F Female; m2 
metre2: y years; ASA American Society of Anesthesiologists Grade.  
N.B pN stage pN1c indicates there are no regional lymph nodes are positive but there are tumour deposits in the subserosa, mesentery or non-
peritonealised pericolic or perirectal/mesorectal tissues. 
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5.3.2 Intra-Operative Results  
Primary Tumour Fluorescence  
The primary tumour was considered mildly fluorescent (relative to background) in 44% (4/9) 
of participants and isofluorescent to background in the remaining 5 participants (56%) (Table 
17). Representative operative images are shown. The most promising results were observed 
in participant EM009 (Figure 38). This 68-year-old female had a pT1 sigmoid tumour and in 
fluorescent light assessment there was distinct delineation of the tumour relative to 
background signal.  
Table 18: Summary of intraoperative results. (Abbreviations: hh: mm Hour: minute) 
 
(n = 9) Frequency n Mean ± S.D 
EMI-137 dose received 
0.13mg/kg 8   
0.09mg/kg 1   
Dose volume administered (mg) 9.5 ± 1.4 
Dosing interval (hh:mm) 01:46 ± 00:17 
Tumour fluorescence 
Highly fluorescence to background 0   
Mild fluorescent to background 4   
Isofluorescent to background 5   
Lymph node fluorescence 
Presence of fluorescence in LN Yes: No 0 : 9   
Surgical procedure performed  
Right hemicolectomy 2   
Extended right hemicolectomy 1   
Left hemicolectomy 3   
High anterior resection 3   
Laparoscopic length of procedure (hh:mm) 02:30 00:47 
Curative resection performed? Yes: No 9 : 0   
Serious intra-operative complications? Yes: No 0 : 9   
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Safety  
EMI-137 was well tolerated by trial participants. There were no Suspected Unexpected 
Serious Adverse Reactions (SUSARs) arising from, or possibly related to the administration 
of EMI-137. Eight Expected Adverse Events (AEs), or known expected complications of major   
abdominal surgery, were recorded (Table 19).  
 
Table 19: Summary of adverse events reported 
 
 
Expected Adverse Events (AEs) 
Respiratory  
Hospital acquired pneumonia  2 
Gastrointestinal  
Constipation 1 
Prolonged ileus 2 
Biochemical: deranged liver function tests 1 
Cutaneous  
Phlebitis at cannula site 1 
Genito-urinary  
Urinary tract infection 1 
Total  8 
Unexpected Adverse Event 
Mechanical fall at home 1 
Total events 9 
Serious Adverse Events (SAE) 
Neurological   
Vasovagal syncope episode  1 
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Protocol Adherence 
There were two protocol deviations reported.  
Participant 
ID 
Deviation Reason Outcome 
EM003 
Fresh frozen tumour 
samples not obtained for 
long-term storage and 
potential future translation 
research. 
Patient safety. Tumour was 
too small to safety take 
tissue for storage and 








Withdrawn from trial after 
consent obtained. 
Patient safety. A lack of high 
dependency post-operative 
beds at the clinical site, 
LTHT meant surgery was 
cancelled on the day. 
Surgery was urgently 
rescheduled but the 
research team could not 
support the new date. 
Participant 
was withdrawn 






Table 20: Protocol deviations reported during trial active phase. 
Table 21: Comparison of pre-operative radiological (CT) TNM v8.0 staging and final 
pathological grade for each subject. 
Subject ID 
T stage N stage 
Radiology (c) Pathology (p) Radiology (c) Pathology (p) 
EM001 T4a pT3 N1c pN0 
EM002 T3 pT3 N0 pN0 
EM003 T3 pT3 N1a pN1b 
EM004 T2 pT2 N0 pN1a 
EM005 T4a pT4b N0 pN2a 
EM007 T3 pT3 N1a pN1c 
EM008 T3 pT3 N1b N0 
EM009 Tx pT1 N0 pN0 
EM010 T3 pT3 N1 pN1b 
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Radiology Accuracy  
Pre-operative radiological CT scan assessment (cT and cN stage) correctly predicted the final 
pathological pT stage and pN status in 67% and 22% of subjects respectively. The correlation 
between CT radiological and final pathological TMN v8.0 was poor and did not reach statistical 
significance. Wilcoxon matched-pairs signed rank test of cT and pT stage and cN and pN 
stage gave a p = > 0.99 value for both comparisons. The accuracy of CT for predicting nodal 
(cN) stage was particularly poor overall and reflects previously published data relating to the 
role of CT in pre-operative colon cancer staging(166,224).  
 
Participant Factors and Influence on Intraoperative Fluorescent 
Signal 
Spearman correlation was performed to try and ascertain the relationship between peri-
operative trial participant characteristics and intraoperative fluorescent signal detected with 
EMI-137. The data did not show a strong monotonic relationship between participant age, 
BMI, gender, ASA grade or tumour location (right versus left sided lesions) or interval from 
EMI-137 administration to assessment of fluorescence, and the p value was not significant 
(Table 22). These results are from a small observation study. No further inference on the 
relationship between these patient demographic factors and fluorescent signal detected with 
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Participant Factor Coefficient R P value 
Age (years) -0.13 0.44 
Gender -0.35 0.33 
BMI (m2) 0.43 0.29 
ASA grade -0.05 0.22 
Tumour location (right>left) 0.36 0.43 
Assessment interval (minutes) -0.09 0.56 
Table 22: Spearman correlation of intraoperative tumour fluorescent signal versus participant 
peri-operative characteristics, p value not significant.  
 
5.3.3 Histopathology Results  
Immunohistochemistry results for each participant are shown below (page 193 to 200) and the 
summary of final pathological stage results are shown in Table 23 below.   
Tumour tissue from all participants demonstrated moderate to high c-Met immunopositivity 
across the samples (8/8) and six (6/8) matched normal mucosa samples were strongly positive 
for c-Met expression. All four of the participant tumour samples deemed mildly fluorescent at 
intraoperative assessment showed strong c-Met immunopositivity with IHC. 
Five participants (5/9, 56%) showed lymph node involvement at final histopathological 
assessment (mean total lymph node yield 24.3 ± 10.7; range 5 – 38 and involved node range 
1 to 4). Eight malignant nodes, from four participants were examined with IHC. All nodes 
showed moderate to high c-Met immunopositivity. Participant 005 had three involved lymph 
nodes, one of which was identified as highly suspicious for malignancy intra-operatively during 
white light assessment, but no fluorescent nodes with EMI-137 were observed.   
192 
 
Name: Gemma Armstrong  
Student No: 201073014 
Table 23: Summary of subject histology results. Abbreviations: S.D standard deviation. * in 
accordance with TNM v8.0. 
(N = 9) Mean ± S.D Range 
Tumour differentiation    
Well/moderate 9   
Poor 0   
Tumour histological sub-type    
Adenocarcinoma 8   
Adenocarcinoma variant - mucinous 1   
Max tumour diameter (mm)  34.2 ± 20.3 15 - 80 
Max distance tumour extends beyond muscularis propria (mm) (≥pT3) (n = 7)  2.5 ± 2.3 1 - 7 
Plane of excision    






Complete resection at all margin achieved?     
R0 (yes) 9   
R1 (no) 0   
Tumour T stage*    
pT1 1   






pT4b 1   
Distance to circumferential margin (mm)  25.4 ± 27.4 2.5 – 75 
Lymph node yield   24.3 ± 10.7 5 – 38 
Total number lymph nodes involved     
0 5   
1 1   
2 1   
3 1   
4 1   
Tumour N stage*    
pN0 4   
pN1a 1   
pN1b 2   






Apical node involvement    
Yes 0   
No 9   
Size largest malignant node (mm) (n = 4)  7.0 ± 1.2 6 – 9 
Deepest level of venous invasion    
None 6   
Intramural 0   
Extramural 3   
Deepest level of lymphatic invasion    
None 4   
Intramural 0   
Extramural 5   
Deepest level of perineural invasion    
None 7   
Intramural 0   
Extramural 2   
Histologically confirmed distant metastatic disease Yes: No 0: 9   
Tumour M stage*    
M0 9   
M1 a/b/c 0   
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EMI-137 was safe and well tolerated by all nine participants. No Serious Adverse Events 
(SAEs) directly related to the administration of EMI-137 were recorded (Table 19). The trial 
intervention was also acceptable to patients with a relatively few declining to participate 
(Figure 37). 
However, EMI-137 guided fluorescent surgery failed to produce consistent detectable tumour 
and metastatic lymph node fluorescence. The tumour was deemed mildly fluorescent in less 
than half of all cases and the tumour was isofluorescent to background in five of the nine 
enrolled participants (Figure 38). A strong monotonic relationship between any single 
participant factor and adverse fluorescent detection could not be identified in this patient 
cohort.   
My preliminary results support the safety data described by Burggraaf et al  in their study of 
EMI-137 (previously known as GE-137) in colonoscopy, where volunteers in both placebo and 
treatment arms (n=31) reported only mild unrelated AEs (commonly headache or somnolence) 
and no SAEs or SUSURS(218).. Burggraaf et al calculated the background clearance half-life 
of EMI137 as 2.5 hours. Within the confines of a pragmatic surgical trial, I was able to achieve 
a mean average assessment interval of 1 hour and 46 minutes. I expected this to have been 
sufficient to produce sufficient signal to noise ratio (tumour relative to background signal). I did 
not identify any correlation between tumour fluorescent signal and interval to 
assessment(218).  
My efficacy data does not support Burggraaf et al’s previously published conclusions of EMI-
137 as a highly specific diagnostic imaging agent in colorectal cancer(218). They found EMI-
137 fluorescence was detectable in all colorectal adenomas (47/47) and 78% (33/42) 
hyperplastic polyps with a prototype fluorescence colonoscope compatible with EMI-137 
excitation. A significant difference with our study is the depth of penetrance of fluorescent light 
required. Colonic tumours are intraluminal lesions, and most participants in my trial were stage 
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T3 or less and by definition had not breeched the colon serosa. Burggraaf et al used an 
endoluminal technique (colonoscopy) to visualise the lesions of interest, the photons of light 
exciting and emitted from the bound EMI-137 had minimal biological tissue to diffuse through 
and there would have been significantly less scattering of light(218). It is estimated at the edge 
of the NIR window at around 600nm the depth of penetrance in biological tissue is only 1 to 
3mm(241). In our trial, the tumour was imaged intracorporeally, but extraluminally. The 
additional serosa, mesentery and omental tissue layers are likely to have impeded 
visualisation in this setting.  
 
Schweiger et al’s analysis of colorectal cancer and pulmonary metastases identified c-Met 
expression as being significantly higher at the invasive margin as compared to central tumour 
areas(205).  They also found median tumour and metastases c-Met expression scores at IHC 
were closely correlated in only 21% (7/33) of cases. This demonstrates c-Met expression may 
vary considerably throughout a single tumour or metastases and between the primary tumour 
and the related secondary metastases. The participant tissue analysed in this trial showed 
significant c-Met expression variance between individuals and between primary tumour and 
lymph node metastases. This supports the findings of Schweiger et al and previous research 
examining c-Met expression in colorectal cancer liver metastases(205,221).  
 
Limitations 
The study population was small (9 participants) and highly heterogenous. This limits the ability 
to draw any firm conclusions on the efficacy of EMI-137 in the detection of colon cancer or 
factors that adversely affect visualisation with the fluorophore. The Snap-on filter was 
manufactured and optimised by Karl Storz® Ltd R&I department for use with a standard D-
Light laparoscopic system. The addition of the filter added another refractive layer and reduced 
the transmission of light. Attaching the filter to the camera head was also time-consuming and 
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cumbersome. Ideally, the filter would have been built into the laparoscope, to reduce the 
refraction of light and improve usability. At the exploratory trial phase this was not feasible. 











In this PhD project, I aimed to explore and evaluate two fluorescent imaging agents for the 
purposes of dynamic intraoperative visualisation in laparoscopic surgery. With the advent of 
commercially available fluorescent laparoscopy systems and multiple compatible 
fluorophores, exploration of their utility and clinical benefit was needed. The potential to 
clearly, in real-time, delineate biliary anatomy and colonic tumour margins and lymph node 
spread with fluorescent compounds and a dedicated light source aimed to aid the decision-
making process and allow individualised surgery tailored to the anatomy and disease 
characteristics.  
To achieve my aims, I divided my research in to three distinct sections. Firstly, I explored and 
optimised the technique of Near Infrared Fluorescent Cholangiography (NIR-FC) with the 
untargeted fluorophore ICG in an early phase clinical trial. Then, I conducted extensive pre-
clinical research in 2D and 3D models of colorectal cancer to evaluate c-Met as a potential 
diagnostic biomarker and imaging target. I also assessed the specificity of EMI-137, a novel 
c-Met targeted peptide for human c-Met and the biodistribution of EMI-137 in a murine model 
of colorectal cancer. This culminated in the exploration of EMI-137 as a diagnostic imaging 
agent during colon cancer resection surgery in a phase IIa clinical trial. 
Through my research I found NIR-FC in laparoscopic cholecystectomy surgery to be a feasible 
intraoperative intervention; it was well-tolerated by patients and gained high surgeon 
satisfaction scores. I was able to demonstrate improved extra-hepatic structure visualisation 
achieved with a longer ICG dosing interval; this is contrary to several previously published 
studies. The exploration of NIR-FC in both the acute and elective laparoscopic setting also 
highlighted several limitations of NIR-FC not widely described; namely limited depth of 
fluorescent tissue penetrance in peri-hilar inflammation and spillage of bile saturating the field 
with ICG and limiting delineation of structures. If I were to perform this study again, I would 
have undertaken a dedicated sub-study of NIR-FC in the index admission (emergency) 
laparoscopic cholecystectomy setting. This would be of higher research value and would have 
allowed greater comparison between the two distinct patient populations. It would have 
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facilitated exploration of fluorescent bile duct mapping in the setting of dense peri-hilar 
inflammation and tissue oedema.  
The role of ICG and several other untargeted fluorophores have been explored previously in 
the surgical setting. The advent of novel, targeted peptides, such as the c-Met protein targeted 
EMI-137, appeared to be a new era in fluorescence guided laparoscopic surgery. I thoroughly 
investigated c-Met protein expression in pre-clinical models of CRC. By immunohistochemical 
appraisal of c-Met expression in a large representative sample of tissue from the CLASICC 
clinical trial, I confirmed tumour tissue consistently expressed higher levels of c-Met protein 
relative to matched normal mucosa tissue (Figure 30). Levels of detectable c-Met expression 
did not correlate with disease pT or pN stage. The median expression scores were variable, 
but significantly higher in tumour tissue relative to normal background mucosa at all stages of 
disease. It therefore appeared that c-Met had potential as an imaging target for fluorescent 
guided resection of colonic tumours irrespective of tumour stage. Although c-Met was possibly 
inferior to CEA as a CRC biomarker(228), c-Met did show superior diagnostic accuracy 
compared to several targets evaluated by other groups. The significant differential expression 
indicated that c-Met was a suitable biomarker in colorectal cancer for further evaluation and a 
potential imaging target. C-met expression also did not appear to correlate with disease stage, 
this justified the inclusion of patients of all suspected Tumour stage in the exploratory trial of 
EMI-137 as an intraoperative fluorescent biomarker in colon cancer surgery.    
Pre-operative staging of colon cancer is imprecise and this makes planning the radicality of 
surgery difficult. The early phase IIa trial of EMI-137 as a diagnostic imaging agent showed 
that EMI-137 was safe and well tolerated, and the trial design applied was feasible to explore 
the trial end points. Intravenous administration of EMI-137 and diagnostic laparoscopy with 
the adapted Karl Storz® fluorescent laparoscope produced detectable fluorescence in all of 
the nine study participants. The colon tumour was deemed mildly fluorescent by the operating 
surgeon in 4/9 (44%) and isofluorescent to background in the remaining 5/9 (56%) of cases. 
The addition of EMI-137 did not delineate any regional lymph nodes in the patient cohort.  
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The cohort was very small and heterogenous so limited conclusions about patient or tumour 
factors that adversely affected visualisation can be made. There was a possible inverse 
relationship between tumour pT stage, number of lymph nodes involved and size of largest 
malignant node; as the colon cancer stage progressed the fluorescence decreased. Takeuchi 
et al showed the greatest incremental increase in c-Met mRNA expression between stage T1 
and T2 compared to T3 and T4, indicating a role for high c-Met expression in early 
invasiveness and local colorectal cancer progression(208). Our sub-group analysis of the 
CLASICC trial TMA population did not support this, and there was no correlation between pT 
stage and differential c-Met expression score observed at IHC in a large RCT cohort (Table 
13, Table 14 and Figure 33). Immunohistochemical analysis of c-Met expression in the eight 
tissue specimens available from the EMI-137 clinical trial cohort also showed that the variable 
intra-operative fluorescent results observed cannot be attributed to pre-operative participant 
factors.  
Future research should focus on optimisation of the fluorescent laparoscopy hardware used 
with EMI-137 and increasing the signal to noise ratio observed intraoperatively. Another area 
of research could include exploration of co-expression of c-Met with other defined biomarkers 
of colorectal cancer. Small studies have described a synergic relationship between c-Met and 
EGFR in colorectal cancer proliferation(242) and high c-Met expression and resistance to anti-
EGFR biologic agents. A fluorescent biomarker targeted to c-Met and a marker such as EGFR, 
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Figure 41: Health Research Authority (HRA) Letter of Approval for trial IRAS ID 212190 Intraoperative 






Figure 42: Health Research Authority (HRA) approval for substantial amendment to trial IRAS ID 
212190 Intraoperative imaging of colon cancer using a fluorescent peptide (EMI-137) against c-met 
receptor. Issued 05th January 2018. 
 
 
